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Abstract
Multiple neural network integration, influence of bradykinesia and rigidity, and bias of upper
limb symptom improvement during deep brain stimulation implementation may attribute to
the variable responsiveness of Parkinsonian gait therapy. Current steering (CS) addresses
variability through fractionating current to fine-tune the stimulation field shape. It was
hypothesized that CS would exhibit greater gait improvements and lower the total electrical
energy delivered (TEED), which reduces power consumption and battery drainage. Divisions
of 70/30 and 50/50 and single-contact stimulation modelled CS and conventions,
respectively. Overall ambulation improved with TEED reduction; further, bilateral CS
improved step time and length but left CS improved stride velocity and the functional
ambulation performance score. However, total double support time exhibited no differences.
Separate sub-cortical networks may regulate amplitude, timing, and velocity versus balance,
and unilateral benefit may elucidate left hemispheric dominance for motor control. Future
studies should personalize fractionations to contact localizations for clinical relevancy.

Keywords
Parkinson’s disease, deep brain stimulation, current steering, multiple independent current
control, electrode, subthalamic nucleus, axial symptoms, spatio-temporal, gait parameters
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Chapter 1
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Introduction

1.1 Epidemiology and etiology of Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease of adult
onset with a prevalence of two per one thousand individuals affected (Bertram & Tanzi,
2005; Tysnes & Storstein, 2017). The etiology of PD is attributed to a complex
interaction between genetic, non-environmental, and environmental factors (Kalia &
Lang, 2015). Synuclein alpha was the first gene associated with inherited forms of early
onset PD and encodes the alpha ()-synuclein protein, which exists in concentrated
aggregates within Lewy bodies—a pathological hallmark of PD (Breydo, Wu, &
Uversky, 2012; Polymeropoulos et al., 1997). In addition, higher risk of PD is associated
with familial diagnosis of PD or tremor (Noyce et al., 2012). Furthermore, age, sex, and
ethnicity are prominent non-environmental risk factors (Kalia & Lang; 2015). Age
serves as the greatest risk factor, as incidence and prevalence increase exponentially with
age peaking at 80 years of life (Kalia & Lang, 2015; Pringsheim, Jette, Frolkis, &
Steeves, 2014). Moreover, males have been reported to exhibit a higher risk of
developing PD with a relative risk factor of 3:2 (DeLau & Breteler, 2006; Kalia & Lang,
2015; Wooten, Currie, Bovbjerg, Lee, & Patrie, 2004). Greater incidence among males
may be attributed to potential neuroprotective effects of estrogen or social determinants
that influence a male dominance in certain occupations such as agricultural roles with
pesticide use (Inestrosa Cantín, 1998; Wooten et al., 2004). PD appears to be more
prevalent in Caucasians than those of African or Asian descent; comparisons of PD
incidence and prevalence in the East (Asia and Middle East) versus the West (Americas,
Australia, and New Zealand) report that PD is less prevalent in the East (Abbas, Xu, &
Tan, 2018). In addition, Noyce and colleagues performed a meta-analysis of potential
environmental factors and concluded that pesticide exposure and previous head injury
exhibited the strongest association with increased PD risk; on the other hand, tobacco
smoking and coffee consumption were most associated with lowering PD risk (Noyce et
al., 2012).
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1.2 Pathophysiology of Parkinson’s disease
Two hallmark features of PD pathophysiology are the loss of dopaminergic neurons of
the substantia nigra pars compacta (SNc) and presence of Lewy pathology, which are
both confirmed post-mortem (Kalia & Lang, 2015). Dopaminergic neurons progressively
degenerate in the SNc; accordingly, motor symptoms only manifest after a certain degree
of dopaminergic cell death (Dickson et al., 2009; Kalia & Lang, 2015; Magrinelli et al.,
2016). When accounting for age, around 30% of neuronal loss in the substantia nigra
(SN) is postulated to elicit motor symptom onset (Cheng, Ulane, & Burke, 2010;
Fearnley & Lees, 1991). In addition, dopaminergic striatal denervation initially arises
asymmetrically, which accounts for the asymmetrical manifestation of motor symptoms
and a tendency for the initial side of onset to remain more severe (Hornykiewicz, 1966;
Lizarraga et al., 2017). Notably, the putamen of the dorsal striatum is particularly
impacted by dopamine deficiencies and degeneration is postulated to occur in other areas
as well, including: the locus coeruleus, pedunculopontine nucleus (PPN), raphe nucleus,
amygdala, and hypothalamus (Dickson, 2012; Kish, Shannak, & Hornykiewicz, 1988).
In addition, PD is characterized by the presence of Lewy bodies and neurites,
throughout the central and peripheral nervous system (Kalia & Lang, 2015). Lewy bodies
and neurites are composed of abnormally folded, insoluble aggregates of the protein synuclein (Breydo et al., 2012; Goedert, Spillantini, Del Tredici, & Braak, 2012; Kalia &
Lang, 2015; Polymeropoulos et al., 1997). The exact mechanism of the association
between Lewy pathology and neurodegeneration is debated; however, generally it is
agreed that certain, not all, -synuclein aggregates are neurotoxic (Breydo et al., 2012;
Kalia, Kalia, McLean, Lozano, & Lang, 2013). Nonetheless, PD is classified as a
synucleinopathy, which encompasses neurodegenerative diseases associated with atypical
accumulation of -synuclein in glial cells, nerve fibres, or neurons (McCann, Stevens,
Cartwright, Halliday, 2014).

1.3 Clinical characteristics of Parkinson’s disease
PD is a neurodegenerative movement disorder characterized by the cardinal motor
symptoms of bradykinesia, rigidity, rest tremor, and postural and gait instability (Gibb &
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Lees, 1988; Kalia & Lang, 2015). Motor symptoms are categorized based on anatomical
influence; therefore, appendicular symptoms affect the limbs and axial symptoms
influence the midline of the body, including the head, neck, and truncal regions.
Accordingly, appendicular motor symptoms include bradykinesia, rigidity, and tremor
and axial motor symptoms include speech deficits, gait impairment, and postural
instabilities. Namely, bradykinesia is the term to describe slowness of on-going
movement (Magrinelli et al., 2016). Appendicular symptoms tend to manifest earlier;
thus, are typically present around diagnosis; however, gait and postural deficits present as
the disease progresses (Kalia & Lang, 2015). Notably, bradykinesia and limb rigidity
contribute to a hypokinetic gait that typically responds to Levodopa (L-DOPA)
manifesting before other treatment-resistant axial symptoms such as freezing of gait
(FOG) (Beradelli, Rothwell, Thompson, & Hallett, 2001; Collomb-Clerc & Welter, 2015;
Kalia & Lang, 2015). Empirically, the late stages of PD refer to the period encompassing
over ten years of motor symptom onset and involves the continuous exacerbation of
motor and non-motor symptoms that often become resistant to previously effective
therapies (Kalia & Lang, 2015). In addition, non-motor symptoms such as dementia and
autonomic dysfunction present and more severe axial motor symptoms such as FOG,
spontaneous falls due to postural instability, dysphagia, and speech deficits manifest
(Kalia & Lang, 2015). Late stages are marked by a substantial decrease in independence,
quality of life, and functionality; hence, an increased mortality risk and need for
institution (Hass et al., 2012).
Motor symptom asymmetry is present throughout the disease as appendicular
symptoms tend to develop unilaterally; however, it is common for the side of onset to
remain more severe for axial and appendicular symptoms. For instance, tremor may
develop unilaterally but disease progression elicits bilateral tremor manifestation with the
side of onset exhibiting greater tremor severity. In addition, gait commonly presents with
a greater reduction of arm swing of the more affected side (Karádi et al., 2015; Lizarraga
et al., 2017). Furthermore, the presentation and severity of cardinal symptoms differs
across patients; therefore, three subtypes are often described: tremor dominant PD, which
presents with minimal manifestation of other motor symptoms and non-tremor dominant
PD, which can be further categorized into an akinetic and rigid or postural and gait
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instability subtype (Kalia & Lang, 2015; Marras & Lang, 2012). In addition, a mixed
phenotype with multiple symptoms of similar severity may manifest (Marras & Lang,
2012).
Clinical presentation of PD is not limited to motor symptoms despite manifesting
as a movement disorder; in fact, non-motor symptoms are common and reduce overall
health and quality of life (Duncan et al., 2014; Kalia & Lang, 2015; Khoo et al., 2013;
Martinez-Martin, Rodriguez-Blazquez, Kurtis, Chaudhuri, & NMSS Validation Group,
2011). Non-motor symptoms include sleep and psychiatric disorders, autonomic and
olfactory dysfunction, cognitive deficits, pain, and fatigue (Duncan et al., 2014; Khoo et
al., 2013; Magrinelli et al., 2016). Non-motor symptoms typically precede motor
symptom onset during the period that is referred to as the pre-motor phase. Similar to
motor symptom development, certain non-motor symptoms present at different stages;
for instance, constipation and rapid eye movement sleep behaviour disorder manifest
around 20 years and 10 years prior to motor symptom onset, respectively (Kalia & Lang,
2015). On the other hand, excessive daytime sleepiness, anosmia, and depression tend to
present immediately prior to motor symptom onset (Kalia & Lang, 2015).
The clinical standard to assess symptom severity is the Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale (UPDRS); namely, part I and III assess
non-motor and motor symptoms, respectively. The UPDRS is an ordinal scale ranging
from zero to four to characterize a non-diseased and the most severe Parkinsonian state,
respectively. Assessments rely on sensory judgements such as visual appraisals; thus,
scores are highly subjective and easily influenced by examiner bias. UPDRS-III assesses
various axial and appendicular motor symptoms; however, the scale exhibits a bias
towards appendicular symptoms. Only four out of fourteen items solely represent axial
motor symptoms, which include the speech, posture, gait, and postural instability subscores.

1.4 Therapeutic interventions for Parkinson’s disease
Pharmacological therapy for Parkinsonian symptoms is the initial form of symptom
management. Therapy is initiated once symptoms begin to interfere with daily function
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and reduce quality of life; thus, patients may not necessarily begin treatment at the time
of diagnosis (Connolly & Lang, 2014; Kalia & Lang, 2015). There is presently no cure
for PD and no therapy reverses, stops, or slows neurodegeneration (AlDakheel, Kalia,
Lang, 2014; Connolly & Lang, 2014; Kalia & Lang, 2015). Agonistic influence of
dopamine receptors or augmentation of dopamine concentrations throughout the central
nervous system are the primary dopaminergic mechanisms of pharmaceuticals (Kalia &
Lang, 2015). Compounds commonly used to treat PD are as follows: dopamine
precursors—L-DOPA, dopamine receptor agonists—apomorphine, monoamine oxidase
type B (MAOB) inhibitors—rasagiline, and catechol-O-methyltransferase (COMT)
inhibitors—entacapone (Kalia & Lang, 2015). These drugs may be prescribed in
combination or independently; notably, the therapy plan is highly subject to change as the
disease progresses with manifestation of long-term complications, worsening of preexisting symptoms, and induction of symptoms such as FOG.
L-DOPA is the direct dopamine precursor, which is utilized to treat PD for its
ability to cross the blood brain barrier, unlike dopamine, to increase dopamine
concentrations in the brain. L-DOPA is converted to dopamine in the central and
peripheral nervous system by the enzyme aromatic L-amino acid decarboxylase (AAAD);
therefore, L-DOPA is administered with a peripheral AAAD inhibitor to ensure sufficient
concentrations cross the blood brain barrier (Dorszewska, Prendecki, Lianeri, &
Kozubski, 2014). Dopamine receptor agonists activate dopamine receptors, which exhibit
reduced activity in hypodopaminergic states. MAOB and COMT inhibitors are
administered to interfere with physiological dopamine metabolism to prevent further
depletion in PD (Kalia & Lang, 2015). Motor symptom severity determines which class
of drugs are prescribed initially. Mild motor symptoms are usually treated with MAOB
inhibitors to delay treatment of L-DOPA or a dopamine agonist, which are preserved for
motor symptoms of greater severity because they are more potent but also associated with
more long-term complications (Connolly & Lang, 2014; Kalia & Lang, 2015). Multiple
large studies have reported that L-DOPA elicits the greatest improvement of
Parkinsonian symptoms but is more associated with motor complications as compared to
dopamine agonists (Connolly & Lang, 2014; Ferreira et al., 2013; Fox et al., 2011;
Holloway et al., 2004; Rascol et al., 2000). On the other hand, psychiatric side effects
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(hallucinations and impulse control disorders) are more common among dopamine
agonists; however, nausea, edema, and daytime sleepiness are common to both drugs
(Connolly & Lang, 2014; Kalia & Lang, 2015).
Due to the progressive nature of PD, patients often develop long term
complications due to reliance on drug therapies for many years; complications include:
motor fluctuations, non-motor fluctuations, dyskinesia, and psychosis (Kalia & Lang,
2015). Fluctuations describe periods of adequate and inadequate symptom alleviation,
commonly referred to as “ON” and “OFF” periods, respectively; in addition, motor and
non-motor fluctuations allude to motor and non-motor symptoms, respectively (Kalia &
Lang, 2015). Dopamine agonists, MAOB inhibitors, and COMT inhibitors may be
introduced to reduce fluctuations (Kalia & Lang, 2015). Dyskinesia refers to involuntary
movements consisted of continuous or repetitive muscle contractions that manifest in
twisting, spasmodic movements, or irregular postures, which most commonly occur at
maximal L-DOPA concentrations termed as peak-dose dyskinesia (Kalia & Lang, 2015;
Magrinelli et al., 2016). Dyskinesia may be addressed by non-dopaminergic compounds
such as clozapine and amantadine (Kalia & Lang, 2015). Furthermore, dopaminergic
drug induced psychosis commonly presents as visual hallucinations, which may be also
addressed by clozapine (Kalia & Lang, 2015). In addition, surgical interventions may
address long-term complications such as deep brain stimulation (DBS) or direct
administration of L-DOPA to the duodenum through a surgically implanted tube (Kalia &
Lang; 2015; Olanow et al., 2014).

1.5 Basal ganglia and associated nuclei
The basal ganglia (BG) are a collection of subcortical nuclei with extensive connections
including but not limited to the brainstem, limbic system, thalamus, and cerebral cortex
(Takakusaki, Tomita, & Yano, 2008; Takakusaki, 2013). Core components are situated in
the telencephalon and include the striatum and globus pallidus (GP) (Fazl & Fleisher,
2018). The striatum serves as the main input and is divided into dorsal and ventral
regions, which are further subdivided into the caudate nucleus and putamen, and the
nucleus accumbens and olfactory tubercle, respectively (Fazl & Fleisher, 2018). The
caudate nucleus and putamen are implicated with motor learning and planning and
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movement execution, respectively (Alexander, DeLong, & Strick, 1986; Fazl & Fleisher,
2018). Associated nuclei of the BG include the subthalamic nucleus (STN) and the SN,
which are in the diencephalon and mesencephalon, respectively (Fazl & Fleisher, 2018).
The internal globus pallidus (GPi) and substantia nigra pars reticulata (SNr) are
functionally categorized as the output nuclei, which directly project to the thalamus and
brainstem (Figure 1a) (Fazl & Fleisher, 2018). The external globus pallidus (GPe) and the
STN serve as intermediary nuclei, and the SNc exerts dopaminergic projections onto the
striatum (Fazl & Fleisher, 2018). The BG nuclei are all predominantly GammaAminobutyric Acid (GABA)ergic except for the STN, which is predominantly
glutamatergic (Hamani et al., 2017; Lanciego, Luquin, & Obeso, 2012).

1.5.1 The subthalamic nucleus—a valuable investigative region
The STN is a major regulator of BG output and is postulated to be implicated in PD
pathophysiology; appropriately, the STN is the most common target for DBS therapy of
motor symptoms (Hamani, Saint-Cyr, Fraser, Kaplitt, & Lozano, 2004; Larson, 2014). In
humans, the STN is dense and lens-shaped with an approximate volume of 240 mm3
encompassing about 560 000 neurons, heavily surrounded by many white-matter fibre
tracts such as the internal capsule, the fields of forel, and the zona incerta (Zi) (Hamani et
al., 2004; Hamani et al., 2017). The thalamus is dorsal to the STN; however, noncontiguous due to the positioning of the Zi and the SN is ventral to the STN (Fazl &
Fleisher, 2018; Hamani et al., 2017).
The STN exhibits functional organization subdivided into a sensorimotor,
associative, and limbic region (Tewari, Jog, & Jog, 2016). The sensorimotor region is
situated in the dorsolateral portion of the STN and receives projections from the primary
motor cortex (MI) and supplementary motor area (SMA) (Hartmann-von Monakow,
Akert, & Künzle, 1978; Tewari et al., 2016). The MI and SMA projections to the
sensorimotor region are somatotopically organized (Nambu, 2011; Romanelli et al.,
2004; Tankus et al., 2017). Leg, arm, and face representations project from the MI and
SMA with mirroring innervations of the lateral and medial STN, respectively (Hamani et
al., 2004; Nambu, 2011; Tewari et al., 2016). Tankus et al. (2017) investigated
somatotopy using spike recordings and found an overrepresentation of the lower limb and
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additional subdivisions representing joint regions (Tankus et al., 2017). Following
standard targeting for STN-DBS procedures, spike recordings displayed that neurons
within the STN encoding ankle movements were represented more superior-medially and
those facilitating wrist movements to be situated more inferior-laterally (Tankus et al.,
2017).
In contrast to other BG nuclei, the STN is predominantly glutamatergic with only
7.5% of its composition containing GABAergic interneurons (Hamani et al., 2017;
LLévesque & Parent, 2005). Within the BG, majority of projections innervating the STN
arise from the GPe, which is part of the canonical indirect pathway. For motor control,
cortical fibres directly innervate the dorsal STN and arise from the MI, SMA, pre-motor
cortex, and pre-SMA (Hamani et al., 2017; Nambu, 2011). A greater proportion of STN
efferents project to the GPi compared to the SNr with the GP exhibiting a greater
representation in the BG motor circuit (Hamani et al., 2004). In addition, projections
between the STN and PPN and dopaminergic interconnections between the STN and SNc
have been found, which may highlight the role of the STN in locomotion and
dopaminergic modulation, respectively (Carpenter, Carleton, Keller, & Conte, 1981;
François et al., 2000; Hamani et al., 2017).

1.5.2 Dopaminergic modulation in the basal ganglia
Majority of the striatum is composed of GABAergic medium-sized spiny neurons
(MSNs), which receive glutamatergic cortical projections and dopaminergic projections
from the SNc (Fazl & Fleisher, 2018). The A9 dopaminergic cell group of the SNc
projects to the dorsal striatum to facilitate voluntary movement control (Hegarty,
Sullivan, & O’Keeffe, 2013). Dorsal striatal MSNs projecting to the output nuclei and
GPe express dopamine subtype 1 receptor (D1) and dopamine subtype 2 receptor (D2),
respectively (Fazl & Fleisher, 2018). Classically, two circuitries encompassing the
cortical-BG-thalamus-cortical loop are postulated to modulate BG activity and to be
functionally altered in PD (Lanciego et al., 2012). The direct pathway is suggested to
facilitate initiation and execution of voluntary movement through dopaminergic
excitation of striatal D1 receptors, which exert direct GABAergic projections to the
output nuclei (Fazl & Fleisher, 2018) (Figure 1a). In PD, decreased excitation of D1
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receptors reduces the direct inhibition of the output nuclei (Figure 1b). The indirect
pathway is proposed to counteract undesirable movement that would impede proper
execution of voluntary movements (Fazl & Fleisher, 2018). Dopaminergic excitation of
the striatal D2 receptors decreases the activity of the D2 expressing MSNs that project to
the GPe. The GPe projects to the STN, which exerts glutamatergic projections to the
output nuclei (Figure 1a) (Fazl & Fleisher, 2018). In PD, reduced dopamine elicits a
greater inhibition of the GPe and a hyperactive STN; thus, increasing the GABAergic
effect of the output nuclei (Figure 1b). More recently, direct glutamatergic modulation of
the STN from the cortex has been postulated and termed the hyperdirect pathway, which
is suggested to quickly restrict an action or decision (Figure 1a) (Fazl & Fleisher, 2018;
Nambu, Tokuno, & Takada, 2002). Greater GABAergic modulation from the output
nuclei in PD results in greater inhibition of the thalamus and reduced excitation of the
cortex, which diminishes the hyperdirect pathway (Figure 1b).
In physiological states, the executed motor plan will exert a net dominance of the
direct pathway over the indirect pathway compared to the various competing motor
programs (Fazl & Fleisher, 2018). In PD, over inhibition of the thalamo-cortical and
thalamo-brainstem projection is postulated to elucidate bradykinesia and gait deficits
(Magrinelli et al., 2016). However, the validity of the classical model of BG circuitry has
been disputed in the literature (Lanciego et al., 2012). Fundamentally, it fails to account
for the array of neurotransmitters influencing the BG and pathological neuronal firing
patterns observed in PD (Brown, 2003; Magrinelli et al., 2016). In addition, the model is
well suited to explain bradykinesia but only partially addresses tremor and rigidity
(Magrinelli et al., 2016). Furthermore, BG lesions should induce involuntary movements
or hyperkinesia through a drastic reduction of inhibition exerted by the output nuclei;
however, clinically implemented lesions of the STN and GPi greatly reduce dyskinesia
(Lanciego et al., 2012; Lozano et al., 1995).
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a)

b)

Figure 1: Summary of the BG circuitry.
Summary of proposed circuitry in the cortical-BG-thalamus-cortical loop, representations
are not anatomically correct. Sharp and blunt arrows represent excitatory and inhibitory
projections, respectively. Inhibitory projections depicted are GABAergic. Excitatory
projections from STN, cortex, and thalamus constitute glutamatergic projections while
excitatory output of the SNc is dopaminergic. Arrow thickness represents the magnitude
of activity for the projection. a) & b) Direct pathway constitutes dopaminergic
modulation of the D1 receptors to the GPi and SNr; indirect pathway constitutes
dopaminergic modulation of the D2 receptors to the GPe; and hyperdirect pathway
constitutes the cortical to STN projection. a) Depiction of the physiological state. b)
Parkinsonian state—loss of dopaminergic neurons in the SNc results in the augmented
activity of the output nuclei due to a hyperactive STN compared to physiological states.
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1.5.3 Motor function lateralization
Dominance of the left hemisphere has been associated with motor control while
dominance of the right hemisphere has been associated with spatial and proprioceptive
processing (Hugdahl, 2011; Serrien, Ivry & Swinnen, 2006). Accordingly, lateralization
of motor control has been postulated to be based on handedness due to the greater
frequency of executed movements with the dominant side (Scholz et al., 2000; Serrien et
al., 2006; Volkmann, Schnitzler, Witte & Freund, 1998). Stroke patients with left sided
lesions have been reported to exhibit greater impairment of voluntary movement as
depicted by gait impairments of greater severity with longer recovery periods compared
to right sided stroke patients (Voos & Ribeiro do Valle, 2008). In addition, left
hemispheric dominance has been depicted using functional magnetic resonance imaging,
Barber et al. (2011) found a strong correlation between the magnitude of the motor
circuit connectivity of the left hemisphere (M1, SMA, thalamus, putamen, and
cerebellum) and motor abilities of right-handed children (Barber et al., 2011). Notably,
the magnitude of connectivity on average was not different between the hemispheres but
the correlation to the motor abilities for the left hemisphere was more robust and
statistically significant (Barber et al., 2011).
More recently, dominance related activation was reported in the BG with a
stronger left-sided lateralization than the motor cortex, which is also postulated to be
associated with handedness (Scholz et al., 2000). Asymmetry of the nigrostriatal network
may allude to lateralization of motor control and performance (de la Fuente-Fernández,
Kishore, Calne, Ruth, & Stoessl, 2000). Post-mortem analysis found that the left GP
exhibits higher dopamine concentrations than the right among a sample predominantly
composed of right-handed individuals (Glick, Ross & Hough, 1982). In addition, the
magnitude of right-handedness was positively correlated with dopaminergic left-sided
lateralization of the putamen (de la Fuente-Fernández et al., 2000). Both the putamen and
GPi have a direct role in facilitating movement amplitude, direction, speed, and timing;
notably, the putamen to thalamus projection of the left hemisphere was found to exhibit
dominance for regulation of movement speed (Barber et al., 2011; O’boyle, Freeman, &
Cody, 1996; Turner & Desmurget, 2010; Yin, 2014).
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1.6 Deep brain stimulation
1.6.1 History of deep brain stimulation
DBS originated as a technique to confirm the localization of deep cerebral nuclei in
stereotactic lesioning neurosurgery; however, observations suggested that stimulation
could be used therapeutically as well (Guiot et al., 1962; Gildenberg, 2005; Sironi, 2011).
Subsequent investigations found that low frequency stimulation (5-10 Hz) exacerbated
symptoms like tremor but high frequency stimulation (50-100Hz) resulted in symptom
reduction (D FESSARD et al., 1963; Blomstedt & Hariz, 2010; Schwalb & Hamani,
2008; Sironi, 2011). However, the introduction of L-DOPA, in the late 60s, drastically
reduced the practice of surgical interventions; thus, therapeutic stimulation was not
reconsidered until Benabid et al. (1987) accounted the alleviation of tremor in PD
patients with high frequency stimulation of the ventral intermediate nucleus (Benabid,
Pollak, Louveau, Henry, & De Rougemont, 1987). Side effect elimination once the
stimulation was turned off provided a considerable benefit over lesioning techniques;
thus, the safety, non-permanency, and efficacy of DBS prompted the transition to the
predominant use of stereotactic stimulation over lesioning for PD therapy (Sironi, 2011).

1.6.2 Mechanism of deep brain stimulation
In general, DBS is considered a therapy of neuromodulation that alleviates various
symptoms over a respective time course, which is attributed to several mechanisms—
neuro-electrical (excitatory or inhibitory) effects, neuro-chemical (neurotransmitter)
effects, regulation of oscillatory activity, synaptic plasticity, and neurogenesis (Ashkan,
Rogers, Bergman & Ughratdar, 2017; Herrington, Cheng, & Eskandar, 2015). The exact
mechanism of DBS remains elusive; thus, traditional hypotheses of an excitatory and
inhibitory effect will be namely discussed (Chiken & Nambu, 2016; Montgomery, 2010).
DBS excites or inhibits local neuronal elements according to the excitation and inhibition
hypothesis, respectively (Chiken & Nambu, 2016). Accordingly, the excitation
hypothesis states that DBS will depolarize the neuronal membrane to facilitate action
potential generation and the inhibition hypothesis suggests that neuronal membrane
hyperpolarization or counter depolarization impedes action potential formation. Majority
of research investigating the mechanism of DBS focuses on the local influence of DBS
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and addresses the firing rate and pattern model, which are commonly used to elucidate
PD pathophysiology (Chiken & Nambu, 2016; Montgomery & Gale, 2008). The firing
rate model proposes that dopamine depletion elicits an increased firing rate on average of
the BG output nuclei, which decreases activity of the cortical-BG-thalamus-cortical loop
(Chiken & Nambu, 2016). The firing pattern model suggests that dopamine reduction in
PD increases the synchrony of neuronal firing patterns, which disrupts the processing and
relaying of signals necessary for motor function (Chiken & Nambu, 2016). Greater
synchrony presents as neural oscillations in the ß frequency range (13-30 Hz), which are
enhanced and present throughout the cortical-BG-thalamus-cortical loop in PD (Brown,
2003; Bergman, Wichmann, Karmon, & DeLong, 1994; Little & Brown, 2014).
Amelioration of bradykinesia has been correlated with a reduction of the augmented ß
oscillatory activity in the STN and cortex (Brown, 2007).
The inhibition hypothesis follows that DBS may suppress excessive output and
pathologically synchronized oscillations of the BG, which addresses the firing rate and
pattern models, respectively (Chiken & Nambu, 2016). Initially, the inhibition hypothesis
was supported due to similar clinical outcomes of DBS and surgical lesioning therapies;
furthermore, studies reported a reduction in firing rates of neurons surrounding the
electrodes of STN-DBS in Parkinsonian patients, monkeys, and rats (Benabid et al.,
1994; Benazzouz, Gross, Féger, Boraud, & Bioulac, 1993; Chiken & Nambu, 2016;
Filali, Hutchison, Palter, Lozano, & Dostrovsky, 2004; Moran, Stein, Tischler,
Belelovsky, & Bar-Gad, 2011; Shi, Luo, Woodward, & Chang, 2006). However, the
findings are open to speculation due to accounts of residual STN neuronal activity and
full termination of firing exhibited by only a minute population (Meissner et al., 2005;
Tai et al., 2003).
More recent research supports the excitation hypothesis, which states that DBS
functions through activation of neural elements, particularly axons (Montgomery, 2010).
Studies have reported increased neuronal firing in the GPi in Parkinsonian monkeys and
the GP and SNr in PD patients during STN-DBS (Galati et al., 2006; Hashimoto, Elder,
Okun, Patrick, & Vitek, 2003; Montgomery & Gale, 2008; Reese et al., 2011).
Furthermore, Windels et al. (2003) found that high frequency stimulation in the STN
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increased glutamate levels in the GP and SNr suggesting activation of the STN upon
stimulation (Windels et al., 2003). In addition, evidence from in vitro studies suggest that
stimulation activates afferent axons within the target nucleus and the net effect depends
on the composition of the neurotransmitters of the axon terminal (Chiken & Nambu,
2016; Lee, Chang, Roberts, & Kim, 2004). Lee et al. (2004) applied high frequency
stimulation to rat STN neurons and reported excitatory and inhibitory postsynaptic
potentials but attributed this to the net effect of neurotransmitter release (Lee et al.,
2004). A substantial number of findings demonstrate DBS to antidromically (along the
axon towards the soma) excite axons that pass near or terminate in the target (Chiken &
Nambu, 2016; Montgomery, 2010). Parkinsonian rodent studies have demonstrated
symptom improvement following antidromic activation; furthermore, activity of evoked
potentials of STN-DBS suggest antidromic activation of cortical projections to the STN
(Gradinaru, Mogri, Thompson, Henderson, & Deisseroth, 2009; Montgomery, 2010).

1.6.3 Neurological targets for deep brain stimulation
The two standard targets for the treatment of PD are the GPi and STN; however, STNDBS is more common (Follett & Torres-Russotto, 2012; Fox et al., 2011; Mahlknecht,
Limousin, & Foltynie, 2015). Several studies have compared the efficacy of these nuclei
as a therapeutic target for DBS; both targets consistently reduce UPDRS scores,
dyskinesia severity, dyskinesia duration, and improve quality of life (Anderson, Burchiel,
Hogarth, Favre, & Hammerstad, 2005; Follett et al., 2010; Mahlknecht et al., 2015;
Odekerken et al., 2013; Okun et al., 2009; Zahodne et al., 2009). However, unique to
STN stimulation is the significantly greater reduction of the L-DOPA dose with some
patients ceasing L-DOPA therapy; in addition, STN-DBS elicits slightly greater
improvements of bradykinesia and rigidity as assessed with UPDRS-III (Anderson,
Burchiel, Hogarth, Favre, & Hammerstad, 2005; Follett et al., 2010; Mahlknecht et al.,
2015; Odekerken et al., 2013). For alleviation of cardinal motor symptoms, electrodes are
localized to the sensorimotor-dorsolateral STN, which exhibits somatotopic organization
(Bot et al., 2018; Kuncel & Grill, 2004; Tewari et al., 2016; Wagle Shukla, Zeilman,
Fernandez, Bajwa, & Mehanna, 2017). Notably, current spread into surrounding fibre
tracts such as the Zi and the fields of forel have been reported to relieve tremor, rigidity,

15

and dyskinesia; however, paradoxically induces FOG and gait hypokinesia (Blomstedt et
al., 2018; Saint-Cyr et al., 2002; Fleury et al., 2016; Hamel et al., 2003).

1.6.4 Therapeutic practicality of deep brain stimulation
DBS is a therapeutic intervention that requires surgical implantation of an impulse
generator (IPG), extension, and macroelectrodes. Treatment relies on delivery of
electrical pulses carried by wires that are implanted into target brain regions using
stereotactic neurosurgery. The leads are insulated coiled wires that contain multiple
macroelectrodes, which consist of non-insulated regions, termed as contacts, that allow
charge to traverse into the surrounding neural tissue. Commonly, two leads are inserted
bilaterally; however, one lead may be inserted for unilateral treatment. The IPG is subdermally embedded in the chest and serves as the source of electrical pulses and contains
the battery to run the system. The IPG is connected to the therapeutic leads through an
extension, which is entirely insulated and traverses subdermally from the chest, up the
neck posteriorly, through a cranial burr hole and into the brain (Figure 2). Therefore,
electrical pulses are carried to the brain by the extension and can only traverse into target
nuclei through the contacts. Electrode geometry and stimulation parameters are set using
an external programmer, which communicates with the IPG to coordinate the selected
features to yield stimulation accordingly.
Electrode geometries dictate cathode and anode designations, which exhibit a
negative and positive electric potential, respectively. Current is drawn towards the
cathode from the anode; thus, the cathode and anode are considered the current sink and
source, respectively. Among all geometries, only the contacts serve as the cathode for
therapeutic stimulation but the IPG or an active contact can be assigned as the anode.
Only unipolar configurations consist of the IPG set as the anode with one or more active
contacts set as the cathode. Other geometries such as bipolar, tripolar, quadrapolar, and
quintipolar consist of two, three, four, and five active contacts, respectively, with one of
the contacts being set as the anode (Kuncel & Grill, 2004). A unipolar electrode
geometry is most commonly implemented followed by the bipolar geometry. Bipolar
geometries are implemented when unipolar configurations inadequately improve
symptoms, especially if side effects are induced at low amplitudes (Wagle Shukla et al.,
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2017; Volkmann, Moro, & Pahwa, 2006). The bipolar electrode geometry programs one
contact as the cathode and another as the anode; commonly, the contact most effective for
symptom relief is set as the cathode and the adjacent contact serves as the anode (Wagle
Shukla et al., 2017).
DBS relies on the delivery of electrical pulses, which is approximated to represent
a square wave; therefore, the stimulation amplitude fluctuates between peaks and troughs
(Montgomery, 2010; Wagle Shukla et al., 2017). The square shaped pulse is described to
exhibit a short-duration stimulation phase with a peak amplitude and a long-duration
recharge phase to minimize tissue damage associated with a trough amplitude (Figure 3)
(Wagle Shukla et al., 2017). The stimulation phase delivers charge to the contact(s)
designated as the cathode, which is associated with cathodal current; however, the
recharge phase returns charge back to the IPG, which is associated with anodal current
(Montgomery, 2010). Since the stimulation amplitude fluctuates over time, impedance is
used to describe the opposition to electrical charge flow in DBS (Montgomery, 2010;
Wagle Shukla et al., 2017). Frequency, pulse width, and current are the stimulation
parameters that can be programmed to regulate stimulation. Current dictates the
stimulation intensity measured in milliamperes (mA), frequency is the rate of stimulation
measured in Hz or the inverse of the period of the electric pulse, and the pulse width
encompasses the period when the electrical pulse is delivered measured in μs (Figure 3)
(Wagle Shukla et al., 2017). For treatment of PD, the clinical standard is to program
STN-DBS with a frequency of 130 Hz and a pulse width of 60 s. Current amplitude is
set within a range that is below the side effect threshold but above the efficacy threshold,
referred to as the therapeutic window (TW); accordingly, the side effect threshold is the
minimal intensity that elicits side effects and the efficacy threshold is the minimal
intensity to elicit symptom alleviation.
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Figure 2: Diagram of the DBS hardware.
a) Image provided courtesy of Boston Scientific (MA, USA) portraying the sub-dermal
implantation of the IPG below the clavicle and the attachment of two leads bilaterally to
the IPG. The extension runs up the neck posteriorly through a cranial burr hole into target
deep brain structures. b) Scout view obtained from a computed tomography displaying
the insulated extension that runs up the neck posteriorly, which connects to an adaptor
allowing the contacts to localize to target brain structures.

Figure 3: Schematic of the electric pulses delivered with DBS.
Cathodal current refers to the charge delivery to the cathode(s) designated as the
contact(s) for the therapeutic application of DBS. Anodal current refers to charge
delivery to the anode, which is set as the IPG. Charge moves away from the source
(anode) and towards the current sink (cathode(s)); the peak is associated with the
stimulation phase and the trough is associated with the longer re-charge phase. Pulse
width measured in s defines the period that the electrical pulse is delivered; current
amplitude measured in mA indicates the stimulation intensity; and frequency measured in
Hz refers to the rate of the pulse delivery or inverse of the period.

1.6.5 Total electrical energy delivered and the relation to power
consumption and the IPG battery life
The total electrical energy delivered (TEED) represents an overall measure of
stimulation. The concept was first introduced by Moro and colleagues in their
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investigation of DBS as a therapy for Huntington’s disease (Moro et al., 2004). However,
it was later modified by Koss and colleagues using derivations with standard physics
equations such as Ohm’s law (Koss, Alterman, Tagliati, & Shils, 2005). TEED is
established by the voltage, frequency, pulse width, and impedance, and represents the
total amount of energy delivered in a given time period of stimulation. Notably, power is
the amount of energy transferred per unit time; thus, TEED may be used to allude to
power consumption. The TEED calculation has been reported as:
TEED1sec =

(𝑣𝑜𝑙𝑡𝑎𝑔𝑒)2 × (𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦) × (𝑝𝑢𝑙𝑠𝑒 𝑤𝑖𝑑𝑡ℎ)
𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒

× 1𝑠𝑒𝑐𝑜𝑛𝑑.

TEED has been studied in the context of practicality through investigations of its effect
on battery life, which influences the need and frequency of IPG replacements (BinMahfoodh, Hamani, Sime, & Lozano, 2003; Helmers et al., 2018; Niemann, Schneider,
Kühn, Vajkoczy, & Faust, 2018; van Riesen et al., 2016). Pulse width and TEED have
been reported to directly correlate with the IPG battery drainage rate (van Riesen et al.,
2016). Therefore, stimulation with smaller values of TEED delay battery depletion and
need for surgical replacement of the IPG battery.
Faster drainage results in an earlier and more probable need for initial and
subsequent re-implantations, which introduces two primary risks—inadequate or unstable
symptom control and infection risk (Allert, Kirsch, Weirich, & Karbe, 2009; Pepper et
al., 2013). Allert and colleagues reported that 20% of patients experience inadequate
symptom alleviation despite accurate restoration of the hardware and programming with
previous parameters that provided alleviation before IPG replacement (Allert et al.,
2009). Re-programming may require diligent re-selection of optimal stimulation
parameters, which is laborious and may not be feasible in large busy centres or in small
centres that are limited in resources (Allert, et al., 2009; Wagle Shukla et al., 2017). In
addition, Pepper et al. (2013) reported that the infection rate associated with the IPG
replacement surgery was more than three times greater than the initial DBS implantation
procedure (Pepper et al., 2013). TEED values are also useful to represent various
stimulation parameters as a uniform measure during clinical investigations; for instance,

19

inadequate axial improvement with low frequency stimulation was attributed to the
reduced TEED of the investigative stimulation (Dayal, Limousin, & Foltynie, 2017).

1.6.6 Factors affecting the clinical outcome of deep brain stimulation
The ideal clinical outcome is achieved by maximizing symptom alleviation and
minimizing side effects, power usage, and tissue damage risk, which is influenced by the
electrode geometry, electrical characteristics of the tissue encompassing the contact,
contact localization, and stimulation parameter selection (Butson, Maks, & McIntyre,
2006; Kuncel & Grill, 2004). Maximal symptom alleviation with minimal side effect
manifestation is best controlled with optimizing current spread; on the other hand, battery
life is related to power usage; therefore, minimal power usage is also pursued to reduce
the IPG battery drainage rate (Kuncel & Grill, 2004). Post-mortem studies depict minor
tissue damage following chronic STN-DBS when stimulus parameters are programmed
with a charge density that is considerably lower than recommended values (Kuncel &
Grill, 2004). Reported neural tissue changes are caused by immune responses such as
gliosis, which introduces lymphocytes, microglia, and macrophages to the neural tissue
surrounding the electrode (Haberler et al., 2000; Henderson et al., 2002). Gliosis is the
proliferation or hypertrophy of various glial cells serving as a non-specific response to
central nervous system damage; notably, extreme gliosis may lead to scar formation,
which impedes axonal regeneration resulting in loss of function (Yiu & He, 2006).
Unipolar geometries elicit a broader electric field since current spreads from the
brain to the chest region compared to the confinement of the field within the brain with
bipolar configurations. The unipolar electric field is approximated to exhibit a spherical
shape around the active contact due to diffuse, radial current spread (Butson, Cooper,
Henderson, &, McIntyre, 2007; Deli et al., 2011; McIntyre, Mori, Sherman, Thakor, &
Vitek, 2004). Unipolar stimulation is programmed conventionally and bipolar
configurations are utilized when unipolar stimulation is inadequate for symptom
alleviation or induces side effects at low amplitudes (Kuncel & Grill, 2004). Unipolar
configurations are associated with a lower efficacy threshold; thus, symptom alleviation
is elicited at lower stimulation amplitudes, which is favourable for reduced power
consumption and maintenance of the IPG battery life (Deli et al., 2011; Volkmann et al.,

20

2006). Therefore, unipolar stimulation is preferred because symptom alleviation is
elicited at higher amplitudes with bipolar configurations, which increases power
consumption and expedites the IPG battery drainage rate (Deli et al., 2011;
O’suilleabhain, Frawley, Giller, & Dewey, 2003; Volkmann et al., 2006).
Electrical characteristics of the neural tissue encompassing the electrode also
influence the spatial distribution of the stimulation field (Kuncel & Grill, 2004). For
instance, grey matter has a lower conductivity; therefore, contact localizations in white
matter fiber tracts such as the Zi exhibit broader electric fields (Li, Bak, & Parker, 1968;
Kuncel & Grill, 2004). Furthermore, large diameter myelinated axons are activated at the
lowest stimulation amplitudes compared to dendrites and the soma (Wagle Shukla et al.,
2017). Nonetheless, the actual neuroanatomical location of the active contact also
influences the success of the clinical outcome. It is generally agreed that the ideal target
for motor symptom alleviation is the dorsolateral STN (Bot et al., 2018; Kuncel & Grill,
2004; Tewari et al., 2016; Wagle Shukla et al., 2017).
The combination of frequency, pulse width, and current amplitude influences
current spread and power consumption, which ultimately affects symptom relief and the
risk of side effects and tissue damage (Kuncel & Grill, 2004). Magnitudes of the
stimulation parameters must be programmed with a compromise between symptom
alleviation and power usage. For instance, frequency is directly related to power
consumption and the IPG battery drainage rate; however, the frequency cannot be
programmed too low (Kuncel & Grill, 2004; Volkmann, Herzog, Kopper, &, Deuschl,
2002; Moro et al., 2002). Frequencies below 100 Hz have been reported to be inadequate
for symptom alleviation and frequencies of 13-30 Hz have been found to aggravate
bradykinesia (Kuncel & Grill, 2004; Volkmann et al., 2002; Moro et al., 2002). Similarly,
shorter pulse widths reduce the charge density of stimulation, which lowers the risk of
tissue damage (Kuncel & Grill, 2004). In addition, shorter pulse widths increase the
therapeutic window; thus, shorter pulse widths are preferred in clinical practice (Rizzone
et al., 2001). However, depending on the impedance of the DBS system, pulse widths
may need to be increased from the clinical standard. Furthermore, the stimulation
amplitude required for symptom alleviation is directly related to the distance of the active
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contact from appropriate neural elements, which emphasizes the importance of accurate
contact localizations (McNeal, 1976) Notably, high amplitudes are associated with
greater power consumption; thus, lower efficacy thresholds are more ideal because lower
amplitudes reduce power consumption and subsequently, the side effect and tissue
damage risk.

1.6.7 Technological development of deep brain stimulation
The emergence of DBS systems arose as voltage-controlled (VC) devices, which
established the design of all DBS devices until the production of current-controlled (CC)
systems. VC devices are adequate for symptom alleviation in straightforward cases;
however, these systems are not ideal when addressing cases that require more
programming. Overall, VC systems exhibit limited ability to regulate and fine-tune
stimulation making programming laborious especially since there are no established
protocols (Wagle Shukla et al., 2017). VC devices are associated with inconsistent charge
delivery due to the lack of regulation of inherent impedance fluctuations at the
contiguous border between the electrode and neural tissue (Butson et al., 2006; Butson &
McIntyre, 2008; Wagle Shukla et al., 2017). For several weeks following implantation,
increased impedance is attributed to an encapsulation layer generated from the body’s
reaction to the foreign electrode through protein and immune cell deposition (Polikov,
Tresco, & Reichert, 2005). Impedance is reported to settle around a month postimplantation; however, impedance also invariably decreases with stimulation changes
(Lempka, Johnson, Miocinovic, Vitek, & McIntyre, 2010; Lempka, Miocinovic, Johnson,
Vitek, McIntyre, 2009). Consequently, VC devices commonly over or under stimulate the
intended target due to impedance fluctuations deviating the stimulation from programed
parameters, which prompted the development of CC systems with multiple independent
current control (Butson et al., 2006). In multiple independent current control technology,
each contact acts as a resistor in its own circuit; therefore, the voltage is manipulated to
address the impedance fluctuations and ensure that current delivery is consistent from
each active contact and matches programmed parameters (Figure 4). CC systems with
multiple current sources has increased the degrees of freedom for programming through
stimulation techniques termed as current steering (CS) (Barbe, Maarouf, Alesch, &
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Timmermann, 2014). CS can be implemented in the axial or coronal plane, which
employs directional and vertical CS, respectively.
Directional CS can only be employed with segmented electrodes that are designed
with two segmented contacts. Each segmented contact is divided into three sections that
together span the electrode circumference in contrast to exhibiting the conventional ringshape (Figure 4b). Directional CS activates contact segments, instead of stimulating from
the entire circumference, to specifically target or avoid neural structures in the axial
plane. Neuroanatomical variations and imprecise contact localizations can be addressed
by activating only one or two segments of the contact. Steigerwald et al. (2016)
performed a pilot study among seven patients with bilateral STN implantation and
reported the feasibility of directional CS, which increased the TW in a patient specific
manner compared to ring style contact activation (Steigerwald, Müller, Johannes,
Matthies, & Volkmann, 2016).
Vertical CS divides the current delivery between multiple active contacts to
manipulate the stimulation field shape. Thus, current fractionation is employed in the
coronal plane along the dorsal-ventral axis. The percentage or proportion of current
stimulation is directly related to the electric field spread; therefore, contacts receiving a
greater percentage will exhibit a broader spread than those receiving a smaller
percentage. Vertical CS allows for manipulation of the conventional unipolar spherical
electric field to fine-tune stimulation, which maximizes targeted stimulation and
minimizes unintended current spread into surrounding neural tissue. This technique
systematically associates current fractionations with contact localizations to improve the
overall efficiency and feasibility of programming; however, the technique is particularly
beneficial for inadequate symptom alleviation that demands repetitive re-programming
(Barbe et al., 2014). In addition, multiple programs can be employed; therefore, different
combinations of stimulation parameters may be implemented for different symptoms,
which ultimately reduces the need for surgical re-implantation. Simulations have depicted
the ability of vertical CS to improve the precision of influencing targeted neural
structures to maximize symptom alleviation and minimize side effects (Chaturvedi,
Foutz, & McIntyre, 2012). Similarly, the first human report fractionated the current
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between four active contacts to yield a tear-drop shaped electric field to elicit symptom
alleviation without dyskinesia at the same amplitude that single-contact stimulation
induced dyskinesia and failed to alleviate symptoms (Barbe et al., 2014). Furthermore,
the most extensive investigation to date with the assessment of 40 individuals with
moderate to severe idiopathic PD across six European countries also found a substantial
clinical benefit of utilizing vertical CS (Timmermann et al., 2015). Timmermann and
colleagues reported the utility of vertical CS to alleviate motor symptoms, improve
quality of life, increase the “ON” period, and reduce the L-DOPA equivalent dose
(Timmermann et al., 2015). Notably, majority of patients initiated programming with
single-contact stimulation; however, 82% of patients shifted to CS (unipolar stimulation
with multiple contacts) by the third month following implantation and this remained for
the majority at six months and one year following implantation (Timmermann et al.,
2015). Promising results from clinical observations and studies have prompted the use of
vertical CS in more clinical settings (Barbe et al., 2014; Chaturvedi et al., 2012; Wagle
Shukla et al., 2017; Timmermann et al., 2015).
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Figure 4: Schematic of the multiple independent current control technology utilized.
Images of leads adapted by the design of Boston Scientific (MA, USA). Simplified
diagram of the electric circuitry associated with the a) VerciseTM lead and b) Vercise
CartesiaTM Directional lead, which has two segmented levels such that the conventional
ring electrode is divided into three segments that are individually controlled. Both leads
are designed with multiple independent current control; therefore, each contact acts as a
resistor in an individual circuit and consistent current delivery is maintained by adjusting
the voltage to account for impedance fluctuations.

1.6.8 Implementation of vertical current steering
The Boston Scientific DBS systems (Valencia, CA) orchestrate vertical CS since they
are designed as CC devices with multiple independent current sources. Boston Scientific
offers segmented and non-segmented leads to operate with the multiple independent
current control technology; the VerciseTM DBS lead contains eight non-segmented
contacts and the CartesiaTM Directional lead consists of 8 contacts with the two middle
levels segmented into 3 portions (Figure 4). The eight contacts of the VerciseTM DBS
lead span 15.5 millimetres (mm); however, the eight contacts of the CartesiaTM
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Directional lead span 7.5 mm (Figure 4). In both leads, the contact length is 1.5 mm
with a separation distance of 0.5 mm between contacts and are designed with an overall
diameter of 1.3 mm (Figure 4). Additionally, the two middle levels of the CartesiaTM
Directional lead are segmented into 3 portions that approximately span 120 degrees
(Steigerwald et al., 2016). Vertical CS is implemented with a unipolar electrode
geometry; thus, the IPG is set as the anode and at least two contacts are assigned a
cathodic designation to allow for current to be fractionated between the active contacts.

1.7 Gait
1.7.1 Role of the central nervous system in gait facilitation
Gait encompasses the bilateral coordination of sequential limb movements for
locomotion, which most commonly manifests as walking. An external or visceral
stimulus initiates volitionally or emotionally primed locomotion through downward
projections from the cerebral cortex and limbic system, respectively (Takakusaki, 2008).
Namely, emotionally primed movements may be reactive such as a fight-or-flight
response (Takakusaki, 2017). Gait execution relies on the correct degree of postural
muscle tone and the rhythmicity of limb movements facilitated by subconscious
processing of the brainstem and spinal cord. Processing of higher order brain regions is
necessary for adaptation to address changes in the ambulation environment such as for
obstacle avoidance (Takakusaki, 2013).
Descending projections from the cortex and brainstem reticular formation
constituting the corticospinal and reticulospinal tracts, respectively, influence -motor
neurons in the spinal cord to control locomotion and posture (Takakusaki, 2013).
Automatic posture regulation maintains the body upright throughout ambulation;
however, dynamic postural control, facilitates adjustments to maintain steady-state
walking in response to environmental disturbances (Takakusaki, 2013). The latter relies
on additional cortical processing and integration of visual, vestibular, and proprioceptive
input; however, the former is predominantly maintained through subconscious processing
in the brainstem and spinal cord (Collomb-Clerc & Welter, 2015; Massion, 1992;
Takakusaki, 2017). Execution of steady-state locomotion occurs with automatic
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processes as with all learned behaviours. The critical role of the brainstem and spinal
cord in facilitating steady-state locomotion was deduced by induced locomotion from
electrical stimulation of locomotor centres in the midbrain of decerebrate cats (Hinsey,
Ranson, & McNattin, 1930). Three locomotor regions are postulated to exist—the
midbrain locomotor region (MLR), subthalamic locomotor region (SLR), and cerebellar
locomotor region (CLR), which have been identified in humans using magnetic
resonance imaging (Jahn et al., 2008). The MLR is postulated to encompass the area in
the mesopontine tegmentum, which includes the cuneiform nucleus (CN) and the PPN,
and the SLR and CLR are situated in the lateral hypothalamus and the mid-cerebellum,
respectively (Mori et al., 1999).
The MLR was discovered in 1966 through stimulation of a region between the
midbrain and hindbrain in cats but is now postulated to be conserved across all vertebrate
classes (Grillner, Georgopoulos, & Jordan, 1997; Shik, Orlovskiĭ, & Severin, 1966). Gait
and posture are controlled with the MLR through afferents from the cerebellum and
motor cortex, outward projections to the reticulospinal tract and thalamo-cortical
pathway, and reciprocal connections with the BG (Magrinelli et al., 2016; Takakusaki,
2017). The MLR has been postulated to regulate central pattern generators in the spinal
cord, which maintain locomotor rhythm, facilitate adaptations, and coordinate the correct
degree of postural control for gait execution (Takakusaki, 2013).
The spinal cord is predominantly involved in the rhythm and pattern generation of
locomotion through projections from the MLR acting on spinal interneurons termed as
the central pattern generators. The central pattern generators exist as two separate
networks for regulation of flexor and extensor muscles that are reciprocally active during
ambulation (Takakusaki, 2013). Central pattern generators subsequently project to second
order interneurons, which shape the pattern of locomotion and ultimately to motor
neurons of the ipsilateral limb (Takakusaki, 2013). The left-right alterations of limb
movements are facilitated by interneurons in lamina VIII that project to motor neurons of
the contralateral limb (Takakusaki, 2013). Sensory feedback from proprioceptive
receptors relay signals upward for adaptation to environment changes through tracts such
as the spino-reticular and spino-cerebellar (Takakusaki, 2013).
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The cerebellum and BG exert downward and upward projections to serve as relay
structures to facilitate automatic features and aspects influenced by the cortex,
respectively (Figure 5) (Takakusaki, 2013). The BG exhibits reciprocal connections with
the cortex, and projects to the brainstem and hypothalamus to coordinate volitional,
automatic, and emotional locomotor processes, respectively; similarly, the cerebellum
also projects to the brainstem and cortex (Figure 5) (Takakusaki, 2013). Cortical circuitry
coordinates planning, learning, and adaptive processes, which is facilitated through
cortical projections to the spinal cord, brainstem, BG, and cerebellum (Figure 5)
(Takakusaki, 2013; Takakusaki, 2017). Precise limb movement is programmed and
planned with the premotor area and the SMA while execution is facilitated with the MI
and corticospinal tract (Takakusaki, 2013). Modifications to maintain steady-state
ambulation heavily rely on visuo-motor processing and the generation and constant
update of body schema information; thus, involving integration of somatosensory,
vestibular, and visual information in the occipital, temporal, parietal, and motor cortices
(Stuart, Lord, Hill, & Rochester, 2016; Takakusaki, 2013). Subsequently, the MI and
somatosensory cortex employ body schemas to generate motor programs to execute
ambulation addressing perturbations (Takakusaki, 2013).

Figure 5: Neural control in the central nervous system for gait facilitation.
Gait facilitation involving the spinal cord, sub-cortex, and cortex. Schematic does not
represent actual anatomical locations, adapted from Takakusaki, 2013.
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1.7.2 Dopamine responsive versus non-dopamine responsive
postural and gait deficits in Parkinson’s disease
Reduced dopamine levels in PD are postulated to augment GABAergic activity of the BG
output nuclei, which increases inhibition of the thalamo-cortical projection and the
brainstem (Fazl & Fleisher, 2018; Magrinelli et al., 2016). Alterations in dopaminergic
and cholinergic projections are postulated to impair sensorimotor integration, motor
programming, and motor execution facilitated predominantly by the brainstem and cortex
necessary for the regulation of gait and posture (Magrinelli et al., 2016). The cardinal
Parkinsonian gait is characterized by a stooped posture; increased flexion at the hip and
knee joints; and reduced limb swing, ground clearance, speed, and step magnitude
(Magrinelli et al., 2016). Postural and gait deficits tend to manifest later as opposed to
appendicular symptoms, which have an earlier onset and are typically present at
diagnosis (Kalia & Lang, 2015). Postural and gait deficits may be further categorized
based on the stage of onset, predominant underlying mechanism, and response to LDOPA and STN-DBS (Lubik et al., 2006; McNeely & Earhart, 2013; Welter et al., 2002).
A correlation between axial motor symptom response to L-DOPA and the clinical
outcome of STN-DBS has been reported in several accounts; therefore, clinicians rely on
an adequate response to L-DOPA as a prerequisite for DBS (Fasano, Aquino, Krauss,
Honey, & Bloem, 2015; Pötter-Nerger & Volkmann, 2013; Welter et al., 2002).
Gait and postural deficits of earlier manifestation tend to be attributed to limb
rigidity and bradykinesia, which contribute to a hypokinetic gait with reduced limb
swing, step size, and gait velocity (Collomb-Clerc & Welter, 2015). Gait measures of
amplitude, rhythm, and velocity tend to improve with L-DOPA and STN-DBS; thus, are
postulated be predominantly facilitated by dopaminergic modulation of the BG and
subsequent influence of the CN in the MLR (Collomb-Clerc & Welter, 2015;
Krystkowiak et al., 2003; Lubik et al., 2006; Magrinelli et al., 2016; Takakusaki, Chiba,
Nozu, & Okumura, 2016). Namely, the subthalamo-pallidal-MLR pathway has been
proposed to regulate spatio-temporal gait parameters particularly through the CN or the
cholinergic neurons in the laterodorsal tegmental nucleus of the MLR that project to the
spinal cord (Collomb-Clerc & Welter, 2015; Takakusaki et al., 2016). Accordingly, post-
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mortem assessment found that the magnitude of neuronal loss in the CN was not
significantly different between those with a tendency to fall and those without; in
contrast, cholinergic neuronal loss in the PPN varied between spontaneous fallers and
non-fallers (Karachi et al., 2010).
FOG, spontaneous falls, and postural sway are suggested to be controlled by nondopaminergic pathways in the brainstem that typically manifest following 10 years of
diagnosis and exhibit a variable responsiveness to L-DOPA and STN-DBS (CollombClerc & Welter, 2015; Kalia & Lang, 2015; Takakusaki, 2017). Non-dopamine
responsive postural and gait dysfunction are influenced by the inability to produce
anticipatory and compensatory postural adjustments; thus, are more representative of
balance deficits (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). Namely, the
subthalamo-nigro-PPN circuit has been implicated in postural control as the lateral SNr
regulates muscle tone through GABAergic projections to the PPN, which is a MLR
nuclei implicated with balance regulation (Collomb-Clerc & Welter, 2015; Takakusaki,
Habaguchi, Ohtinata-Sugimoto, Saitoh, & Sakamoto, 2003). Cholinergic-based deficits
have been supported through lesioning studies of PPN neurons in primates, which elicited
L-DOPA resistant gait and postural deficits (Grabli et al., 2013). In addition, a correlation
between reduction of cholinergic PPN neuronal size and quantity with FOG presentation
and fall frequency was confirmed post-mortem (Zweig, Jankel, Hedreen, Mayeux, &
Price, 1989; Rinne, Ma, Lee, Collan, & Röyttä, 2008).

1.7.3 Spatio-temporal gait parameters
Spatio-temporal gait parameters may be analyzed for disease or injury diagnosis, fall risk
evaluation, and assessment of the efficacy of various therapies such as DBS (Egerton,
Thingstad, & Helbostad, 2014). Quantitative gait descriptions are often expressed with
respect to a stride or step. A stride is the distance between the initial heel contact to the
consecutive heel contact of the ipsilateral foot. A stride is composed of two steps; thus,
one step is the distance between the initial heel strike to the consecutive heel strike of the
contralateral foot. Step based expressions are preferred over stride expressions because
steps reveal the potential right-left asymmetry of gait, which is indicative of an irregular
gait pattern common in PD (Johnsen, Sunde, Mogensen & Østergaard, 2010).
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Gait parameters are categorized into respective domains, which may elucidate
separate neural circuits facilitating various gait features—namely spatio-temporal or
postural measures. A spatial (length), temporal (time and double support time), and
spatiotemporal domain (velocity) often model the cardinal Parkinsonian gait as step
length and gait velocity reductions and step time and total double support time (TDST)
increases (Morris, Iansek, Matyas, & Summers, 1994). Definitions for the
aforementioned parameters follow: step length—distance between consecutive heel
strikes of opposite feet measured parallel to the advancement trajectory (measured in
cm); step time—period to advance from one foot contact to the consecutive heel strike of
the opposite foot (measured in seconds); stride velocity—ratio of stride length to time
(measured in cm/sec); and TDST—sum of all time periods during which, both feet are
supporting the body and making direct contact with the ambulation surface (measured in
seconds) (Huxham, Gong, Baker, Morris, & Iansek, 2006). Notably, TDST is a postural
measure but may be assessed in the temporal domain (Collomb-Clerc & Welter, 2015).
Step length, step time, and gait velocity reflect the amplitude, rhythm or timing,
and velocity of locomotion, respectively; thus, reflecting spatio-temporal gait features,
which are regulated by BG such as the striatum (Alexander et al. 1986). On the other
hand, TDST is more representative of postural control and has been correlated to FOG
and spontaneous fall risk, which are axial deficits that manifest later in PD and tend to be
less responsive to L-DOPA and STN-DBS (Collomb-Clerc & Welter, 2015; Hausdorff et
al., 2003; Plotnik, Giladi, Dagan, & Hausdorff, 2011). Therefore, TDST is postulated to
be regulated by cholinergic networks in the brainstem that involve the spinal cord,
cerebellum, BG, and cortex (Collomb-Clerc & Welter, 2015; Takakusaki, 2017).

1.7.4 Technology utilized for gait research
Gait can be recorded using pressure sensitive mats embedded with sensors to record foot
falls, which are subsequently extracted as spatio-temporal gait parameters using analysis
software. The GAITRite (NJ, USA) and ZenoTM (PA, USA) walkways are utilized
alongside GAITRite and ProtoKinetics Movement Analysis Software (PKMAS),
respectively. GAITRite is a more established program while PKMAS and the ZenoTM
walkway are a newer system (Egerton et al., 2014). Vallabhajosula et al. (2017) reported
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an acceptable validity of the recording ability of both walkway systems with differences
only reported with fast pace walking; however, differences in surface texture, walkway
dimensions, and walking assessment protocol were not accounted for and could address
differences (Vallabhajosula, Humphrey, Cook, & Freund, 2017). Egerton et al. (2014)
demonstrated that there was no difference between the outputs of PKMAS and the
GAITRite analysis software except for base width and foot angle, which requires further
validation of the PKMAS calculation (Egerton et al., 2014). In addition, gait analysis
softwares calculate the functional ambulation performance (FAP) score, which is an
overall measure of gait used to assess ambulation at self-selected paces (Gouelle, 2014).
The score is calculated by deducting points from a maximal score of 100 for deviations
from a healthy gait; notably, scores between 95 to 100 represent gait in a non-diseased
adult population (Gouelle, Mégrot, Presedo, Penneçot, & Yelnik, 2011; Gouelle, 2014).

1.7.5 Literature investigating the effect of deep brain stimulation on
Parkinsonian gait
Improvement of appendicular symptoms elicited by DBS has been consistently replicated
in scientific investigations; however, axial symptom response is more variable in the
clinical realm and literature. Stimulation may worsen or have no effect on axial
symptoms postulated to be predominantly regulated by non-dopaminergic mechanisms
such as FOG (Adams, Keep, Martin, McVicker, & Kumar, 2011; Collomb-Clerc &
Welter, 2015; Cossu & Pau, 2017; Ferraye et al., 2008; Fleury et al., 2016; van Nuenen et
al., 2008; Stolze et al., 2001). Gait dysfunction that is dopamine responsive typically
improves upon initial stimulation but in a more variable degree than appendicular
symptoms; in addition, these improvements may fail to maintain over time (Anderson et
al., 2005; Collomb-Clerc & Welter; Cossu & Pau, 2017; Fasano et al., 2010; Ferrarin et
al., 2005; Krystkowiak et al., 2003; Moro et al., 2010; Rodriguez-Oroz et al., 2005). In
present clinical practice, patients with axial symptoms that are non-responsive to LDOPA or exhibit severe postural and gait instabilities are excluded from DBS.
Many studies investigate the effect of DBS on gait using quantitative analyses of
spatio-temporal gait parameters. Significant improvements in gait velocity and length are
most commonly reported (Allert et al., 2001; Cantiniaux et al., 2009; Faist et al., 2001;
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Ferrarin et al., 2002; Ferrarin, Rizzone, Lopiano, Recalcati, & Pedotti, 2004; Ferrarin et
al., 2005; Krystkowiak et al., 2003; Stolze et al., 2001; Vallabhajosula et al., 2015; Xie,
Krack, Benabid, & Pollak, 2001). Improvements in TDST are also often reported and
expressed as the reduction of dual stance support during the gait cycle (Faist et al., 2001;
Ferrarin et al., 2002; Johnsen et al., 2010; Krystkowiak et al., 2003; Xie et al., 2001).
However, effects on step time are much more variable with accounts reporting no effect,
an increase, or a decrease to step time following DBS (Allert et al., 2001; Krystkowiak et
al., 2003; Lubik et al., 2006). Altogether, STN-DBS tends to improve amplitude and
velocity gait features; however, FOG and postural instability tend to be aggravated or
inadequately improved (Collomb-Clerc & Welter, 2015; Cossu & Pau, 2017).
In addition, gait response is substantially affected by contact localization
(Collomb-Clerc & Welter, 2015; Cossu & Pau, 2017; Fleury et al., 2016; Johnsen et al.,
2010; Tommasi et al., 2007). Johnsen et al. (2010) used magnetic resonance imaging to
confirm contact localization and found that contacts targeted to the dorsal STN
significantly improved UPDRS motor scores and quantitative measures of step length,
step velocity, and gait balance compared to ventral STN stimulation (Johnsen et al.,
2010). In addition, adverse effects such as FOG and gait hypokinesia were induced with
current spread into dorsal and anterior regions of the STN influencing the Zi and the
fields of forel, which paradoxically improved tremor, rigidity, and dyskinesia (Cossu &
Pau, 2017; Fleury et al., 2016; Tommasi et al., 2007). Improvement of dyskinesia may be
attributed to the influence of the pallidofugal fibres, which have been implicated with
dyskinesia relief (Hamani et al., 2004).
DBS has also been reported to elicit poor clinical outcomes of Parkinsonian gait;
for instance, the frequency of falling increases following DBS, especially when
comparing STN-DBS to GPi-DBS (Hausdorff, Gruendlinger, Scollins, O’herron, &
Tarsy, 2009). In rare and severe cases, DBS was reported to induce freezing or postural
deficits in patients with no history of these symptoms such as a dystonia patient, which
suggests an underlying cause directly related to DBS (Cossu & Pau, 2017; Tommasi et
al., 2007; Zauber, Watson, Comella, Bakay, & Metman, 2009). In less severe cases,
worsening of axial symptoms may be attributed to disease progression (Cossu & Pau,
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2017). Axial symptoms manifest in later stages and DBS is not disease protective;
therefore, induction or worsening of axial symptoms is plausible (Cossu & Pau, 2017;
Kalia & Lang, 2015). Inadequate alleviation of gait symptoms may also arise from
standard clinical practices that bias improvement of upper limb symptoms during DBS
implementation procedures such as contact selection. Furthermore, another profound
clinical enigma is the worsening or resistance of gait deficits that initially improved
following stimulation around five years following surgical implantation (Fasano et al.,
2010; Rodriguez-Oroz et al., 2005).
Unsatisfactory and inconsistent clinical outcomes of gait following DBS has
motivated researchers to explore different applications such as altering stimulation
parameters and assessing various targets. Commonly, frequency reduction is investigated
as reports state that low frequency stimulation may be beneficial for axial symptoms;
however, results have been inconsistent (Ramdhani, Patel, Swope, & Kopell, 2015;
Sidiropoulos et al., 2013). Among five patients, stimulation of 60 Hz improved the
worsening of L-DOPA responsive gait dysfunction that was worsened by stimulation at
130-185 Hz in all patients but one (Ramdhani et al., 2015). However, the largest sample
to date investigated the switch from 130 Hz to 80 Hz and did not find significant
differences in the total motor UPDRS scores or within the gait sub-score (Sidiropoulos et
al., 2013). In addition, the PPN is commonly investigated due its involvement in
locomotion (Fasano et al., 2015; Mazzone et al., 2005; Plaha & Gill, 2005; Stefani et al.,
2007; Takakusaki, 2017). Stefani et al. (2007) reported that PPN-DBS, STN-DBS, and
STN & PPN DBS provided significant reductions in the UPDRS motor scores compared
to “OFF” stimulation; however, PPN-DBS elicited significantly smaller reductions
compared to STN-DBS and simultaneous STN and PPN DBS (Stefani et al., 2007). In
addition, all three stimulation conditions elicited significant reductions in the axial subscores; however, no target was superior (Stefani et al., 2007). Overall, studies suggest
that PPN-DBS is unfeasible due to the difficulty of localizing the target and the
associated mild improvement of L-DOPA resistant gait deficits (Fasano, et al., 2015;
Mazzone et al., 2005; Plaha & Gill, 2005; Stefani et al., 2007).
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1.8 Rationale
The response of Parkinsonian gait deficits to STN-DBS is more variable compared to
other motor symptoms such as tremor. This phenomenon extends to L-DOPA responsive
gait symptoms as well, which are expected to improve. The variable responsiveness may
be attributed to the physiological and pathological features of gait. Physiologically, gait
facilitation relies on multiple interacting circuits within the musculoskeletal and nervous
system; namely, the cerebral cortex, basal ganglia, thalamus, cerebellum, brainstem, and
spinal cord. Pathologically, other Parkinsonian motor symptoms such as rigidity and
bradykinesia influence gait. Furthermore, clinical implementation procedures of DBS
including intraoperative contact localization and postoperative contact selection bias the
improvement of upper limb symptoms leading to an oversight of gait improvement. The
paradoxical worsening of gait despite improvement of tremor and dyskinesia when
current spreads into the anterior zona incerta and fields of forel with STN stimulation
demonstrates the difficulty of achieving gait alleviation in present clinical practice
(Fleury et al., 2016). Altogether this reasonably suggests that Parkinsonian gait therapy is
more sensitive to the contact localization and the resultant stimulation area.
The variable outcome of L-DOPA responsive gait deficits may be addressed by
CS, which fractionates current to fine-tune the stimulation field shape to provide more
regulatory control to improve neuroanatomical targeting. Current fractionations may be
tailored to contact localizations to systemize programming. Therefore, the spherical field
shape exhibited by unipolar stimulation can be shaped to reduce the radial spread to
improve the efficacy of the practical and clinical outcome. In a practical context, CS
reduces the TEED to each contact, which yields stimulation that is associated with the
reduction of power consumption, the IPG battery drainage rate, and tissue damage risk. In
a clinical context, CS should reasonably improve Parkinsonian gait deficits to a greater
degree compared to conventional single-contact stimulation through the improved
accuracy of neuroanatomical targeting and reducing tissue damage risk. The feasibility of
CS has been reported in the literature; the first human case study exhibited the ability of
CS to lower the efficacy threshold by providing symptom alleviation at the same
amplitude that single-contact stimulation yielded dyskinesia and inadequate symptom
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relief (Barbe et al., 2014). In addition, the first multicentre study reported that majority of
patients that initiated programming with single-contact stimulation switched to CS by the
one year follow up (Timmermann et al., 2015). However, a direct comparison of vertical
CS and conventional single-contact stimulation has yet to be performed especially in
context of practical and clinical effectiveness at the level of individual gait parameters
and overall ambulation using gait recording technology.

1.9 Hypothesis
It is hypothesized that CS is an effective programming technique that improves the
efficacy of the clinical outcome of Parkinsonian gait deficits and practical utility of the
DBS system compared to conventional, single-contact DBS.

1.10 Objectives
1. Chapter 1—To compare the clinical and practical efficacy of CS versus conventional
stimulation for Parkinsonian gait therapy by determining the differential effect on the
FAP score and the TEED value and to assess the correlation between the two measures.
2. Chapter 2—To determine the differential effect on individual gait parameters, as
measured by percent changes from baseline when comparing various stimulation settings
and models encompassing unilateral CS, bilateral CS, or non-CS (conventional singlecontact) DBS across increasing amplitudes in the TW.
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Chapter 2

2

Assessing the clinical and practical efficacy of
vertical current steering in deep brain stimulation
for Parkinsonian gait therapy

2.1

Introduction

2.1.1 Parkinson’s disease & deep brain stimulation
Following Alzheimer’s, Parkinson’s disease (PD) is the second most common
neurodegenerative disease (Bertram & Tanzi, 2005). Family history of PD or tremor
increases PD risk and age serves as the greatest risk factor as PD manifests with adult
onset (Kalia & Lang, 2015). When accounting for age, approximately 30% of neuronal
degeneration in the substantia nigra is associated with motor symptom onset, which
typically coincides with time of diagnosis (Cheng, Ulane, & Burke, 2010; Fearnley &
Lees, 1991). PD is characterized by the cardinal motor symptoms—bradykinesia, rigidity,
rest tremor, and postural and gait instability; the latter represents axial symptoms that
manifest later in disease and the remainder constitute appendicular symptoms that are
usually present around diagnosis (Gibb & Lees, 1988; Kalia & Lang, 2015).
Deep brain stimulation (DBS) is a secondary therapy to address disabling
dyskinesia and motor fluctuations from long-term use of Levodopa (L-DOPA) through
chronic transmission of electrical pulses to neural tissue through stereotactic localized
electrodes (Kalia & Lang, 2015; Tran, Vo, Frei, & Truong, 2018). DBS does not reverse
or cure disease pathology; however, it consistently relieves appendicular symptoms but
its effect on axial symptoms remains more elusive and variable (Cossu & Pau, 2017). The
dorsolateral subthalamic nucleus (STN) is somatotopically organized and associated with
sensorimotor function; suitably, it is the most common target for treating motor
symptoms. STN-DBS consistently alleviates appendicular symptoms and substantially
decreases the L-DOPA dose with some ceasing L-DOPA therapy, which is a unique
feature compared to other common targets such as the internal globus pallidus (Anderson,
Burchiel, Hogarth, Favre, & Hammerstad, 2005; Follett et al., 2010; Mahlknecht,
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Limousin, & Foltynie, 2015; Odekerken et al., 2013; Okun et al., 2009; Tankus et al.,
2017; Tewari, Jog, & Jog, 2016; Zahodne et al., 2009).
In present clinical practice, patients with severe or L-DOPA resistant postural and
gait instabilities are often excluded from DBS. Gait deficits attributed to rigidity and
bradykinesia such as reduced step size and gait velocity tend to respond to L-DOPA and
STN-DBS; however, deficits such as freezing of gait tend to worsen or manifest no
change (Allert et al., 2001; Cantiniaux et al., 2009; Collomb-Clerc & Welter, 2015;
Follett et al., 2010; Stolze et al., 2001; Vallabhajosula et al., 2015). Nonetheless, LDOPA responsive gait deficits still exhibit a more variable responsiveness to STN-DBS
compared to appendicular symptoms. Parkinsonian gait is influenced by bradykinesia and
rigidity and requires the extensive physiological integration of the musculoskeletal
system and the spinal cord, brainstem, cerebellum, basal ganglia, and cerebral cortex to
facilitate gait (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). Thus, the variable
responsiveness may be attributed to a greater sensitivity of gait therapy to the resultant
stimulation area and the clinical bias towards upper limb symptom improvement during
intraoperative contact localization and postoperative contact selection. Thus, gait
improvement may require greater regularity of the resultant stimulation field.

2.1.2 Advances in deep brain stimulation technology
Until recently, DBS systems have been conventionally voltage-controlled (VC), which
inconsistently deliver charge due to impedance fluctuations at the contiguous border
between the neural tissue and contact (Butson, Maks, & McIntyre, 2006; Miocinovic et
al., 2007). Thus, charge delivery may not match the programmed value, which renders
frequent programming adjustments due to inadequate stimulation of the target (Wagle
Shukla, Zeilman, Fernandez, Bajwa, & Mehanna, 2017). Notably, variable stimulation
may additionally account for the elusive effect of DBS on gait since its improvement may
be particularly sensitive to the resultant stimulation area.
Inadequate improvement of symptoms and the difficulty with programming in
complex cases prompted the development of current-controlled (CC) systems with
multiple independent current control (Butson et al., 2006; Lempka, Miocinovic, Johnson,
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Vitek, McIntyre, 2009; Wagle Shukla et al., 2017). CC devices adjust the voltage to
account for impedance fluctuations to ensure that charge distribution is consistent and the
current amplitude matches the programmed value (Butson et al., 2006; Wagle Shukla et
al., 2017). Multiple independent current control allows for individual manipulation of
current delivery from each contact as a separate entity; thus, the current distribution can
be divided among multiple contacts or contact segments of segmented leads to facilitate
vertical current steering (CS) (Butson & McIntyre, 2008). Division of the current
distribution is referred to as vertical CS or CS for short and serves as a systemized
technique to fine-tune the stimulation field for accurate neuroanatomical targeting
(Chaturvedi, Foutz, & McIntyre, 2012). Current division shapes the stimulation field
since the percentage of current stimulation is directly related to the electric field spread;
therefore, contacts stimulating with a greater percentage will exhibit a broader spread. In
addition, divisions are quantifiable; thus, algorithms associating divisions to contact
localizations may replace present, empirical approaches to DBS programming (Wagle
Shukla et al., 2017).
Presently, single-contact, unipolar stimulation is programmed in standard clinical
care; the resultant stimulation produces an approximate spherical field around the active
contact due to diffuse, radial current spread. The broad distribution of the electric field
increases side effect risk, which is particularly problematic for sub-optimally localized
electrodes but poses a risk regardless of localization at high amplitudes (Butson, Cooper,
Henderson, &, McIntyre, 2007; Deli et al., 2011; McIntyre, Mori, Sherman, Thakor, &
Vitek, 2004). Therefore, CS can reduce radial spread of conventional stimulation fields to
optimize neuroanatomical targeting to potentially address inadequate symptom
alleviation with present systems.

2.1.3 Therapeutic practicality of deep brain stimulation
In addition to adequate symptom alleviation, effective programming requires the
minimization of tissue damage risk and power consumption to prolong battery life of the
impulse generator (IPG). Tissue damage risk is based on charge density levels and is
calculated by dividing the product of current and pulse width by the surface area of the
contact (Kuncel & Grill, 2004). Thus, charge density is directly related to the current
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amplitude. Tissue damage associated with chronic DBS is minimal when the charge
density is considerably below recommended levels (Haberler et al., 2000; Kuncel & Grill,
2004). Minimal tissue damage is often a result of gliosis, which constitutes the
proliferation or hypertrophy of glial cells as a response to central nervous system damage.
In extreme cases, gliosis may result in scarring, which impedes axonal regeneration (Yiu
& He, 2006). Moreover, power usage is directly related to the IPG battery drainage rate,
which is influenced by programming factors such as the electrode geometry and
magnitude of stimulation parameters. Factors such as the system impedance, frequency of
programming changes, and total duration of stimulation also influence the battery life but
are harder to regulate. Nonetheless, minimal power consumption is pursued to maintain
battery life since need for IPG replacement may arise as early as three to five years postimplantation in non-rechargeable systems (Kuncel & Grill, 2004).
Unipolar electrode geometries designate the IPG as the anode and typically one
contact as the cathode; however, multiple contacts can serve as the cathode, which is
implemented with CS. Unipolar configurations are associated with a lower side effect and
therapeutic threshold; therefore, lower amplitudes provide symptom alleviation, which is
beneficial to reduce tissue damage risk and power consumption (Kuncel & Grill, 2004).
Bipolar configurations are conventionally implemented when single-contact, unipolar
stimulation is ineffective for symptom alleviation. At higher amplitudes, bipolar
configurations may be less likely to induce side effects since the stimulation field is more
confined. Both the anode and cathode are situated in the brain since one contact is set as
the anode and another is set as the cathode. However, power consumption is higher with
bipolar stimulation; thus, unipolar stimulation is still preferred to prolong battery life
(Butson et al., 2007; Deli et al., 2011; Kuncel & Grill, 2004; Volkmann, Moro, & Pahwa,
2006). Furthermore, frequency, pulse width, and current magnitudes must be
programmed with a compromise between adequate symptom alleviation and minimized
tissue damage risk and power usage to prolong battery life. For instance, low frequency
stimulation between 13-130 Hz may worsen bradykinesia and increasing the current
amplitude within the therapeutic window provides greater symptom alleviation but
stimulation at higher amplitudes expedites drainage of the IPG battery (Moro et al.,
2002).
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2.1.4 Total electrical energy delivered
The total electrical energy (TEED) delivered is an integrative measure incorporating
stimulation parameters and impedance, which are variables that influence the electric
field (Butson et al., 2006; Kuncel & Grill, 2004). The concept was first introduced by
Moro and colleagues; however, it was later modified by Koss and colleagues using
derivations with standard physics equations such as Ohm’s law (Koss, Alterman, Tagliati,
& Shils, 2005; Moro et al., 2004). The TEED equation suggested by Koss and colleagues
is as follows:
TEED1sec =

(𝑣𝑜𝑙𝑡𝑎𝑔𝑒)2 × (𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦) × (𝑝𝑢𝑙𝑠𝑒 𝑤𝑖𝑑𝑡ℎ)
𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒

× 1𝑠𝑒𝑐𝑜𝑛𝑑.

TEED has been studied in the context of practical efficacy through its effect on
IPG battery life (Bin-Mahfoodh, Hamani, Sime, & Lozano, 2003; Helmers et al., 2018;
Niemann, Schneider, Kühn, Vajkoczy, & Faust, 2018; van Riesen et al., 2016). In
addition, the TEED measure integrates stimulation parameters such as current and pulse
width, which are used to calculate the charge density of stimulation that is associated
with tissue damage risk (Kuncel & Grill, 2004). Therefore, the TEED measure may be
used to reflect tissue damage risk as well. Pulse width and TEED are directly related to
the IPG battery drainage rate; therefore, stimulation with lower TEED and pulse width
values delay battery depletion and need for surgical replacement of the IPG (van Riesen
et al., 2016). Faster drainage results in an earlier and more probable need for reimplantation, which is a minor surgical procedure; however, surgical replacements of the
IPG are an elective procedure; thus, are often delayed due to availability of surgical staff
and operating rooms. In addition, risk of inadequate symptom alleviation following IPG
replacement is common and requires tedious, manual re-selection of stimulation
parameters, which is laborious due to the lack of established protocols (Allert, Kirsch,
Weirich, & Karbe, 2009; Wagle Shukla et al., 2017). Allert and colleagues reported that
around 20% of cases of inadequate symptom alleviation, following IPG replacement, are
attributed to idiopathic reasons that are not related to evident reasons such as errors in
hardware restoration, which makes programming particularly difficult (Allert et al.,
2009). In addition, Pepper et al. (2013) reported that the infection rate was more than
three times higher than the initial implantation (Pepper et al., 2013).
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2.1.5 Rationale
CS is a stimulation technique that may account for clinical and practical logistics of DBS.
CS shapes the stimulation field, which reduces the diffuse radial spread of the
conventional spherical field to improve neuroanatomical targeting and the resultant
clinical outcome. In addition, CS should reduce the TEED through current fractionation,
which ultimately decreases power consumption and the IPG battery drainage rate to
improve the practical outcome. Reducing the TEED additionally improves the clinical
outcome by decreasing the side effect and tissue damage risk. Altogether, it is reasonable
to suggest that CS may address the variable improvement of L-DOPA responsive gait
deficits in a feasible systemized manner.
L-DOPA responsive gait deficits exhibit a more inconsistent response to STNDBS compared to other motor symptoms such as tremor. The varying response may be
attributed to the extensive integration that facilitates gait physiologically, the influence of
bradykinesia and rigidity in PD, and the bias of upper limb symptom improvement during
DBS implementation. Thus, tailoring current fractionations to contact localizations may
minimize current spread and improve the accuracy of targeting the array of interacting
circuits that regulate gait within the cerebral cortex, thalamus, basal ganglia, brainstem,
cerebellum, and spinal cord. In addition, the ability to employ separate fractionation
programs may be implemented to alleviate appendicular and axial symptoms to overcome
the bias towards upper limb symptom improvement during intraoperative contact
localization and postoperative contact selection. The predicted clinical benefit should be
accompanied by an improved practicality of the DBS system through reduction of the
TEED value.
The feasibility of CS has already been reported in the literature; the first human
case study found that CS reduces the efficacy threshold and the first multicentre study
reported that majority of patients initiated programming with single-contact stimulation
but switched to CS by the one year follow up (Barbe, Maarouf, Alesch, & Timmermann,
2014; Timmermann et al., 2015). However, comparisons of CS to conventional singlecontact stimulation regarding the outcome of Parkinsonian gait deficits and the practical
outcome of the DBS system in the context of power consumption measured by the TEED
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have yet to be investigated. In addition, distinct to other studies, the present investigation
assesses gait with quantitative measures provided by gait recording technology and
analysis software, which eliminates examiner bias and variation associated with the
Unified Parkinson’s Disease Rating Scale (UPDRS)—the clinical standard that provides
ordinal measures.

2.1.6 Objectives
1. To assess the effect of CS and conventional single-contact stimulation on
functional ambulation performance (FAP) scores and TEED values individually.
2. To determine and compare the correlation between FAP and TEED in CS and
conventional single-contact stimulation.

2.1.7 Hypotheses
For the first objective, it is hypothesized that CS will improve FAP scores to a greater
degree and TEED values will be reduced when compared to single-contact stimulation.
For the second objective, it is hypothesized that TEED values and FAP scores will be
more positively correlated when implementing CS, which exhibits greater practical and
clinical efficacy through yielding higher FAP scores at lower TEED values.

2.2 Methods
2.2.1 Study sample & inclusion and exclusion criteria
The present investigation was approved by the Human Subjects Research Ethics Board
(REB) at Western University (REB #108453). Patients were selected based on clinical
standards. Inclusion criteria included: diagnosis of idiopathic PD with L-DOPA
responsive motor symptoms as assessed with the standard L-DOPA challenge test,
disabling motor fluctuations and dyskinesia, and absence of dementia or psychiatric
abnormalities confirmed by neuropsychological testing (Albanese et al., 2001).
Additionally, participants were excluded based on: history of brain surgery, previous
implantation of a cardiac pacemaker, overall poor health, and tendency to exhibit lack of
compliance. Ultimately, nine participants provided informed consent; however, two
patients were withdrawn for adverse health concerns unrelated to the study or ineligibility
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due to implantation with a DBS system unable to perform CS. The analyzed sample of
seven were diagnosed with idiopathic PD for an average duration of 12.5 years and
included three males and four females with an average age of 61.

2.2.2 Clinical Procedures—surgical implantation and contact
selection
All DBS devices were implanted by a surgeon trained in functional neurosurgery
practicing at University Hospital, London Health Sciences Centre (London, ON, CA);
electrodes and the IPG were implanted within the same day unless complications arose.
All participants were implanted with the VerciseTM PC IPG and the CartesiaTM
Directional leads or the VerciseTM IPG and the associated leads, which are equipped with
multiple independent current control (Boston Scientific, Valencia, CA, USA). Local
anesthesia was utilized for electrode implantation; however, the participant was
subsequently under general anesthesia for IPG implantation. Pre-surgical magnetic
resonance imaging identified the neuroanatomical positioning of the STN through
standard stereotactic coordinates based on the anterior commissure (AC) and posterior
commissure (PC). Standardly the dorsolateral STN is targeted following these
guidelines—4.0 mm ventral to the AC-PC plane, 2.0 mm posterior to the midcommissural point, and 12.0 mm lateral to the midline of the plane (Rabie, Verhagen
Metman, & Slavin, 2016). Intraoperatively, a stereotactic Leksell frame mounted the
head and a computed tomography scan was used to merge stereotactic coordinates from
the magnetic resonance image to the surgical computer. The STN positioning in the
dorsal to ventral axis was confirmed with recordings from five microelectrodes
temporarily implanted to denote a central, anterior, posterior, medial, and lateral channel.
Each microelectrode detected spike potentials denoting signatures of nuclei as it traversed
ventrally in the dorsal to ventral axis. In addition, the microelectrodes provided
stimulation to assess the clinical outcome based on localization. The implantation
trajectory of the therapeutic electrode was determined by the microelectrode that
exhibited the most extensive STN spike signature and provided the greatest improvement
of tremor and rigidity.
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Two contact reviews were performed to select two contacts in the left and right
STN for implementation of CS. The initial contact review was performed when the IPG
was turned on, approximately one month following surgical implantation and the second
review was performed around two weeks after the initial contact review. A unipolar
contact review of all contacts was performed for the initial review to identify the
individual contact eliciting the widest TW; however, the second contact review paired the
initial contact, determined by the previous review, with all the other contacts to find the
pair of contacts that elicited the widest TW. During the second contact review, each
contact of the pair was stimulated with 50% of the current. The TW was defined by the
upper and lower limit or the side effect and efficacy threshold, respectively. To determine
the TW, the current amplitude was increased with increments of 0.5 mA until side effect
manifestation. Subsequently, the previous amplitude was programmed and increments of
0.1 mA confirmed the exact side effect threshold. UPDRS motor items including: finger
taps, upper limb rigidity, and rest tremor served as the primary measures of symptom
improvement but postural tremor was assessed additionally for some patients. Blurry
vision, face pulling, dystonia, dysarthria, and any uncomfortable, intolerable sensations
were noted as side effects. Namely, dystonia describes twisting or atypical fixed postures
attributed to continuous or repetitive muscle contractions (Magrinelli et al., 2016). After
the IPG was turned on, the patient accustomed to stimulation with an amplitude of 0.5
milliamperes (mA) until the start of the CS investigations. The frequency and pulse width
were consistent throughout the entire investigation as 130 Hz and 60 µs, respectively.
Notably, one patient was stimulated with a pulse width of 90 µs.

2.2.3 Study Design
CS investigations began immediately after the second contact review, which was
approximately six weeks following surgical implantation. Bilateral applications of CS
were compared to conventional, single-contact stimulation among eight investigational
settings that represented bilateral CS or bilateral non-CS stimulation models (Table 1).
CS was implemented with unipolar stimulation with current divisions of 50/50 and 70/30
between two contacts. Notably, segmented leads (CartesiaTM Directional leads) were
always stimulated in the ring mode; therefore, all three segments were active and current
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was divided equally. All investigational settings were repeated over four consecutive
weeks such that the amplitude was increased by approximately 20% each week (Table 2).
Investigational settings were randomized across patients; however, the order remained
consistent throughout the consecutive weeks for each participant. Following the
programming of each investigational setting, a 25-minute washout period was enforced
before the subsequent gait assessment.
Table 1: Investigational settings of bilateral CS and bilateral non-CS stimulation.
A) represents the ventral contact and B) represents the dorsal contact.
Setting Number

Stimulation Model

Left STN

1
2
3
4
5
6
7
8

Bilateral non-CS
Bilateral non-CS
Bilateral non-CS
Bilateral non-CS
Bilateral CS
Bilateral CS
Bilateral CS
Bilateral CS

A): 100% B): 0%
A): 100% B): 0%
A): 0% B): 100%
A): 0% B): 100%
A): 70% B): 30%
A): 70% B): 30%
A): 50% B): 50%
A): 50% B): 50%

Right STN

A): 100% B): 0%
A): 0% B): 100%
A): 100% B): 0%
A): 0% B): 100%
A): 70% B): 30%
A): 50% B): 50%
A): 70% B): 30%
A): 50% B): 50%

Table 2: Stimulation amplitudes with respect to the CS investigational week.
Week refers to the CS investigational week.
Week
1
2
3
4

Current Amplitude
(Therapeutic windowminimum) + (Therapeutic windowdifference *0.2)
(Therapeutic windowminimum) + (Therapeutic windowdifference *0.4)
(Therapeutic windowminimum) + (Therapeutic windowdifference *0.6)
(Therapeutic windowminimum) + (Therapeutic windowdifference *0.8)

2.2.4 Gait Assessments
Gait assessments were recorded using a 0.61 metre by 6.1 metre ZenoTM walkway
(ProtoKinetics, Peekskill, NY) without shoes, assistive walking devices (verbal cues,
splints, or orthoses), or ambulatory aids (canes, crutches, or walkers) (Gouelle, 2014).
Standard, non-skid hospital socks were worn to reduce fall risk when walking adjacent to
the ZenoTM walkway. Forwards walking was assessed at a self-selected pace, as
participants were instructed to walk at their daily ambulatory pace. Subjects arose from a
seated position to walk for five continuous loops in a clockwise direction to maintain
speed through gradual turns and to allow recordings in a uniform direction. Ambulation
away from the initial seated position was always recorded on the pressure sensitive
walkway; however, walking towards the start position was exercised off the walkway.
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2.2.5 Extraction and calculation of the TEED value
TEED value calculations for each investigational setting at each stimulation amplitude
required extraction of the associated current amplitude and impedance. Frequency and
pulse width remained at 130 Hz and 60 s (and 90 s for one patient)— respectively.
Current amplitude corresponded to the investigational week with an increasing magnitude
throughout the consecutive weeks as displayed in Table 2. Impedance values for each
active contact were retrieved from a single time point at least nine weeks following
surgical implantation to ensure that impedance values were relatively consistent. The
impedance between each individual contact and the IPG was recorded since a unipolar
electrode geometry was implemented. Notably, impedance values for each individual
segment and the IPG were obtained for segmented levels of directional leads.
TEED values were calculated for each individual contact following the
International System of Units; therefore, current was converted from milliamperes to
amperes and pulse width was converted from microseconds to seconds. Using Ohm’s
law, the voltage component was replaced with current and all TEED calculations
followed this equation:
TEED1sec = (𝑐𝑢𝑟𝑟𝑒𝑛𝑡)2 × (𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒) × (𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦) × (𝑝𝑢𝑙𝑠𝑒𝑤𝑖𝑑𝑡ℎ).
The current amplitude for each contact was computed based on the current
fractionations for each respective setting. For instance, if the current division was 50/50,
the amplitude was divided equally among the two contacts. Furthermore, stimulation in
the ring mode approximated all segmented contacts to receive equal percentages of
current. Therefore, 50% of the current stimulating a segmented level would approximate
each segment to be stimulated with 50% of the amplitude divided by 3. TEED for the
segmented levels of the CartesiaTM Directional lead required summation of individual
TEED values for each segmented contact. For instance, the TEED value for the
segmented level of contacts 13,14, and 15 was calculated as TEED131415 = TEEDcontact 13 +
TEEDcontact 14 + TEEDcontact 15. Following this rule, setting TEED values were calculated
by summating TEED values of both contacts of the left and right lead (Setting TEED =
TEEDLEFTContactA + TEEDLEFTContactB + TEEDRIGHTContactA + TEEDRIGHTContactB).
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2.2.6 Functional ambulation performance calculation
The ZenoTM walkway recorded foot falls during the walking assessments with embedded
sensors sensitive to pressure. The ProtoKinetics Movement Analysis Software (PKMAS,
Havertown, PA) automatically calculated the FAP score. The ZenoTM walkway and
PKMAS are validated through comparisons to the established GAITRite system
(Egerton, Thingstad, & Helbostad, 2014; Vallabhajosula, Humphrey, Cook, & Freund,
2017). Overall ambulation was assessed with the FAP score, which was computed
automatically by PKMAS. The score was calculated by deducting points for deviations
from a healthy gait from a maximal score of 100 among four categories (Gouelle, 2014).
For the left and right step functions category, 22 points were subtracted for abnormal
values of step time and abnormal ratios of step length and velocity to leg length for the
left and right side separately (Gouelle, 2014). The step length to leg length ratio
differentials category assessed differences between the left and right ratios to identify
abnormal step length asymmetries, which warranted deductions up to eight points
(Gouelle, 2014). A maximum of eight points were deducted for a base that was too wide
or narrow compared to the clinically deemed healthy range for the dynamic base of
support category, and five points were deducted for use of ambulatory aids and assistive
devices (Gouelle, 2014). Notably, scores between 95 to 100 represent gait in a nondiseased adult population (Gouelle, Mégrot, Presedo, Penneçot, & Yelnik, 2011).

2.2.7 Data and Statistical Analyses
All statistical analyses were performed by GraphPad Prism 6.00 (La Jolla, CA, USA)
using an alpha criterion of ≤ 0.05. Data were removed if found to be below the difference
of the first quartile and the interquartile range multiplied by 1.5, above the sum of the
third quartile and the interquartile range multiplied by 1.5, or based on clinical discretion.
Three clinical outliers were identified as gait was skewed by dyskinesia or dystonia.
Normality was assessed using the Shapiro—Wilk test and a two-tailed, Wilcoxon
matched-pairs signed-rank test assessed the differential effect on FAP and TEED
individually. A Spearman, two-tailed, correlation was performed to identify the potential
correlation between the FAP and TEED values with the FAP score set as the dependent
variable. Lastly, slopes of the linear trend (line of best fit) of the regression between FAP
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and TEED values in both stimulation conditions were extracted sing Excel. Subsequently,
means of the slopes for each participant in both stimulation models were assessed for
differences using a two-tailed, paired, Student’s t-test.

2.3 Results
Significant differences were found between the average TEED values elicited by the two
stimulation models (p < 0.0001) (Figure 6a); however, the FAP score means of both
stimulation models were not significantly different (p = 0.7861) (Figure 6b). TEED
values elicited by bilateral CS stimulation were significantly lower than those elicited by
stimulation without CS (Figure 6a). Furthermore, no correlation was found between the
FAP and TEED values in the bilateral non-CS stimulation condition (r = 0.132, p =
0.053) (Figure 7a). However, a positive correlation was found between FAP and TEED in
the bilateral CS stimulation condition (r = 0.174, p = 0.011) (Figure 7b). The slope for the
linear trend line of the correlation was steeper in the bilateral CS stimulation condition;
specifically, the values were found to be 0.1839 and 0.428 for the bilateral non-CS and
bilateral CS stimulation condition, respectively (Figure 7). The slopes averaged across all
patients were significantly lower with the bilateral CS stimulation model; specifically
averages of 0.0639 and 0.5683 in the bilateral non-CS and bilateral CS stimulation model
were found, respectively (p = 0.0435) (Figure 8; Table 3).
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Figure 6: The effect of CS and non-CS stimulation on FAP and TEED values.
Means of the a) TEED values multiplied by 100000 and b) FAP values evaluated during
normal pace walking in bilateral non-CS and bilateral CS stimulation conditions
including all stimulation amplitudes (around 20%, 40%, 60%, and 80% of the TW).
Boxplots with N=7; solid horizontal lines represent the median and the upper and lower
whiskers represent the maximum and minimum values, respectively. a) TEED values on
average were significantly lower in the bilateral CS stimulation condition compared to
the bilateral non-CS stimulation condition (****, p < 0.0001; two-tailed, Wilcoxon
matched-pairs signed rank test) b) FAP scores on average were not significantly different
in the two stimulation conditions (p = 0.7861; two-tailed, Wilcoxon matched-pairs signed
rank test).

67

Figure 7: Correlation between FAP and TEED for CS and non-CS stimulation.
Correlation between TEED and FAP as the independent and dependent variable,
respectively; evaluated during normal pace walking and stimulation a) without CS and b)
with CS at all investigative amplitudes (around 20%, 40%, 60%, and 80% of the TW)
with N=7. TEED values represented were multiplied by 100000. a) No correlation was
found; the slope of the linear trend line was found to be 0.1839 (p = 0.0530, r =0.1320;
two-tailed, Spearman correlation). b) Positive correlation was found with the slope of the
linear trend line being 0.428 (*, p<0.05, r =0.1740; two-tailed, Spearman correlation).
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Stimulation Condition

Figure 8: Comparison of the slope of the linear trend of the correlation between
FAP and TEED in CS and non-CS stimulation.
Slope of the correlation between FAP and TEED with FAP as the dependent variable;
evaluated during normal pace walking with and without CS across all investigative
amplitudes (around 20%, 40%, 60%, and 80% of the TW). Means represented  SD with
N=7. Slope of the bilateral CS condition was significantly greater than the slope of the
bilateral non-CS condition (*, p<0.05; two-tailed, Paired student’s t-test).
Table 3: Slopes of the linear trend line of the correlation between FAP and TEED.
Participant Code
BSC-01
BSC-02
BSC-03
BSC-05
BSC-06
BSC-07
BSC-08
AVERAGE

Bilateral non-CS
0.0633
-0.1647
-0.0416
0.483
-0.0599
0.1749
-0.0077
0.0639

Bilateral CS
0.1686
1.0886
0.1565
1.4016
-0.0194
0.2115
0.971
0.5683

2.4 Discussion
TEED was minimized when CS was employed but no differential effect was found on the
FAP score when comparing the two stimulation types, which partially supports the
hypothesis (Figure 6). The average TEED elicited by the bilateral CS stimulation settings
was significantly lower than the average TEED elicited by the non-CS settings (Figure
6a); however, there was no significant difference between the FAP values in the two
stimulation conditions (Figure 6b). CS minimizes the TEED to an individual contact
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through current fractionation; thus, the TEED and charge delivery is divided between
multiple active contacts rather than involving a single-contact. Raw TEED values
exhibited lower magnitudes with CS; for instance, 1.83 x 10^-4 (A2•  • Hz • s) and
9.03 x 10^-5 (A2•  • Hz • s) yielded TEED scores of setting one and six, a bilateral
non-CS and bilateral CS setting, respectively (Table 1). TEED reduction may suggest the
benefit of employing CS to reduce power consumption, which prolongs battery life and to
minimize risk of current spread into non-intended neural structures that may induce side
effects or tissue damage (Kuncel & Grill, 2004; Henderson et al., 2002; Yiu & He, 2006;
van Risen et al., 2016).
TEED was reported to be inversely related to the drainage rate of the IPG battery;
therefore, reduced TEED helps delay the need for surgical IPG re-implantation, which
has been reported to elicit a higher infection rate compared to the initial implantation and
often requires a greater frequency of programming changes to address inadequate
symptom alleviation (Allert et al., 2009; Pepper et al., 2013). Allert and colleagues
reported that 20% of patients experience sub-optimal symptom alleviation despite
accurate restoration of the hardware and programming with parameters that provided
alleviation before IPG replacement (Allert et al., 2009). Notably, this may not be a
substantial issue for multiple independent current controlled systems since it was
postulated that inadequate programming may be attributed to a change in the electrode
impedance, which conventional VC systems poorly address (Lempka et al., 2009; Wagle
Shukla et al., 2017). In addition, tissue damage risk has been associated with charge
density levels, which is directly related to the current amplitude stimulating the contact
(Kuncel & Grill, 2004). Therefore, the reduced TEED to each contact additionally
decreases the charge density and tissue damage risk since current fractionations reduce
the current delivered to each contact. Arguably, charge delivery from multiple contacts
may interact and superimpose; however, the present methodology cannot confirm this. In
addition, severe dyskinesia that interfered with gait assessment manifested with singlecontact stimulation rather than CS. Nonetheless it is necessary to reduce the charge
density because chronic stimulation below the limit can still induce gliosis, which in
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extreme cases may result in inhibition of axonal regeneration and loss of function
(Kuncel & Grill, 2004; Yiu & He, 2006).
The FAP and TEED values in the bilateral non-CS stimulation condition
exhibited no correlation (Figure 7a); however, a positive correlation was reported for the
bilateral CS stimulation condition (Figure 7b). FAP scores were directly related to TEED
values when CS was implemented; thus, gait performance improved as the current
amplitude increased within the patients’ TW. This supports the hypothesis that TEED
values would be correlated to FAP scores with CS. The positive correlation may be
attributed to all the administered amplitudes being within the TW. The enhanced
therapeutic effect associated with amplitude increases within the TW acts synonymously
to a higher dosage of oral pharmacotherapy within the patients’ tolerance. Lack of
correlation exhibited by non-CS stimulation may represent the response variability when
stimulating from one contact (Wagle Shukla et al., 2017). Conventional stimulation is
more sensitive to contact localization and the resultant stimulation area since singlecontact stimulation is associated with a greater radial spread that arises from a single part
of the electrode (Kuncel & Grill, 2004). However, radial current spread is reduced with
CS since the electric field is more elongated as a result of current fractionation between
multiple active contacts. Therefore, this suggests that CS requires less programming
adjustments compared to single-contact stimulation, which is particularly laborious since
there are no established protocols for programming (Wagle Shukla et al., 2017). Thus, the
positive correlation of FAP and TEED depicts the clinical effectiveness of CS to improve
gait as current amplitude increases within the TW, which opposes the more variable
outcome of gait with non-CS stimulation, which failed to exhibit a correlation between
FAP and TEED (Figure 7).
Furthermore, the slope for the linear trend line between the FAP and TEED values
was steeper with CS, which means that higher FAP scores were elicited at lower TEED
values (Figure 7). On average, implementing CS bilaterally elicited a significantly steeper
slope compared to stimulation without CS (Figure 8; Table 3). The slope reflects the
clinical and practical efficacy; therefore, a steeper slope suggests that CS is more
effective in clinical and practical terms because higher FAP scores—better gait
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performance—were elicited at lower TEED values. TEED reduction exhibits practical
efficacy since it is associated with reduced power consumption, side effect risk, tissue
damage risk, and IPG battery drainage rate. However, as previously mentioned, CS
cannot be concluded to improve gait to a greater degree compared to stimulation without
CS since FAP scores were not significantly different when comparing the two stimulation
types (Figure 6b).
The FAP score integrates gait velocity and step length as ratios of leg length and
measures of dynamic support; in the literature, gait velocity, step/stride length, and total
double support time are commonly reported to improve following STN-DBS (Allert et
al., 2001; Cantiniaux et al., 2009; Faist et al., 2001; Ferrarin et al., 2002; Ferrarin,
Rizzone, Lopiano, Recalcati, & Pedotti, 2004; Ferrarin et al., 2005; Gouelle, 2014;
Johnsen, Sunde, Mogensen, & Østergaard, 2010; Krystkowiak et al., 2003; Stolze et al.,
2001; Vallabhajosula et al., 2015; Xie, Krack, Benabid, & Pollak, 2001). Accordingly,
the FAP score improvement elicited by CS is comparable to conventional DBS, which is
an established therapy for L-DOPA responsive gait parameters (Collomb-Clerc & Welter,
2015; Wagle Shukla et al., 2017).
These findings support the utility of CS regarding its clinical and practical
effectiveness since it can elicit the same FAP scores but at lower TEED values; therefore,
gait improvement was achieved at lower current amplitudes with reduced power
consumption. The first case study of CS reported similar findings; in particular, symptom
alleviation without side-effect induction was elicited at the same amplitude single-contact
stimulation elicited dyskinesia with sub-optimal symptom alleviation (Barbe et al., 2014).
Thus, among patients with L-DOPA responsive gait, CS may be implemented to improve
ambulation with lower TEED values, which minimizes power consumption, tissue
damage and side effect risk, IPG battery drain rate, and need for IPG replacement.

2.4.1 Limitations
The primary limitation to this scientific investigation is the lack of a direct measure of
battery life. All participants were subject to both types of stimulation; therefore,
recruitment of novel participants subdivided into those strictly receiving CS or non-CS
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stimulation should be compared for the time it takes for the battery to drain for a more
accurate assessment. Another major limitation of the study is related to the integrated
analysis of segmented contacts and non-segmented contacts. TEED values for segmented
contacts compared to conventional ring-style contacts were inherently smaller because
current is additionally fractionated between the segments. Thus, segmented contacts
stimulate with a lower current and exhibit a lower TEED value especially since the
current component of the TEED equation is squared. However, due to the small sample
all types of electrodes were analyzed together; to address this limitation, future analysis
should analyze segmented contacts and non-segmented contacts separately.
Notably, conventional stimulation was modelled with single-contact stimulation
with CC devices; thus, non-CS stimulating settings may not be a true representative of
conventional stimulation, which employs single-contact stimulation with VC devices that
are susceptible to variable charge delivery. Furthermore, TEED values may not precisely
reflect the administration of the setting at the given time point since impedance measures
were obtained from a single time point following the end of the investigation. The
literature suggests that impedance may decrease during stimulation; therefore, the
impedance utilized for the calculation may not accurately reflect the impedance during
each stimulation setting (Lempka et al., 2009).
In addition, a 25-minute washout period was implemented based on the
recommendation of the supervising movement disorder specialist; however, the literature
states that the period required for adequate wash-out of STN-DBS varies across
participants and is inversely related with disease duration (Cooper, McIntyre, Fernandez,
& Vitek, 2013). Therefore, the wash-out period implemented in the present investigation
may not be adequate for some patients. Furthermore, unequal fractionations of 70%/30%
modelled CS but the counterpart was not investigated; therefore, the more ventrally
located contact was biased with a greater proportion of current. Thus, future studies
should personalize fractionations to contact localizations allowing for fewer sessions
spread out by a greater amount of time allowing for a more appropriate wash-out period,
which reduces the confound of residual effects induced by other settings.
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2.4.2 Conclusions
CS was concluded to exhibit greater practical efficacy through TEED reduction;
however, CS exhibited a similar clinical outcome for improvement of Parkinsonian gait
deficits compared to conventional DBS. Thus, CS may be applied to DBS to reduce
TEED values and to improve L-DOPA responsive gait parameters to a degree that is
comparable to present clinical standards of DBS. The ability to stimulate with lower
TEED values reduces power consumption, tissue damage and side effect risk, IPG battery
drainage rate, and need for IPG replacement.
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Chapter 3

3

Assessing the clinical outcome of spatio-temporal
gait parameters when utilizing vertical current
steering in deep brain stimulation for Parkinsonian
gait therapy

3.1 Introduction
3.1.1 Parkinson’s disease
With a prevalence of two per one thousand individuals affected, Parkinson’s disease (PD)
is the second most common neurodegenerative disease of adult onset (Tysnes &
Storstein, 2017). Pesticide exposure, age, and family history of PD or tremor serve as the
greatest environmental, non-environmental, and genetic risk factors for PD (Kalia &
Lang, 2015; Noyce et al., 2012). When accounting for age, motor symptom onset is
associated with an approximate neuronal loss of 30% in the substantia nigra and
neurodegeneration is postulated to also occur in the pedunculopontine nucleus (PPN)
(Cheng, Ulane, & Burke, 2010; Fearnley & Lees, 1991; Rinne, Ma, Lee, Collan, &
Röyttä, 2008; Zweig, Jankel, Hedreen, Mayeux, & Price, 1989). Appendicular symptoms
such as bradykinesia, tremor, and rigidity are usually present around diagnosis; however,
axial symptoms—including speech, postural, and gait deficits— tend to manifest in later
disease stages (Kalia & Lang, 2015). Dopaminergic degeneration manifests
asymmetrically; thus, appendicular symptoms commonly develop unilaterally and disease
progression elicits bilateral presentation of appendicular and axial symptoms
(Hornykiewicz, 1966; Kalia & Lang, 2015). However, it is common for motor symptoms
of the side of onset to remain more severe, even axial symptoms may present
asymmetrically as gait deficits typically manifest with a greater reduction of ground
clearance or arm swing of the more affected side (Karádi et al., 2015).
Deep brain stimulation (DBS) provides chronic delivery of electrical pulses
through stereotactic localization of electrodes, which addresses disabling dyskinesia and
motor fluctuations from long-term use of Levodopa (L-DOPA) (Kalia & Lang, 2015).
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The dorsolateral region of the subthalamic nucleus (STN) associated with sensorimotor
function is most commonly targeted for PD therapy since it consistently alleviates
appendicular symptoms, addresses motor complications,, and substantially decreases the
L-DOPA dose with some ceasing L-DOPA use (Anderson, Burchiel, Hogarth, Favre, &
Hammerstad, 2005; Follett et al., 2010; Mahlknecht, Limousin, & Foltynie, 2015;
Odekerken et al., 2013; Okun et al., 2009; Tankus et al., 2017; Tewari, Jog, & Jog, 2016;
Zahodne et al., 2009). DBS consistently relieves appendicular symptoms but its effect on
gait deficits remains more elusive and variable (Collomb-Clerc & Welter, 2015; Cossu
& Pau, 2017).

3.1.2 Motor control involving the basal ganglia
Dominance of the left hemisphere has been associated with motor control while
dominance of the right hemisphere has been associated with spatial and proprioceptive
processing (Hugdahl, 2011; Serrien, Ivry, &, Swinnen, 2006). Left cerebral hemispheric
dominance in motor control has been reported during assessments of unilateral and
bilateral movements (Barber et al., 2011; Scholz et al., 2000; Volkmann, Schnitzler,
Witte & Freund, 1998). A functional magnetic resonance imaging study demonstrated a
correlation between the magnitude of connectivity of the motor circuit in the left
hemisphere (motor cortex, thalamus, putamen, cerebellum, and supplementary motor
cortex) and motor abilities of right-handed children (Barber et al., 2011). In addition,
Voos and colleagues reported that stroke patients with left sided lesions exhibit gait
impairments of greater severity with longer recovery periods compared to patients with
right sided lesions (Voos & Ribeiro do Valle, 2008).
The predominant role of the left hemisphere in motor control has also been
exhibited in the basal ganglia (BG), which is postulated to be attributed to handedness
(Scholz et al., 2000). Assessments of unilateral and bilateral movements of the upper and
lower limbs exhibited greater activation of the BG and motor cortex in the left
hemisphere with the BG exhibiting a greater asymmetric activation (Scholz et al., 2000).
Accordingly, it has been suggested that asymmetry of the nigrostriatal dopaminergic
network and the globus pallidus (GP) in healthy individuals and PD patients may allude
to lateralization of motor control and performance (de la Fuente-Fernández, Kishore,
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Calne, Ruth, & Stoessl, 2000; Glick, Ross & Hough, 1982; Kish, Shannak, &
Hornykiewicz, 1988). Namely, the putamen and internal globus pallidus (GPi) have been
implicated in facilitating movement amplitude, direction, speed, and timing (O’boyle,
Freeman, & Cody, 1996; Yin, 2014).

3.1.3 Parkinsonian Gait
In present clinical practice, patients with severe or L-DOPA resistant postural and gait
deficits are often excluded from DBS. Gait deficits may be categorized based on stage of
onset and responsiveness to L-DOPA and STN-DBS, which are therapeutic interventions
that elicit similar clinical outcomes (Welter et al., 2002). Axial motor symptoms that are
non-responsive to L-DOPA develop around 10 to 15 years post-diagnosis and include
freezing of gait (FOG) and spontaneous falls that tend to worsen or exhibit no change
following STN-DBS (Kalia & Lang, 2015). L-DOPA resistant gait deficits are postulated
to be predominantly controlled by cholinergic brainstem locomotor regions such as the
PPN (Collomb-Clerc & Welter, 2015; Rinne et al., 2008; Takakusaki, 2017; Zweig et al.,
1989). On the other hand, rigidity and bradykinesia contribute to a hypokinetic gait that
manifests earlier than L-DOPA resistant gait deficits (Magrinelli et al., 2016). A
hypokinetic gait yields reductions in amplitude, rhythm, timing, and velocity, which are
gait features that tend to be L-DOPA responsive and associated with at least initial
improvement following STN-DBS (Beradelli, Rothwell, Thompson, & Hallett, 2001;
Collomb-Clerc & Welter, 2015). For instance, significant improvements in gait velocity
and step or stride length are most commonly reported in analyses of the effect of STNDBS on spatio-temporal gait parameters (Allert et al., 2001; Cantiniaux et al., 2009; Faist
et al., 2001; Ferrarin et al., 2002; Ferrarin, Rizzone, Lopiano, Recalcati, & Pedotti, 2004;
Ferrarin et al., 2005; Johnsen, Sunde, Mogensen, & Østergaard, 2010; Krystkowiak et al.,
2003; Stolze et al., 2001; Vallabhajosula et al., 2015; Xie, Krack, Benabid, & Pollak,
2001). Nonetheless, gait improvement exhibits a more variable responsiveness to STNDBS compared to appendicular symptoms, which may be attributed to the complex
integration required for gait facilitation (Cossu & Pau, 2017).
Gait in PD has a physiological and pathological context unlike motor symptoms
such as tremor, which manifests solely due to pathology. In PD, gait deficits are
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influenced by other symptoms including bradykinesia and rigidity (Collomb-Clerc &
Welter, 2015). However, gait facilitation additionally relies on the physiological
integration between the musculoskeletal system and the spinal cord, brainstem,
cerebellum, BG, and the cortex to regulate postural muscle tone to sustain an upright
position and to bilaterally coordinate rhythmic, sequential movements of the upper and
lower limbs (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). Two regions of the
midbrain locomotor region (MLR); namely, the cuneiform nucleus (CN) and PPN are
postulated to predominantly facilitate spatio-temporal gait parameters and balance,
respectively (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). Post-mortem
assessment found that the magnitude of neuronal loss in the CN was not significantly
different between those with a tendency to fall and those without; however, a correlation
was found between the reduction of size and quantity of PPN cholinergic neurons and the
presentation of spontaneous falls and FOG (Rinne et al., 2008; Zweig et al., 1989).
Therefore, reduced dopamine in PD may elicit STN hyperactivity, which subsequently
augments Gamma-Aminobutyric Acid (GABA)ergic output to the thalamo-cortical
projection and CN accounting for gait deficits influenced by bradykinesia and rigidity
that manifest earlier and tend to be L-DOPA responsive (Fazl & Fleisher, 2018;
Magrinelli et al., 2016). Consequently, gait therapy may be inherently more sensitive to
the stimulation area; therefore, the bias towards improvement of upper limb rigidity and
rest tremor during intraoperative contact localization and postoperative contact selection
may additionally lead to a variable inadequate response of L-DOPA responsive gait
deficits to STN-DBS.

3.1.4 Factors influencing the clinical outcome of DBS
The clinical outcome of DBS is directly related to the electric field distribution and
resultant neuroanatomical structures influenced. The electric field is influenced by
programmed features—electrode geometry and stimulation parameters; and nonprogrammed features—contact localizations, neural tissue properties, and impedance of
the contact and tissue interface (Butson, Maks, & McIntyre, 2006; Kuncel & Grill, 2004).
Unipolar electrode geometries are initially programmed in standard clinical care due to
the lower efficacy and side effect thresholds; however, the radially diffuse distribution of
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the electric field increases risk of un-intended stimulation (Butson, Cooper, Henderson,
&, McIntyre, 2007; Deli et al., 2011; McIntyre, Mori, Susumu, Sherman, Thakor, &
Vitek, 2004). Furthermore, an optimal combination of frequency, pulse width, and
amplitude stimulates appropriate neural elements at a necessary magnitude to maximize
symptom alleviation and minimize side effect manifestation and power usage to prolong
battery life (Kuncel & Grill, 2004). Increasing the amplitude within the therapeutic
window (TW) elicits greater symptom alleviation until the side effect threshold is reached
(Kuncel & Grill, 2004). The stimulation amplitude influences the electric field spread;
accordingly, higher amplitudes are subject to greater current spread that may be
associated with side effects particularly with single-contact stimulation that elicits spread
radially (Deli et al., 2011). Side effect induction is more pronounced with poorly
localized contacts but is more likely at high amplitudes regardless of contact localization
(Kuncel & Grill, 2004).
Slight variations in contact localizations are inherent due to neuroanatomical
variation and brain shift induced by air entering the burr hole intraoperatively (Nambu,
2011; Romanelli et al., 2004; Tankus et al., 2017; Tewari et al., 2016). In addition, DBS
is complicated by neural tissue properties that influence current spread (Kuncel & Grill,
2004). Following that DBS mechanisms are excitatory, axon diameter is inversely related
to the amount of charge required to produce an action potential (Montgomery, 2010). The
greater surface area associated with a larger diameter allows for greater charge
accumulation; therefore, large myelinated axons are activated at lower magnitudes
compared to the soma or dendrites (Wagle Shukla, Zeilman, Fernandez, Bajwa, &
Mehanna, 2017). Accordingly, contacts localized to white matter fiber tracts exhibit
broader electric fields compared to those in grey matter suggesting a higher conductance
(Li, Bak, & Parker, 1968; Kuncel & Grill, 2004). Therefore, stimulation spread may elicit
variable effects depending on the neural tissue influenced, which is less regulated and
predictable in centres that program solely based on clinical improvement using the
Unified Parkinson’s Disease Rating Scale (UPDRS) rather than additionally relying on
imaging techniques. In addition, impedance fluctuations inherent to the contact and tissue
interface inversely influence the charge delivery and are poorly regulated with
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conventional voltage-controlled (VC) systems, which has prompted the development of
current-controlled (CC) DBS systems that regulate impedance changes.

3.1.5 Advances in deep brain stimulation technology
DBS systems have been traditionally VC, which inconsistently deliver charge due to
impedance fluctuations (Butson et al., 2006; Miocinovic et al., 2007). VC systems have
been adequate for alleviating symptoms in straightforward cases; however, variable
charge delivery often under or over stimulates the target. In addition, deviations between
the programmed and actual stimulation render a greater need for programming changes,
which is tedious and laborious since there are presently no established protocols (Wagle
Shukla et al., 2017). These inefficiencies prompted the development of CC systems,
which allow for consistent charge delivery through voltage manipulations to account for
impedance fluctuations; thus, the actual stimulation matches the programmed value
(Butson et al., 2006; Lempka, Miocinovic, Johnson, Vitek, McIntyre, 2009; Wagle
Shukla et al., 2017). Multiple independent current control associated with CC devices
allows for manipulation of charge delivery from each contact as a separate entity; thus,
current distribution may be divided among multiple contacts or segments of a contact to
facilitate vertical current steering (CS) (Butson & McIntyre, 2008). The substantial
benefit of implementing vertical CS, or CS for short, is the ability to fine-tune the
stimulation field shape to improve the precision of neuroanatomical targeting
(Chaturvedi, Foutz, & McIntyre, 2012). The current fractionation associated with a
particular contact is proportional to the spread of the electric field; therefore, contacts
receiving a greater percentage of current will exhibit a broader spread than those
receiving a smaller percentage. Thus, CS can reduce the radial spread of conventional
stimulation fields by elongating and shaping the field across multiple active contacts
(Kuncel & Grill, 2004). The first reported human application of CS divided the current
between four contacts to alleviate motor symptoms at an amplitude that failed to improve
symptoms and induced dyskinesia with single-contact stimulation; thus, CS lowered the
efficacy threshold (Barbe, Maarouf, Alesch, & Timmermann, 2014). Furthermore, CS
can address contact localization deviations, neuroanatomical variations, and the varying
influence of particular neural structures such as the soma versus the axon through
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systematic programming that fine-tunes the stimulation field, which avoids surgical reimplantation. Current fractionations may be tailored to the patients’ contact localizations
to increase programming efficiency and reduce the empirical nature of programming; in
addition, different fractionations may be employed to address appendicular and axial
symptom improvement separately if necessary. The efficacy of CS has been exhibited in
a multicentre European study that reported the improvement of motor symptoms and
quality of life and reduction of motor fluctuations and the L-DOPA equivalent dose
(Timmermann et al., 2015). Notably, the majority switched to CS by the one year follow
up despite initiating programming with single-contact conventional stimulation
(Timmermann et al., 2015).

3.1.6 Rationale
Optimal DBS programming maximizes symptom alleviation with minimal side effects;
however, improving both appendicular and axial motor symptoms with conventional
DBS systems has been particularly difficult. Gait therapy may be particularly sensitive to
the resultant stimulation area since gait deficits in PD are influenced by bradykinesia and
rigidity. In addition, an array of neural circuitries is postulated to be affected by PD
pathology to elicit Parkinsonian gait deficits. The ability to employ various current
fractionations to fine-tune the stimulation field shape would provide more regulatory
control to improve the variable outcome of L-DOPA responsive gait deficits. Tailoring
current fractionations to contact localizations should systematically improve
neuroanatomical targeting, which may address the variable improvement that potentially
arises from a bias for upper limb symptom improvement during DBS implementation and
a greater sensitivity of gait therapy to the stimulation area. In addition, CS may be
implemented unilaterally to address disease asymmetry or to elucidate hemispheric
dominance in motor control (Scholz et al., 2000). The actual comparison between the
effect of conventional stimulation, unilateral and bilateral applications of CS, and LDOPA at the level of individual gait parameters has yet to be investigated. Thus, we will
investigate the potential difference between the aforementioned therapies utilizing
quantitative measures recorded with gait analysis software, which provides a more
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detailed comparison in contrast to clinical ordinal scales such as the UPDRS, which is
subject to examiner bias and variation.

3.1.7 Objectives
1. To compare the differential effect of stimulation with unilateral and bilateral
applications of CS and single-contact conventional stimulation at various TW
amplitudes on gait variable changes representing amplitude—step length;
representing timing—step time; representing velocity—stride velocity;
representing balance—total double support time (TDST); and an overall measure
of gait— functional ambulation performance (FAP) score.
a. Gait variable changes assessed from a non-therapeutic state (“OFF”
stimulation, OFF L-DOPA—OFF-therapy baseline).
b.

Gait variable changes assessed from a therapeutically compatible state
(OFF L-DOPA, “ON” stimulation) within the same period following
surgical implantation (weekly baseline).

2. To assess the difference of implementing CS unilaterally that may be attributed to
hemispheric differences or disease asymmetry using hemispheric stimulation
models (right CS and left CS) and laterality stimulation models (more affected
side and less affected side) at various TW amplitudes on gait variable changes—
FAP score, step length, step time, stride velocity, and TDST.
3. To compare the effects of L-DOPA with unilateral and bilateral applications of
CS and single-contact conventional stimulation at various TW amplitudes on gait
variable changes— FAP score, step length, step time, stride velocity, and TDST.

3.1.8 Hypotheses
For the first objective, it is hypothesized that unilateral or bilateral applications of CS to
the STN will elicit greater improvements of overall ambulation and spatio-temporal gait
measures but may not elicit a differential effect on balance as compared to conventional,
single-contact stimulation, which highlights the feature specific neural facilitation of the
BG. Therefore, step length, step time, stride velocity and the FAP score are predicted to
improve to a greater degree with CS; however, TDST is expected to respond similarly
with CS or conventional stimulation due to its predominant regulation by cholinergic
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midbrain nuclei such as the PPN. For the second objective, it is hypothesized that
unilateral applications of CS will differentially affect gait measures based on hemispheric
dominance of the motor cortex and BG or asymmetry of symptom severity. For the third
objective, it is hypothesized that L-DOPA and all stimulation types will not exhibit a
differential effect on gait variable changes. All patients in the sample were responsive to
L-DOPA and the outcome of conventional STN-DBS has been correlated with the LDOPA response; thus, it is predicted that the CS will be comparable to L-DOPA (Fasano,
Aquino, Krauss, Honey, & Bloem, 2015; Welter et al., 2002).

3.2 Methods
3.2.1 Study Sample
The present investigation was approved by the Human Subjects Research Ethics Board
(REB) at Western University (REB #108453). Patients were selected based on clinical
standards intended to maximize symptom alleviation and minimize side effects. Inclusion
criteria encompassed: diagnosis of idiopathic PD with L-DOPA responsive motor
symptoms as assessed with a standard L-DOPA challenge test and motor complications
(Albanese et al., 2001). Exclusion criteria included: overall poor health, previous brain
surgery or implantation of a cardiac pacemaker, diagnosis of dementia and severe
psychiatric symptoms (notably, hallucinations and depression) according to the
Diagnostic and Statistical Manual of Mental Disorders –V, and tendency to exhibit lack
of compliance. All participants analyzed were diagnosed with idiopathic PD for an
average duration of 12.5 years and included four females and three males with an average
age of 61. Nine participants provided informed consent; however, one patient withdrew
from the study for adverse health reasons unrelated to the study and another patient was
no longer eligible following implantation of a DBS device incapable of performing CS.

3.2.2 Experimental Timeline and Study Design
Overall, the experiment included the pre-assessment that was performed at least one
week prior to surgical implantation, the initial contact review that was conducted
approximately one month following surgical implantation, the second contact review that
was executed at least two weeks following the initial review, and the CS investigations
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that were performed immediately after the second contact review (Figure 9). Notably, the
contact reviews will be described in detail in the following section. The pre-assessment
was performed pre-surgically to confirm an adequate response to L-DOPA and the OFFL-DOPA condition was used as a baseline condition to assess improvement from a nontherapeutic state. Bilateral and unilateral applications of CS were compared to stimulation
without CS utilizing 16 investigational settings that represented bilateral CS, right CS,
left CS, and bilateral non-CS stimulation models (Table 4). CS was investigated using
unipolar, dual contact configurations with current divisions of 50/50 and 70/30.
Stimulation without CS was implemented through single-contact stimulation; thus,
represented as divisions of 0/100 or 100/0. Non-CS stimulation was intended to model
conventional clinical standards. Notably, segmented leads (CartesiaTM Directional leads)
always employed ring mode stimulation; therefore, all three segments were active to
stimulate as a ring-shaped contact. All investigational settings were repeated at four
various stimulation amplitudes over four consecutive weeks, which increased in
amplitude by 20% of the TW (Table 5). Amplitude was increased gradually to allow for
the patient to accustom to stimulation; however, amplitudes always remained in the TW.
Each participant was subject to all 16 investigational settings over a period of four days;
thus, four settings were tested each day. Order of application was randomized for each
patient; however, the order remained consistent when settings were repeated at higher
amplitudes across weeks.
A 25-minute washout period was enforced prior to the gait assessments after each
setting was programmed. Gait was assessed with every setting, in addition to, a baseline
walk that was performed prior to implementation of the settings. Therefore, each CS
investigational day consisted of five testing sessions categorized into one baseline session
and four investigational sessions, with 25-minute washout periods in between (Figure
10). The baseline walk was performed with a lower amplitude than the subsequent
investigational sessions with a setting that was deemed optimal for symptom alleviation
by the supervising movement disorders specialist. Baseline walks served as a state of
comparison (weekly baseline) for how the patient performs in a clinically stable state at
that given time point following surgical implantation with a matching therapeutic
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protocol. Thus, the baseline walks matched the CS investigational sessions as both were
performed with stimulation but without L-DOPA.

Figure 9: Experimental timeline.
* denotes the earliest time point that event would occur. Time in reference to the
electrode implantation surgery.

Figure 10: Summary of testing sessions within one week of the CS investigation.
Summary schematic of the testing session schedule within one week during the CS
investigation protocol (~Week 6-9 post-surgical implantation). Baseline sessions
preceded investigational setting sessions each day and a 25-minute washout period was
enforced before each investigational setting session. During a given week, stimulation
amplitudes of baseline sessions and investigational setting sessions were consistent with
each other, represented by squares and circles, respectively. However, baseline
amplitudes were lower than investigational amplitudes.
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Table 4: Investigational settings with single-contact stimulation and bilateral and
unilateral applications of CS.
A) represents the ventral contact and B) represents the dorsal contact.
Setting
Number

Stimulation Model

Left
STN

Right
STN

1

Bilateral non-CS

A): 100% B): 0%

A): 100% B): 0%

2

Right sided, unilateral CS

A): 100% B): 0%

A): 70% B): 30%

3

Right sided, unilateral CS

A): 100% B): 0%

A): 50% B): 50%

4

Bilateral non-CS

A): 100% B): 0%

A): 0% B):100%

5

Left sided, unilateral CS

A): 70% B): 30% A): 100% B): 0%

6

Bilateral CS

A): 70% B): 30% A): 70% B): 30%

7

Bilateral CS

A): 70% B): 30% A): 50% B): 50%

8

Left sided, unilateral CS

A): 70% B): 30% A): 0% B):100%

9

Left sided, unilateral CS

A): 50% B):50% A): 100% B): 0%

10

Bilateral CS

A): 50% B):50% A): 70% B): 30%

11

Bilateral CS

A): 50% B):50% A): 50% B): 50%

12

Left sided, unilateral CS

A): 50% B):50% A): 0% B):100%

13

Bilateral non-CS

A): 0% B):100% A): 100% B): 0%

14

Right sided, unilateral CS

A): 0% B):100% A): 70% B): 30%

15

Right sided, unilateral CS

A): 0% B):100% A): 50% B): 50%

16

Bilateral non-CS

A): 0% B):100% A): 0% B):100%

Table 5: Stimulation amplitudes with respect to the CS investigational week.
Week refers to the CS investigational week.
Week
1

Stimulation Amplitude
(Therapeutic windowminimum) + (Therapeutic windowdifference *0.2)

2
3
4

(Therapeutic windowminimum) + (Therapeutic windowdifference *0.4)
(Therapeutic windowminimum) + (Therapeutic windowdifference *0.6)
(Therapeutic windowminimum) + (Therapeutic windowdifference *0.8)

3.2.3 Clinical Procedures—surgical implantation and contact
selection
Therapeutic macroelectrodes and the impulse generator (IPG) were implanted on the
same day, unless complications arose, by a surgeon trained in functional neurosurgery
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practicing at University Hospital, London Health Sciences Centre (London, ON, CA).
Investigational devices consisted of the VerciseTM IPG and associated DBS leads or the
VerciseTM PC IPG and the CartesiaTM Directional leads, which are Boston Scientific DBS
systems equipped with multiple independent current control (Boston Scientific, Valencia,
CA, USA). Local anesthesia was utilized for neuro-targeting and macroelectrode
implantation; however, general anesthesia was administered subsequently for IPG
implantation. Pre-surgically, the neuro-targeting portion began with magnetic resonance
imaging to locate the STN based on positioning of the anterior commissure (AC), and
posterior commissure (PC). The STN was targeted using standard stereotactic coordinates
based on AC-PC positioning—2.0 mm posterior to the mid-commissural point, 12.0 mm
lateral to the midline, and 4.0 mm ventral to the AC-PC plane (Rabie, Verhagen Metman,
& Slavin, 2016). Intraoperatively, a stereotactic Leksell frame was mounted to the head
and a computed tomography scan was used to merge stereotactic coordinates from the
magnetic resonance image to the surgical computer. Recordings from five
microelectrodes temporarily implanted to denote a central, anterior, posterior, medial, and
lateral channel confirmed the STN positioning in the dorsal to ventral axis through the
associated spike signature. Microelectrodes provided intra-operative stimulation to
associate symptom alleviation and localization. Thus, the most extensive STN spike
signature and the greatest improvement of tremor and rigidity upon intra-operative
stimulation determined the implantation trajectory of the therapeutic macroelectrode.
The IPG was turned on approximately one month following surgical implantation,
upon which the initial contact review was performed. The initial contact review selected
the first contact and the second review selected the second contact for a total of two
investigational contacts in each hemisphere; contact selection was based on the
extensiveness of the TW. A single-contact unipolar review identified the first contact;
however, the second contact review paired the most clinically efficacious contact
(determined by the initial review) with every other contact to find the pair of contacts that
elicited the widest TW with each contact stimulated with 50% of the current. The TW
was defined by the upper and lower limit or the side effect and efficacy threshold,
respectively. For all TW assessments, current amplitude was increased with increments
of 0.5 milliamperes (mA) until side effects were elicited; subsequently, the previous
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amplitude was programmed and increments of 0.1 mA confirmed the exact side effect
threshold. UPDRS items including: finger taps, upper limb rigidity, and upper limb rest
tremor served as primary measures of symptom improvement. Dysarthria, blurry vision,
face pulling, dystonia, and any uncomfortable, intolerable sensations were markers for
the upper limit. Namely, dystonia is characterized by irregular fixed postures or
contortions as a result of consistent or repetitive muscle contractions (Magrinelli et al.,
2016). Upon turning on the IPG, the patient accustomed to stimulation at 0.5 mA until the
start of the CS investigations and the frequency and pulse width remained at 130 Hertz
(Hz) and 60 µs, respectively for the entire study. For one patient, a pulse width of 90 µs
was used.

3.2.4 Changes to medication dosages throughout the experimental
investigation and stimulation changes
The CS investigations and TW assessments were performed in an OFF-L-DOPA state to
reduce potential confounding effects of L-DOPA. Discontinuation of L-DOPA for at least
12 hours was enforced prior to CS investigations, TW assessments, and the preassessment (Albanese et al., 2001). The pre-assessment followed the standard protocol
for the L-DOPA challenge test; therefore, patients took a suprathreshold dose compared
to their regular morning dose (typically 130 % of the standard dosage) for the “ON”
assessments (Albanese et al., 2001). Patients were able to take Parkinsonian medications
following the CS investigational sessions while adhering to the approximate 12-hour
withdrawal prior to initiation of the subsequent CS investigation.
As the stimulation amplitude increased throughout the study, the Parkinsonian
medications including L-DOPA taken outside of testing hours were also reduced.
Reduction in quantity and frequency of consumption was prescribed by the supervising
movement disorders specialist to optimize symptom alleviation while avoiding
dyskinesia to titrate concurrent Parkinsonian therapies. The protocol did not demand a
strict withdrawal schedule for other Parkinsonian medications such as amantadine or
dopamine agonists. Instead, the supervisor monitored and regulated a gradual reduction
of these medications to avoid adverse side effects.
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3.2.5 Technology assessing gait variables—spatio-temporal
parameters and functional ambulation performance score
The ZenoTM walkway (ProtoKinetics, Peekskill, NY) recorded foot falls during walking
assessments with embedded sensors sensitive to pressure and recordings were analyzed
with respect to spatio-temporal gait parameters using ProtoKinetics Movement Analysis
Software (PKMAS, Havertown, PA). The ZenoTM walkway and PKMAS have been
validated in the literature particularly with comparisons to the more traditional GAITRite
system (Egerton, Thingstad, & Helbostad, 2014; Vallabhajosula, Humphrey, Cook, &
Freund, 2017). Spatio-temporal gait parameters representing spatial (length), temporal
(time and TDST), and spatiotemporal (velocity) domains were expressed as a stride or
step. A step is defined as the distance between the initial heel contact to the consecutive
heel contact of the contralateral foot, and a stride is composed of two steps. Accordingly,
step length, step time, stride velocity, TDST, and the FAP score were extracted using
PKMAS. Reduction of TDST and step time, and increases in step length, gait velocity,
and the FAP score modeled improvements compared to the bradykinetic, Parkinsonian
gait (Morris, Iansek, Matyas, & Summers, 1994; Nelson et al., 2002).
Step length was measured in cm as the distance between consecutive heel strikes
of opposite feet measured parallel to the advancement trajectory; the step time was
recorded in seconds as the period to advance from one heel strike to the consecutive heel
strike of the opposing foot; stride velocity was quantified as the ratio of stride length to
time in cm/sec; and TDST in reference to seconds was the sum of all time periods during
which, both feet were supporting the body and making direct contact with the ambulation
surface (Huxham, Gong, Baker, Morris, & Iansek, 2006). Notably, TDST was assessed in
the temporal domain but is more representative of balance. The FAP score is an
integrative measure, which assesses overall ambulation at a self-selected pace (Gouelle,
2014). The FAP score was automatically calculated by PKMAS through subtracting
points from a maximal score of 100 for aberrations from a healthy gait (Gouelle, 2014).
The left and right step functions category accounted for abnormal step time values and
ratios of step length and velocity to leg length, which warranted subtractions up to 22
points for each respective side (Gouelle, 2014). The step to leg length ratio differentials
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category identified abnormal asymmetries, which warranted deductions up to eight points
(Gouelle, 2014). The dynamic base of support category deducted up to eight points for a
base of support that was too wide or narrow (Gouelle, 2014). Lastly, five points were
deducted for use of ambulatory aids (canes, crutches, or walkers) or assistive devices
(verbal cues, splints, or orthoses) (Gouelle, 2014).

3.2.6 Gait Assessments
All gait assessments were recorded using a 0.61 m by 6.1 m ZenoTM walkway without
shoes, ambulatory aids, or assistive walking devices; however, standard, non-skid socks
were worn to reduce fall risk. Forwards walking was assessed at a self-selected pace, as
participants were instructed to ambulate consistently at their daily pace. Five continuous
loops in a clockwise direction were performed for execution of gradual turns with a
consistent speed. Ambulation away from the initial seated position was always recorded
on the ZenoTM walkway; however, walking towards the start position was exercised off
the walkway. Therefore, straight walking was always recorded away from the starting
point. PKMAS averaged the five passes on the walkway to yield the means of the FAP
score, step length, step time, stride velocity, and TDST.

3.2.7 Data and Statistical Analyses
All gait measures were calculated based on equations stated in the PKMAS
Measurements & Definitions document developed by ProtoKinetics, LLC; all analyzed
gait measures have been validated with the established GAITRite software (Egerton et
al., 2014; Vallabhajosula et al., 2017). Prior to statistical analyses, step length, step time,
stride velocity, TDST, and the FAP score were normalized and assessed for outliers,
which were all included for analysis due to the small sample size unless categorized as a
clinical outlier. For instance, three data points were omitted for gait interference due to
dyskinesia and dystonia. Utilizing equations established by Hof (1996), gait parameter
(step length, step time, stride velocity, and TDST) means were normalized to leg length
(Table 5) (Hof, 1996). Subsequently, FAP scores and normalized gait parameter means
were expressed as % changes from baseline with respect to two conditions—the weekly
baseline or the OFF-therapy baseline. The weekly baseline represented the gait variable
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on average during the given week of investigation with a matching therapeutic protocol;
therefore, the weekly baseline value was calculated by averaging across all baseline
walks within the week to constitute the baseline mean using the % change from baseline
equation (Table 6). However, outliers among the baseline walks were removed, which
were performed for each individual week and gait variable. Data were removed if found
to be below the difference of the first quartile and the interquartile range multiplied by
1.5 or above the sum of the third quartile and the interquartile range multiplied by 1.5.
The OFF-baseline mean was obtained from the OFF- L-DOPA condition during the preassessment. Therefore, gait parameter means and FAP scores expressed as % changes
from the weekly baseline or the OFF-therapy baseline were assessed for differences
among the treatment groups being set as the stimulation models or individual settings.
Analysis with the stimulation models utilized means of the constituent settings. Unilateral
applications of CS were categorized for the hemisphere of application or the hemisphere
facilitating motor control for the side of greater or less symptom severity. The former
reference designated right and left CS stimulation models referred to as hemispheric
stimulation models, while the latter designated unilateral CS-less severe side or unilateral
CS-more severe side stimulation models, referred to as laterality stimulation models.
All statistical analyses were performed by GraphPad Prism 6.00 (La Jolla, CA,
USA) or an open-source statistical platform, R (version 3.5.1, Boston, MA, USA) using
an alpha criterion of ≤ 0.05. Normality was assessed with the Shapiro—Wilk test
utilizing GraphPad Prism 6.00; ultimately, non-parametric tests were applied to all data
sets due to the inconsistency in normality and the small sample size. All non-parametric
multiple comparisons and associated post-hoc tests were performed using R (version
3.5.1, Boston, MA, USA). Differences were assessed using the Friedman test but the
Skillings—Mack test was used for incomplete data sets due to clinical outliers. The
blocking factor was set as the various stimulation amplitudes or the various participants
to assess differences at particular stimulation amplitudes (Table 5). The Nemenyi posthoc test was utilized following the Friedman and Skillings—Mack test to perform pairwise comparisons to account for family wise error in a conservative manner; therefore, no
p-value adjustments were performed (Nemenyi, 1962). The Friedman and Nemenyi post-
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hoc test utilized the package “PMCMRplus”, and the Skillings—Mack test was
conducted with the package “Skillings.Mack”.
Table 6: Summary of equations utilized for analysis.
Normalizing gait parameters for the effects of leg length and gravity expressed as 9.81
m/s2, modified by Hof AL, 1996.
Analysis Variable
Equation
𝑢𝑛𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑙𝑒𝑛𝑔𝑡ℎ
Step length
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑆𝑡𝑒𝑝 𝐿𝑒𝑛𝑔𝑡ℎ =

Step Time
Double Support
Time
Stride Velocity

% Change from
Baseline

𝑙𝑒𝑔 𝑙𝑒𝑛𝑔𝑡ℎ
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑆𝑡𝑒𝑝 𝑇𝑖𝑚𝑒 𝑜𝑟 𝑇𝑜𝑡𝑎𝑙 𝐷𝑜𝑢𝑏𝑙𝑒 𝑆𝑢𝑝𝑝𝑜𝑟𝑡 𝑇𝑖𝑚𝑒
𝑢𝑛𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑡𝑖𝑚𝑒
=
1
𝑙𝑒𝑔 𝑙𝑒𝑛𝑔𝑡ℎ ^(2)
(
)
𝑔𝑟𝑎𝑣𝑖𝑡𝑦
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑆𝑡𝑟𝑖𝑑𝑒 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦
𝑢𝑛𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦
=
1
(𝑙𝑒𝑔 𝑙𝑒𝑛𝑔𝑡ℎ ∗ 𝑔𝑟𝑎𝑣𝑖𝑡𝑦)^(2)
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑚𝑒𝑎𝑛 –𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑚𝑒𝑎𝑛
% 𝑐ℎ𝑎𝑛𝑔𝑒 = [
]*100
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑚𝑒𝑎𝑛

3.3 Results
3.3.1 Effect on step length
Significant differences in the percent change of step length from the OFF-therapy and
weekly baseline between hemispheric stimulation models were found during a
stimulation amplitude around 80% of the TW (Figure 11). The average stimulation
amplitude across all participants at the given stage was 3.39 mA and 3.56 mA for the left
and right STN, respectively (Table 7). Significantly greater increases in the percent
change in step length from the OFF-therapy baseline were elicited by the bilateral CS
stimulation model compared to the bilateral non-CS stimulation model (p = 0.02) (Figure
11a). In addition, significant differences in the percent change in step length from the
weekly baseline were elicited between the bilateral CS and non-CS stimulation model (p
= 0.02) (Figure 11b). The percent change in step length elicited by the bilateral non-CS
stimulation model was negative on average (Figure 11b).

3.3.2 Effect on step time
Significant differences in the percent change of step time from the OFF-therapy baseline
were found between hemispheric stimulation models when administered across
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stimulation amplitudes (p = 0.031) (Figure 12a). In particular, significant differences
were found around 60% and 80% of the TW, which stimulated with an average amplitude
of 2.90 mA and 2.99 mA and 3.39 mA and 3.56 mA for the left and right STN,
respectively (Table 7). At these stimulation amplitudes, significantly greater reductions in
the % change in step time were elicited with the right CS stimulation model compared to
the bilateral CS stimulation model (p60% = 0.02 & p80% = 0.01) (Figure 12b & 12c).
Notably, no significant differences were found between the laterality stimulation models
at the same amplitude stages (Figure 13). For the more affected side, the average
stimulation amplitude across participants was 3.10 mA and 3.70 mA and for the less
affected side, the average stimulation amplitude was 2.80 mA and 3.30 mA; listed for
stimulation around 60% then 80% of the TW (Table 8).

3.3.3 Effect on stride velocity
Significant differences in the percent change of stride velocity from the weekly baseline
were found between stimulation settings when administered across various amplitudes (p
= 0.032) (Figure 14). In particular, significantly greater increases in the percent change in
stride velocity were elicited by setting 8 compared to setting 1 (Figure 14). Setting 8
implemented CS unilaterally to the left hemisphere and setting one consisted of bilateral
single-contact stimulation. However, no significant differences were found in the percent
change in stride velocity between hemispheric and laterality stimulation models with
slight differences between the means and medians (Figure 15).

3.3.4 Effect on the FAP score
Significant differences in the percent change of the FAP score from the OFF-therapy and
weekly baseline between hemispheric stimulation models were found during a
stimulation amplitude around 80% of the TW (poff = 0.048 & pweek= 0.048) (Figure 16).
The average stimulation amplitude across all participants at the given stage was 3.39 mA
and 3.56 mA for the left and right STN, respectively (Table 7). Significant differences
were elicited between the percent change in FAP scores between the left CS stimulation
model and the bilateral non-CS stimulation model (Figure 16). In particular, the percent
change of the FAP score from the weekly baseline elicited by the bilateral non-CS
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stimulation model averaged around zero (Figure 16b). No significant differences were
found between the laterality stimulation models when the percent change in the FAP
score was assessed from the OFF-therapy and weekly baseline at stimulation around 80%
of the TW (Figure 17). At this stimulation stage, amplitudes averaged at 3.70 mA and
3.30 mA for the more and less affected side, respectively (Table 8).

3.3.5 Effect on total double support time
No significant differences were found between the percent changes in TDST elicited by
various stimulation settings and models applied across all amplitudes (Figure 18). All
averages of the percent change in TDST from the weekly baseline or OFF-therapy
baseline exhibited negative changes; therefore, less time was spent in double support
following stimulation (Figure 18).

3.3.6 Comparison of stimulation with L-DOPA
Significant differences were found between the effect of L-DOPA and stimulation for the
percent change in step time and step length from the OFF-therapy baseline (Figure 1922). At stimulation around 20% of the TW, L-DOPA had a differential effect on the
percent change in step length from the OFF-therapy baseline compared to implementing
CS unilaterally to the more symptomatically severe side (p =0.02) (Figure 19). The
average stimulation amplitude across all participants at the given stage was 1.90 mA and
1.60 mA for the more and less severe side, respectively (Table 8). On average,
significantly smaller increases in the percent change in step length were implemented by
the unilateral CS stimulation model compared to L-DOPA (Figure 19).
At particular stimulation amplitudes, the use of L-DOPA had a differential effect
on the percent change in step time compared to various stimulation settings, hemispheric
stimulation models, and laterality stimulation models (Figure 20-22). L-DOPA elicited a
positive mean percent change in step time compared to the OFF-therapy baseline;
however, the median indicated no change (Figure 20-22). Regarding stimulation settings,
the percent change in step time was significantly different between L-DOPA and setting
16 (bilateral non-CS) at stimulation around 40% of the TW, which averaged 2.36 mA and
2.33 mA to the left and right STN, respectively (p = 0.013) (Figure 20a). At stimulation
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around 60% and 80% of the TW, significant differences were elicited between L-DOPA
and settings constituting bilateral non-CS, right CS and left CS (Figure 20b & 20c). The
average stimulation amplitude around 60% and 80% of the TW was 2.90 mA and 2.99
mA and 3.39 mA and 3.56 mA for the left and right STN, respectively (Table 7). In
particular, at stimulation around 60% of the TW, differences were found among settings
4, 13, and 16 (bilateral non-CS), setting 14 (right CS), and setting 12 (left CS)
(pLDvs.setting4 = 0.00806, pLDvs.setting13 = 0.00075, pLDvs.setting16 = 0.02867, pLDvs.setting14 =
0.00806, pLDvs.setting12 = 0.00894) (Figure 20b). At stimulation around 80% of the TW,
differences were found among settings 4 and 16 (bilateral non-CS), settings 14 and 15
(right CS), and setting 8 (left CS) (pLDvs.setting4 = 0.00894, pLDvs.setting16 = 0.00059,
pLDvs.setting14 = 0.03435, pLDvs.setting15 = 0.03140, pLDvs.setting8 = 0.03435) (Figure 20c).
At all stimulation amplitudes, L-DOPA affected the percent change in step time in
a significantly different manner compared to the right CS stimulation model (p20% =
0.012, p40% = 0.00096, p60% = 0.00096, p80% = 0.00096) (Figure 21). The average
amplitude for stages in increasing order were 1.83 mA and 1.69 mA; 2.36 mA and 2.33
mA; 2.90 mA and 2.99 mA; and 3.39 mA and 3.56 mA for the left and right STN,
respectively (Table 7). At stimulation amplitudes around 60% and 80% of the TW,
significant differences between L-DOPA and the bilateral non-CS stimulation on the
percent change in step time were found (p60% = 0.01987, p80% = 0.01154) (Figure 21c &
21d). In addition, certain stimulation amplitudes elicited a differential effect between LDOPA and particular laterality stimulation models on the percent change in step time
(Figure 22). At stimulation amplitudes around 40%, 60% and 80% of the TW, significant
differences in the percent change in step time were elicited between L-DOPA and the
unilateral implementation of CS to the electrode in the hemisphere controlling the less
symptomatically severe side (p40% = 0.012, p60% = 0.0065, p80% = 0.0065) (Figure 22).
The average amplitude for stages in increasing order were 2.50 mA and 2.20 mA; 3.10
mA and 2.80 mA; 3.70 mA and 3.30 mA for the more affected and less affected side,
respectively (Table 8). However, significant differences in the percent change in step
time were elicited between L-DOPA and the unilateral implementation of CS to the
electrode in the hemisphere controlling the more symptomatically severe at the higher
stimulation amplitudes of around 60% and 80% of the TW (p60% = 0.0331, p80% = 0.0331)
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(Figure 22b & 22c). In addition, at higher stimulation amplitudes of around 60% and 80%
of the TW, significant differences were elicited in the percent change in step time
between L-DOPA and bilateral non-CS stimulation (p60% = 0.0199, p80% = 0.0115)
(Figure 22b & 22c). Among the settings and hemispheric and laterality stimulation
models, no significant differences were found between L-DOPA and bilateral CS
stimulation (Figure 20-22).

b)

*

210

% Change in Step Length

180
150
120
90
60
30
0

15
10

*

5
0
-5

S
C
FT
LE

T
H
R

TE
LA
BI

IG

A
R

O
N
L
A
R

Stimulation Model

BI

LA

TE

C

S
C
L

-C
N

C
FT

IG
R

LE

T
H

L
A
R
TE

LA
BI

S

S
C

S
C

S
-C
N
O
N
L
A
R
TE
LA
BI

Stimulation Model

S

-10
S

% Change in Step Length

a)

Figure 11: % Change in step length from the OFF-therapy and weekly baseline with
respect to the hemispheric stimulation model with stimulation around 80% of the
TW.
Data presented as box plots with solid horizontal lines representing the median, crosses
representing the mean, the upper and lower whiskers representing the upper and lower
fence—respectively, and closed circles representing outliers above or below the upper
and lower fence, respectively. Step length normalized to the a) OFF-therapy baseline or
b) weekly baseline and leg length with N=7, participants set as the blocking factor.
Significant differences in the % change in step length were elicited by the bilateral CS
stimulation model compared to the bilateral non-CS stimulation model (*, p < 0.05;
Skilling—Mack, post-hoc Nemenyi).

101

a)

*

% Change in Step Time

5
0
-5
-10
-15
-20

LE
FT

T
H
IG
R

% Change in Step Time

80
40

*

0
-40

LA

S

S
LE
FT

T
H
IG
R

C

C

S
C

LA
BI

TE

R

A

L

TE

N

R

O

A

N

L

-C

S

S

-80

C
LE
FT

C
H
IG

Stimulation
Model

C
S

S
C

S
C

120

Stimulation Model

BI

LA
BI

R

TE

N

R

O

A

N

L

T

C

-C

S

S

*

L
A
R
TE
LA
BI

c)

150
120
90
60
30
0
-30
-60
-90
S

% Change in Step Time

b)

Stimulation Model

BI

LA

BI

TE

R

LA

A

L

TE

N

R

O

A

N

L

-C

S

-25

Figure 12: % Change in step time from the OFF-therapy baseline with respect to
the hemispheric stimulation model.
Percent change in step time from baseline was calculated from normal pace walking
following administration of the 16 stimulation settings assessed with respect to the
hemispheric stimulation model a) across all stimulation amplitudes (around 20%, 40%,
60% and 80% of the TW), b) around 60% of the TW, and c) around 80% of the TW. Data
presented as box plots with solid horizontal lines representing the median, crosses
representing the mean, the upper and lower whiskers representing the upper and lower
fence—respectively, and closed circles representing outliers above or below the upper
and lower fence, respectively. Step time normalized to the OFF-therapy baseline and leg
length with N=7, a) various stimulation amplitudes or b) & c) participants set as the
blocking factor. Significant differences in % change in step time were elicited with the
bilateral CS stimulation model compared to the right CS stimulation model a) & c) (*,
p<0.05; Skillings—Mack, post-hoc Nemenyi) and b) (*, p<0.05; Friedman, post-hoc
Nemenyi).
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Figure 13: % Change in step time from the OFF-therapy baseline with respect to
the laterality stimulation model.
Percent change in step time from baseline was calculated from normal pace walking
following administration of the 16 stimulation settings assessed with respect to the
laterality stimulation model at stimulation a) around 60% and b) around 80% of the TW.
Data presented as box plots with solid horizontal lines representing the median, crosses
representing the mean, the upper and lower whiskers representing the upper and lower
fence—respectively, and closed circles representing outliers above or below the upper
and lower fence, respectively. Step time normalized to the OFF-therapy baseline and leg
length with N=7, participants set as the blocking factor. No significant differences in %
change in step time were elicited a) (Friedman, post-hoc Nemenyi) and b) (Skillings—
Mack, post-hoc Nemenyi).
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Figure 14: % Change in stride velocity from the weekly baseline with respect to the
setting across all stimulation amplitudes.
Percent change in stride velocity from baseline was calculated from normal pace walking
following administration of the 16 stimulation settings across all stimulation amplitudes
(around 20%, 40%, 60%, and 80% of the TW). Data presented as box plots with solid
horizontal lines representing the median, crosses representing the mean, the upper and
lower whiskers representing the upper and lower fence—respectively. Stride velocity
normalized to the weekly baseline and leg length with N=7, various stimulation
amplitudes set as the blocking factor. Significant differences in the % change in stride
velocity from baseline were elicited between setting 1(bilateral non-CS) and setting 8
(left CS) (*, p<0.05; Skillings—Mack, post-hoc Nemenyi).

103

S

60
55
50
45
40
35
30
25
20
15
10
5
0
-5
-10
N

R

O

TE

L

Stimulation Model

BI

BI

LA

LA

BI

TE

R

LA

A

R

LE

IG

N

H

FT

T

-C

C
S

S
C

S
C

Stimulation Model

BI

TE

R

LA

A

L

TE

N

R

O

A

N

L

-C

S

% Change in Stride Velocity

55
50
45
40
35
30
25
20
15
10
5
0
-5

A
L
C
S
-L Uni
es lat
s s er
ev al
er C
es S
U
id
-M n
e
i
l
or at
e s er
ev al
er CS
es
id
e

b)
% Change in Stride Velocity

a)

Figure 15: % Change in stride velocity from the weekly baseline with respect to the
hemispheric and laterality stimulation models across all stimulation amplitudes.
Percent change in stride velocity from baseline was calculated from normal pace walking
following administration of the 16 stimulation settings assessed with respect to the a)
hemispheric or b) laterality stimulation model across all stimulation amplitudes (around
20%, 40%, 60%, and 80% of the TW). Data presented as box plots with solid horizontal
lines representing the median, crosses representing the mean, the upper and lower
whiskers representing the upper and lower fence—respectively, and closed circles
representing outliers above or below the upper and lower fence, respectively. Stride
velocity normalized to weekly baseline and leg length with N=7, various stimulation
amplitudes set as the blocking factor. No significant differences found in the % change in
stride velocity (Skillings—Mack, post-hoc Nemenyi).
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Figure 16: % Change in FAP from the OFF-therapy & weekly baseline with respect
to the hemispheric stimulation model during stimulation around 80% of the TW.
Percent change in FAP from baseline was calculated from normal pace walking following
administration of 16 stimulation settings assessed with respect to the hemispheric
stimulation model at an amplitude around 80% of the TW. Data presented as box plots
with solid horizontal lines representing the median, crosses representing the mean, upper
and lower whiskers representing the upper and lower fence—respectively, and closed
circles representing outliers above or below the upper and lower fence, respectively. FAP
scores normalized to a) OFF-therapy or b) weekly baseline with N=7, participants set as
the blocking factor. Significant differences in the % change in FAP were elicited between
the left CS and bilateral non-CS model (*, p<0.05; Skillings—Mack, post-hoc Nemenyi).
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Figure 17: % Change in the FAP from the OFF-therapy and weekly baseline with
respect to the laterality stimulation model during stimulation around 80% of the
TW.
Percent change in FAP from baseline was calculated from normal pace walking following
administration of the 16 stimulation settings assessed with respect to the laterality
stimulation model at a stimulation amplitude of around 80% of the TW. Data presented
as box plots with solid horizontal lines representing the median, crosses representing the
mean, the upper and lower whiskers representing the upper and lower fence—
respectively, and closed circles representing outliers above or below the upper and lower
fence, respectively. FAP scores normalized to the a) OFF-therapy baseline or b) weekly
baseline with N=7, participants set as the blocking factor. No significant differences in
the % change in FAP from baseline were elicited (Skillings—Mack, post-hoc Nemenyi).
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Figure 18: % Change in the TDST from the OFF-therapy and weekly baseline with
respect to the setting and stimulation models including all stimulation amplitudes.
Percent change in TDST from baseline was calculated from normal pace walking
following administration of the 16 stimulation settings assessed with respect to the a) &
b) setting, c) & d) hemispheric stimulation model or e) & f) laterality stimulation model
across all stimulation amplitudes (around 20%, 40%, 60%, and 80% of the TW). Data
presented as box plots with solid horizontal lines representing the median, crosses
representing the mean, the upper and lower whiskers representing the upper and lower
fence—respectively, and closed circles representing outliers above or below the upper
and lower fence, respectively. TDST normalized to the a), c) & e) OFF-therapy baseline
or b), d) & f) weekly baseline with N=7, various stimulation amplitudes set as the
blocking factor. No significant differences in the % change in TDST were found
(Skillings—Mack, post-hoc Nemenyi).
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Figure 19: % Change in step length from the OFF-therapy baseline with respect to
the laterality stimulation model and L-DOPA administration during stimulation
around 20% of the TW.
Percent change in step length from baseline was calculated from normal pace walking
following administration of the 16 stimulation settings assessed with respect to the
laterality stimulation model at an amplitude around 20% of the TW. Data presented as
box plots with solid horizontal lines representing the median, crosses representing the
mean, the upper and lower whiskers representing the upper and lower fence—
respectively. Step length normalized to the OFF-therapy baseline with N=7, participants
set as the blocking factor. Significant differences in the % change in step length from
baseline were elicited with L-DOPA compared to the unilateral CS stimulation model
implementing CS to the electrode in the hemisphere controlling the side of greater
symptom severity (*, p<0.05; Friedman, post-hoc Nemenyi).
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Figure 20: % Change in step time from the OFF-therapy baseline with respect to
the stimulation setting and L-DOPA administration.
Percent change in step time from baseline was calculated from normal pace walking
following administration of L-DOPA and the 16 stimulation settings at stimulation
amplitudes of around a) 40% b) 60 % c) 80% of the TW. Data presented as box plots
with solid horizontal lines representing the median, crosses representing the mean, the
upper and lower whiskers representing the upper and lower fence—respectively, and
closed circles representing outliers above or below the upper and lower fence,
respectively. Step time normalized to the OFF-therapy baseline and leg length with N=7,
participants set as the blocking factor. a) Significant differences in the % change in step
time were elicited with setting 16 (bilateral non-CS) compared to the ON L-DOPA, OFF
stimulation condition (*, p<0.05; Skillings—Mack, post-hoc Nemenyi). b) Significant
differences in the % change in step time were elicited with settings 4, 13, and 16
(bilateral non-CS), setting 14 (right CS), and setting 12 (left CS) compared to the ON LDOPA, OFF stimulation condition (*, p<0.05; **, p < 0.01; ***, p < 0.001; Friedman,
post-hoc Nemenyi). c) Significant differences in the % change in step time were elicited
with setting 4 and 16 (bilateral non-CS), setting 14 and 15 (right CS), and setting 8 (left
CS) compared to the ON L-DOPA, OFF stimulation condition (*, p<0.05; **, p < 0.01;
***, p < 0.001; Skillings—Mack, post-hoc Nemenyi).
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Figure 21: % Change in step time from the OFF-therapy baseline with respect to
the hemispheric stimulation model and L-DOPA administration.
Percent change in step time from baseline was calculated from normal pace walking
following administration of L-DOPA and the 16 stimulation settings assessed with
respect to the hemispheric stimulation model at stimulation amplitudes around a) 20% b)
40 % c) 60% d) 80 % of the TW. Data presented as box plots with solid horizontal lines
representing the median, crosses representing the mean, the upper and lower whiskers
representing the upper and lower fence—respectively, and closed circles representing
outliers above or below the upper and lower fence, respectively. Step time normalized to
the OFF-therapy baseline and leg length with N=7, participants set as the blocking factor.
Significant differences in the % change in step time were elicited with L-DOPA
compared to the right CS stimulation model a) & c) (*, p<0.05, ***, p < 0.001;
Friedman, post-hoc Nemenyi) b) & d) (***, p < 0.001; Skillings—Mack, post-hoc
Nemenyi). Significant differences in the % change in step time were elicited with LDOPA compared to the bilateral non-CS stimulation model c) (*, p<0.05; Friedman,
post-hoc Nemenyi) d) (*, p<0.05; Skillings—Mack, post-hoc Nemenyi).
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Figure 22: % Change in step time from the OFF-therapy baseline with respect to
the laterality stimulation model and L-DOPA administration.
Percent change in step time from baseline was calculated from normal pace walking
following administration of the 16 stimulation settings assessed with respect to the
laterality stimulation model around a) 40% b) 60% & c) 80% of the TW. Data presented
as box plots with solid horizontal lines representing the median, crosses representing the
mean, the upper and lower whiskers representing the upper and lower fence—
respectively, and closed circles representing outliers above or below the upper and lower
fence, respectively. Step time normalized to the OFF-therapy baseline and leg length with
N=7, participants set as the blocking factor. Significant differences in the % change in
step time from baseline were elicited with L-DOPA compared to the bilateral non-CS
stimulation model b) (*, p<0.05; Friedman, post-hoc Nemenyi) c) (*, p<0.05; Skillings—
Mack, post-hoc Nemenyi). Significant differences in the % change in step time from
baseline were elicited with L-DOPA compared to the unilateral CS stimulation model
implementing CS to the electrode in the hemisphere controlling the side of less symptom
severity a) & c) (*, p<0.05; **, p<0.01; Skillings—Mack, post-hoc Nemenyi) b) (**,
p<0.01; Friedman, post-hoc Nemenyi). Significant differences in the % change in step
time from baseline were elicited with L-DOPA compared to the unilateral CS stimulation
model implementing CS to the electrode in the hemisphere controlling the side of greater
symptom severity b) (*, p<0.05; Friedman, post-hoc Nemenyi) c) (*, p<0.05; Skillings—
Mack, post-hoc Nemenyi).
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Table 7: Stimulation amplitudes for the left and right STN for each participant
across each investigative week.
Week 1, 2, 3, and 4 represents current amplitudes around 20%, 40%, 60%, and 80%
of the TW, respectively of the left STN (L) and right STN (R). Current amplitudes are
expressed as milliamperes (mA).
Participant
Code

Week
1-L

Week
1- R

Week
2- L

Week
2-R

Week
3-L

Week
3-R

Week
4-L

Week
4-R

BSC-01
BSC-02
BSC-03
BSC-05
BSC-06
BSC-07
BSC-08

2.8
1.5
1.7
1
1.9
1.9
2
1.83

1.8
1.4
1.8
1.1
1.6
2.3
1.8
1.69

3.6
2
2.4
1.5
2.3
2.2
2.5
2.36

2.8
1.8
2.6
1.7
2.2
3.1
2.1
2.33

4.4
2.5
3.1
2
2.7
2.6
3
2.9

3.9
2.2
3.4
2.3
2.8
3.9
2.4
2.99

4.8
3
3.8
2.5
3.1
3
3.5
3.39

4.4
2.6
4.2
2.9
3.4
4.7
2.7
3.56

AVERAGE

Table 8: Stimulation amplitudes for the more and less affected side for each
participant across each investigative week.
Week 1, 2, 3, and 4 represents current amplitudes around 20%, 40%, 60%, and 80%
of the TW, respectively of the more affected (MA) and less affected (LA) side. Current
amplitudes are expressed as milliamperes (mA).
Participant
Code

Week
1-MA

Week
1-LA

Week
2-MA

Week
2-LA

Week
3-MA

Week
3-LA

Week
4-MA

Week 4LA

BSC-01
BSC-02
BSC-03
BSC-05
BSC-06
BSC-07
BSC-08
AVERAGE

2.8
1.5
1.7
1.1
1.9
2.3
2
1.9

1.8
1.4
1.8
1
1.6
1.9
1.8
1.6

3.6
2
2.4
1.7
2.3
3.1
2.5
2.5

2.8
1.8
2.6
1.5
2.2
2.2
2.1
2.2

4.4
2.5
3.1
2.3
2.7
3.9
3
3.1

3.9
2.2
3.4
2
2.8
2.6
2.4
2.8

4.8
3
3.8
2.9
3.1
4.7
3.5
3.7

4.4
2.6
4.2
2.5
3.4
3
2.7
3.3

3.4 Discussion
3.4.1 General Discussion
Variable benefits were found for step length, step time, stride velocity, and the FAP score
when applying CS unilaterally versus bilaterally (Figure 11, 12, 14 & 16). No significant
differences were found between various stimulation settings and models for TDST
(Figure 18). Notably, none of the investigated gait measures significantly benefited from
conventional single-contact stimulation; cumulatively, these findings support the
hypothesis of objective one. In addition, an apparent benefit on stride velocity and the
FAP score arose from unilaterally applying CS to the left STN that appears to reflect
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hemispheric dominance, which supports the hypothesis for objective two (Figure 14 &
16). Furthermore, L-DOPA appeared to elicit a differential effect on step length
compared to unilaterally applying CS to the more severe side at the lowest investigated
amplitude, and L-DOPA elicited a differential effect compared to bilateral non-CS and
unilateral hemispheric and laterality stimulation models, which does not support the
hypothesis of objective three (Figure 19-22).
Lack of significant improvements exhibited by conventional single-contact
stimulation may allude to the variable clinical outcome of this practice due to limited
regulation of the resultant stimulation area (Wagle Shukla et al., 2017). The variable
response was best reflected by clinical extremes elicited by different single-contact
stimulation settings within the same patient. Tolerable and adequate symptom alleviation
was contrasted with the induction of severe, disabling dyskinesia that prevented proper
gait assessment (clinical outliers) and voluntary refusal to proceed with gait assessments
in around 40% of the participant sample. Disregarding variability, the non-significant
improvements may reflect the inferiority of the conventional practice to CS. Since the
protocol biased upper limb symptom improvement during contact localization and
selection according to clinical standards, the non-significant improvements may depict
the perils of the inability to regulate the stimulation field for gait therapy. As reported in
the literature radial spread associated with single-contact stimulation may paradoxically
improve tremor, rigidity, and dyskinesia but induce gait hypokinesia and freezing when
the zona incerta (Zi) and fields of forel are influenced (Fleury et al., 2016; Tommasi et
al., 2007).
The benefit of CS appeared to be particularly substantial during higher
stimulation amplitudes as depicted by unilateral or bilateral applications of CS benefiting
the FAP score, step time, and step length at the highest investigated amplitude around
80% of the TW (Figure 11, 12 & 16). Fine-tuning the stimulation field is more necessary
at higher amplitudes during which, conventional stimulation exhibits greater current
spread around the active contact (Kuncel & Grill, 2004). The red nucleus or cranial nerve
III may be influenced medially, which potentially induces psychological (impulsivity) or
ocular side effects (diplopia); the internal capsule laterally, anteriorly, dorsally and
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ventrally, which potentially induces contralateral muscle contractions; the hypothalamus
anteriorly, which potentially induces autonomic symptoms; the medial lemniscus
posteriorly, which potentially induces paresthesia; the thalamus and Zi dorsally, which
potentially worsens gait but paradoxically improves appendicular symptoms; and the
substantia nigra pars reticulata (SNr) ventrally, which potentially induces mood changes
(Wagle Shukla et al., 2017). Overall, there appears to be a benefit on gait from
implementing CS unilaterally to the left STN or bilaterally; however, a few findings must
still be addressed: the non-differential effect on TDST, the varying effect of unilaterally
applying CS, and the differential effect of L-DOPA and stimulation on step length and
time.

3.4.2 Non-differential effect of implementing CS for total double
support time
Overall ambulation and gait measures of amplitude, timing and velocity yielded
improvements with either unilateral or bilateral applications of CS as opposed to TDST,
which elicited a negative percent change that was non-differential between all stimulation
settings and models (Figure 11, 12, 14, 16 & 18). The negative percent change in TDST
represents improvements that may be attributed to reductions in trunk flexion in the
forward direction associated with stooped posture induced by axial muscle rigidity, which
consistently improves with STN-DBS (Cossu & Pau, 2016; Crenna et al., 2006; Wagle
Shukla et al., 2018). On the other hand, the responsiveness of step length, step time, and
stride velocity to STN-DBS corresponds to the hypothesis that separate sub-cortical
pathways predominantly facilitate amplitude, timing, and velocity of gait as compared to
postural control portrayed by TDST (Collomb-Clerc & Welter, 2015). The MLR plays a
substantial role in gait and postural control; however, the CN has been suggested to
predominantly facilitate spatio-temporal gait parameters while the PPN has been
implicated with balance regulation (Collomb-Clerc & Welter, 2015; Takakusaki, 2017).
Collomb-Clerc et al. (2015) proposed that the subthalamo-pallidal-MLR pathway
regulates gait features such as amplitude, rhythm, and velocity while the subthalamonigro-PPN circuit facilitates balance but are related through functional projections to the
frontal, parietal, and sensorimotor areas of the cortex (Collomb-Clerc & Welter, 2015).
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In addition to stooped posture elicited by axial rigidity, TDST has been correlated
with risk of spontaneous falls and FOG, which are axial symptoms that are typically
resistant to L-DOPA and STN-DBS and manifest later in the disease (Collomb-Clerc &
Welter, 2015; Plotnik, Giladi, Dagan, & Hausdorff, 2011; Takakusaki, 2017). Therefore,
spontaneous falls and FOG are postulated to be predominantly elicited by cholinergic
deficits in the brainstem and the interplay with the spinal cord, cerebellum, BG, and the
cortex (Takakusaki, 2017). The role of cholinergic PPN neurons in postural control is
highlighted through the correlation between reduced cholinergic PPN neuronal size and
quantity with FOG and fall frequency (Rinne et al., 2008; Zweig et al.,1989).
Furthermore, the lateral SNr has been suggested to regulate muscle tone through
GABAergic projections to the PPN; thus, alluding to the predominant role of the
subthalamo-nigro-PPN circuit in facilitating balance (Collomb-Clerc & Welter, 2015;
Takakusaki, Habaguchi, Ohtinata-Sugimoto, Saitoh, & Sakamoto, 2003; Takakusaki,
Obara, Nozu, & Okumura, 2011). In addition, cognitive decline of the frontal lobe, visuospatial dysfunction of the occipital and parietal cortex, and motor programming
deficiencies in the pre-motor area and SMA have been attributed to non-dopaminergic
postural instabilities (Bartels & Leenders, 2008; Stuart, Lord, Hill, & Rochester, 2016).
Thus, irrespective of the stimulation practice, targeting electrodes to the STN may
not sufficiently influence critical brainstem and cortical regions associated with postural
control. Step length and time, stride velocity, and FAP score improvements may be
attributed to projections of the STN to the GPi and subsequently the CN or the
laterodorsal tegmental nucleus (Takakusaki, Chiba, Nozu, & Okumura, 2016). The
projection of the SNr to the PPN may not be predominantly influenced as primate studies
portray a greater representation of STN axonal projections to the GPi compared to the
SNr and a greater representation of the GPi in the BG motor circuit (Hamani, Saint-Cyr,
Fraser, Kaplitt, & Lozano, 2004). On the other hand, the sample did not exhibit nondopamine responsive axial motor symptoms; therefore, the non-differential effect on
TDST between conventional and CS stimulation may be due to the lack of substantial
postural deficits.
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3.4.3 Benefit of unilaterally implementing current steering
The benefit of unilaterally applying CS to the left STN for stride velocity and FAP score
improvement may be explained by the lateralized functional dominance of the brain.
From a clinical standpoint, implementing CS unilaterally to the left hemisphere may be
beneficial since majority of participants exhibited a greater symptom severity on the right
side of the body, which is predominantly controlled by the left hemisphere. However,
stride velocity and the FAP score did not exhibit any significant differences when
comparing unilateral applications of CS to the electrode in the hemisphere predominantly
controlling the more or less affected side (Figure 15 & 17). Notably, stimulation
amplitudes were tailored towards symptom asymmetry; thus, for the majority, a higher
amplitude stimulated the hemisphere controlling the more affected side. This may suggest
that the fine-tuning ability of CS does not address asymmetric symptom severity when
already accounted for by stimulation amplitude.
Furthermore, the findings may be explained by the predominant role of the left
hemisphere in bilateral coordination and control of complex movement sequences, which
has been exhibited in studies assessing unilateral and bilateral movements (Barber et al.,
2011; Goto et al., 2009; Haaland, Elsinger, Mayer, Durgerian, & Rao, 2004; Scholz et al.,
2000). The BG have been reported to exhibit a stronger left-sided lateralization compared
to the motor cortex; as depicted by, a greater activation of the BG in the left hemisphere
during unilateral and bilateral movements using functional magnetic resonance imaging
(Scholz et al., 2000). Lateralization of the BG may be attributed to the asymmetry of the
nigrostriatal network; for instance, post-mortem analysis found that the left GP exhibits
higher dopamine concentrations than the right GP among right handed individuals (Glick
et al., 1982). The striatum also exhibits lateralization as it was found that the magnitude
of right handedness was correlated to the degree of left-sided dominance of the putamen,
and the putamen to thalamus projection in the left hemisphere is predominantly related to
movement speed regulation (Barber et al., 2011; de la Fuente-Fernández et al., 2000).
Furthermore, the putamen is suggested to be more affected by dopamine depletion in PD
compared to the caudate nucleus (Kish et al., 1988). Thus, lateralized benefit of
implementing CS to the left hemisphere for stride velocity improvements may be
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attributed to fine-tuning the stimulation field on the side that is associated with motor
dominance and the influence of structures (putamen) more affected in PD (Barber et al.,
2011; de la Fuente-Fernández et al., 2000; Kish et al., 1988).
Notably, all participants were right handed except for one, which supports the
hemispheric dominance theory for the present findings over asymmetrical symptom
severity. Thus, the unilateral benefits of CS found may allude to the importance of motor
control lateralization for bilateral, sequential movements. This may suggest that the left
STN may be more sensitive to the resultant stimulation area because circuitry of the left
hemisphere is more implicated in coordinating bilateral sequential movement.
Nonetheless, it warrants clinical consideration of hemispheric dominance in addition to
symptom severity when implementing asymmetric therapy particularly for gait, which is
a bilateral phenomenon.
Furthermore, unilateral benefit of implementing CS to the left STN was only
exhibited by stride velocity and FAP, despite calculation of the FAP score incorporating
measures of step time, step length, gait velocity, and dynamic base of support (Gouelle,
2014). This may suggest the predominant influence of stride velocity as a marker for
healthy ambulation. Espy and colleagues reported that gait velocity may independently
reduce locomotion when both step length and velocity are deviated from healthy values
(Espy, Yang, Bhatt, & Pai, 2010). In addition, gait speed at a self-selected pace has been
correlated with functional ability and confidence that may predict health decline,
mortality, and need for hospitalization; therefore, serving as a valid and specific marker
of ambulation health (Stacy & Lusardi, 2009).
Similarly, the argument for implementing CS unilaterally to the left STN may be
exhibited by the effects of the stimulation settings and models on step time. Significant
reductions in step time were exhibited by unilateral applications of CS to the right STN
compared to bilateral applications (Figure 12). In reference to a hypokinetic,
Parkinsonian gait, reductions in step time may represent faster ambulation, which is more
representative of a healthy gait (Morris et al., 1994). However, decreases in step time
must be assessed in regard to clinical context; for instance, step time reductions are also

116

associated with shuffling of gait. The right CS stimulation model elicited reductions by
nearly 50% at the highest investigated stimulation models; in contrast to, L-DOPA which,
elicited modest increases in step time by a magnitude no larger than 10% with the median
suggesting negligible changes (Figure 21 & 22). Therefore, step time changes elicited by
the bilateral CS stimulation model were more similar to L-DOPA, which is an established
therapy and all participants exhibited L-DOPA responsive symptoms (Kalia & Lang,
2015). Hausdorff and colleagues also reported negligible changes between step time
elicited by independent L-DOPA therapy and independent DBS therapy, which
corresponds to the two therapeutic conditions of the present investigation (Hausdorff,
Gruendlinger, Scollins, O’herron, & Tarsy, 2009). Therefore, step time changes induced
by bilateral CS may be interpreted as improvements. Furthermore, L-DOPA elicited
significant differences between both laterality stimulation models, which also induced
reductions in step time (Figure 22). Perhaps, unilaterally implementing CS elicits an
imbalance in the circuitry that disrupts the rhythmicity of ambulation that is exacerbated
when applying CS to the hemisphere less dominant in motor control (Figure 21).

3.4.4 Differential effect of L-DOPA compared to stimulation
A differential effect between L-DOPA and stimulation was found for step length and
time, which does not support the hypothesis. The outcome of STN-DBS has been
correlated with the L-DOPA response as clinical practice relies on an adequate response
to L-DOPA as an inclusion criterion for DBS (Fasano et al., 2015; Welter et al., 2002).
Changes to gait velocity, step length, step time, and TDST have been reported to be
uniformly affected by L-DOPA and STN-DBS (Cantiniaux et al., 2009; Faist et al., 2001;
Krystkowiak et al., 2003; Stolze et al., 2001). The differential effect of L-DOPA and
stimulation on the percent change in step length was exhibited among laterality
stimulation models (Figure 19). L-DOPA exhibited significant increases from baseline,
which has been reported in the literature; however, at the lowest investigated stimulation
amplitude (around 20% of the TW) L-DOPA elicited a significantly greater increase
compared to unilateral applications of CS to the electrode in the hemisphere controlling
the more symptomatically severe side (Figure 19; Table 8). All stimulation models
elicited a smaller increase in the percent change in step length; however, the significant
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difference elicited by unilateral CS influencing the more severe side may arise from the
larger variation of this stimulation model (Figure 19). Nonetheless, it is possible that at
lower stimulation amplitudes current fractionation may under stimulate the active contact
receiving a smaller proportion of current, which suggests its inferiority to improve step
length as compared to conventional stimulation, bilaterally applied CS stimulation, and
unilateral applications of CS to the hemisphere influencing the less severe side.
In addition, there was a differential effect on the percent change in step time
between L-DOPA and conventional stimulation, the unilateral right hemispheric and both
laterality stimulation models but not bilateral applications of CS (Figure 20-22). L-DOPA
elicited modest increases from baseline no larger than 10% in the present study, which is
similar to reports of Hausdorff and colleagues who reported negligible changes of step
time when comparing therapeutic conditions of L-DOPA and STN-DBS (Hausdorff et
al., 2009). The findings suggest the ability of bilaterally implemented CS to influence
step time similarly to L-DOPA, which is an established therapy (Kalia & Lang, 2015).

3.4.5 Limitations
The predominant limitation of this study is the inaccurate representation of clinical
implementation of CS. All participants were recruited pre-surgically and programmed
with CS despite some exhibiting adequate symptom alleviation with conventional singlecontact stimulation. Therefore, the sample did not entirely consist of those experiencing
inadequate gait improvement following conventional programming standards. In
addition, CS was implemented without personalization whereas in actual clinical practice,
CS would be applied following inadequate symptom alleviation with conventional
programming and current fractionations would be tailored to contact localizations. With a
larger sample, the technique could be implemented only in those requiring fine-tuning,
which more precisely reflects clinical practices.
Hence, a second major limitation is related to the size and demographics of the
sample. Statistical analyses with the small sample size may be sensitive to inherent
variations in disease phenotype; furthermore, an unbalanced representation of right
handedness and disease asymmetry of the right-side warrants further investigation of

118

unilateral applications of CS. For instance, a left CS stimulation setting elicited
significantly greater increases of stride velocity compared to a setting using singlecontact stimulation; however, median comparisons portray opposite trends from
presenting findings such that right CS and single-contact stimulation are most beneficial
for stride velocity improvement (Figure 14). In addition, the BG are involved with
timing, amplitude, and movement features; therefore, the benefit from left-sided
implemented CS should presumably be elicited among step length and time as well.
Particularly for step length, asymmetrical benefits of CS are reasonable since step length
asymmetries are also common in healthy adults (Lizarraga et al., 2017).
Minor limitations include modelling conventional stimulation with CC devices,
the washout period, and the current fractionations implemented. The single-contact
unipolar stimulation in the present investigation may not truly reflect conventional
stimulation, which is implemented with VC systems. Single-contact stimulation
programmed with CC systems may not truly reflect conventions since VC IPGs deliver
charge inconsistently as a result of impedance fluctuations. A true comparison should
involve recruitment of patients implanted with VC devices or to include patients whose
gait has been evaluated with VC IPGs but receive subsequent implantation of IPGs
capable of CS. However, the former fails to provide for repeated measures and the latter
may be biased because subsequent implantation would occur at a substantially later time
point in the disease. In addition, a 25-minute washout period was implemented based on
recommendation of the supervising specialist; however, the literature has reported that
the period required for adequate washout of STN-DBS varies across participants and is
inversely related with disease duration (Cooper, McIntyre, Fernandez, & Vitek, 2013).
Therefore, assessments may be confounded by residual effects of previous settings.
Furthermore, unequal fractionations of 70%/30% modelled CS but the 30%/70%
counterpart was not implemented, which biased the more ventrally located contact with a
greater proportion of current. Arguably, greater stimulation of more ventrally located
contacts decreases the likelihood of stimulating fibre tracts such as the Zi associated with
gait worsening (Fleury et al., 2016). In future studies, personalized fractionations tailored
to contact localizations should be implemented with sessions spread out by a greater
amount of time to ensure an adequate wash-out period for all patients.
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3.4.6 Conclusion
Results of the present study suggest implementing CS bilaterally for step time and length
improvement and unilaterally to the left STN for improvement of stride velocity and the
FAP score. No differential effect between stimulation types were found for TDST; in
addition, non-CS stimulation did not elicit any significant improvements reflecting the
variable outcome associated with single-contact stimulation. Failure to find a differential
effect between CS and conventional stimulation for TDST may allude to separate subcortical networks predominantly regulating amplitude, rhythm/timing, and velocity of
movement versus balance. Furthermore, L-DOPA appears to elicit a similar outcome for
all gait parameters compared to all types of stimulation except for step time, which
exhibited a variable outcome from unilaterally implementing CS and single-contact,
conventional stimulation. In addition, unilaterally implementing CS at low amplitudes
improved step length to a poorer degree than L-DOPA; however, this inadequacy of CS
was only found for step length at the lowest investigated amplitude.
Lack of significant differences between implementing CS unilaterally to the more
versus less affected side suggests that the benefit of asymmetrically implementing CS
reflects the dominance of the left hemisphere in facilitating motor control exhibited by
the BG and motor cortex (Barber et al., 2011; Scholz et al., 2000). Therefore, present
findings suggest hemispheric dominance to explain the benefit of unilateral applications
of CS; however, disease asymmetry should not be completely dis-regarded for explaining
the unilateral benefit since the present sample is imbalanced with greater right-sided
severity. Overall, the findings of this study suggest the potential advantage of utilizing
CS over conventional stimulation to effectively improve gait while accounting for
hemispheric laterality, particularly at higher stimulation amplitudes.
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Chapter 4

4

General Discussion & Conclusions

Bilaterally implementing current steering (CS) exhibited greater practical and clinical
efficacy through eliciting improvement of overall ambulation with lower total electrical
energy delivered (TEED) values. Thus, CS elicited better ambulation performance with
lower TEED values as CS was able to significantly reduce the TEED (Figure 6a & 7b).
Assessments of individual gait parameters and inclusion of unilateral applications
portrayed a particular benefit of implementing CS bilaterally for step time and length
improvement and unilaterally to the left subthalamic nucleus (STN) for stride velocity
and functional ambulation performance (FAP) score improvement (Figure 11, 12, 14,
16). As predicted, conventional single-contact stimulation did not elicit significant
improvements over unilateral and bilateral CS, and a non-differential effect between CS
and conventional stimulation was found for total double support time (TDST) (Figure
18). Notably, CS improved step length, stride velocity, TDST, and overall ambulation
(FAP) to a similar degree as Levodopa (L-DOPA); however, only bilateral applications
of CS elicited a comparable effect on step time, which may suggest that unilateral
applications induce asymmetric modulation that is unfavourable for rhythm regulation
(Figure 20-22). Significant improvements elicited by bilateral and unilateral CS tended to
manifest at higher stimulation amplitudes when single-contact stimulation is more
susceptible to radial current spread, which may influence surrounding neural structures
and undermine the clinical outcome (Kuncel & Grill, 2004).
The unilateral benefit of implementing CS to the left STN may demonstrate
dominance of the left hemisphere in motor control, which is exhibited by the basal
ganglia (BG) and motor cortex (Barber et al., 2011; Scholz et al., 2000). Lack of superior
benefit portrayed by conventional stimulation on the individual gait parameters exhibits
the variable responsiveness and disadvantage of this practice. In addition, the nondifferential effect of various stimulation types on TDST suggests separate neural control
of spatio-temporal gait parameters and balance for which, the former may be more related
to the STN-internal globus pallidus (GPi)-cuneiform nucleus projection and the latter
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may be more related to cholinergic modulation in the brainstem involving the STNsubstantia nigra pars reticulata-pedunculopontine nucleus projection (Collomb-Clerc &
Welter, 2015; Takakusaki, 2017). The non-differential effect of CS on balance measures
as opposed to the greater improvement of amplitude, timing, and velocity gait deficits in
L-DOPA responsive patients may reflect the greater representation of the GPi in the BG
motor circuit and a similar therapeutic influence of the cortical-BG-thalamus-cortical
loop to L-DOPA (Hamani, Saint-Cyr, Fraser, Kaplitt, & Lozano, 2004).
Present findings portray the practical benefit of implementing CS to reduce TEED
values, which reduces power consumption, tissue damage and side effect risk, impulse
generator (IPG) battery drainage rate, and need for IPG replacement. In addition, benefits
of applying CS unilaterally to the left STN suggests that the circuitry of the left
hemisphere may be more dominant in coordinating bilateral sequential movement; thus,
benefiting more from the fine-tuning effect. Nonetheless, it warrants clinical
consideration of hemispheric dominance in addition to symptom severity when applying
therapy asymmetrically. Overall, the results suggest the practical and clinical efficacy of
CS over conventional stimulation, particularly at high stimulation amplitudes. CS allows
for fine-tuning of the stimulation field to address the complex integration of neural
networks facilitating gait, neuroanatomical variations, contact localization deviations, and
potential deficits induced by a bias of upper limb symptom improvement during deep
brain stimulation implementation procedures. However, present findings are limited by a
small sample size and an imbalanced representation of right handedness and greater
motor symptom severity of the right side of the body; therefore, further investigation
particularly for unilateral CS applications should be conducted.
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Appendix B: Letter of Information and Consent

Letter of Information and Consent
Study Title: The use of whole-body kinematic technology for optimizing current steering
deep brain stimulation in Parkinson’s disease patients
Principal investigator: Dr. Mandar Jog, London Health Science Movement Disorders
Clinic, UWO
Protocol Version: 8.0
Protocol Date: 1/June/2018
Participant Number: BSC - __ __
In this Consent document, “you” always refers to the study participant. Participants
of this study must be able to give informed consent and cannot have a substitute decision
maker (SDM) (i.e. someone who makes the decision of participation on behalf of a
participant).
This consent form explains the research study you are invited to join. Please ask
the study doctor or the study staff to explain any words or facts that you do not
understand. You should keep a signed copy of this consent form. You may wish to
discuss this study with your family and friends before making your decision. If you
decide to take part in the research study, you must sign this form before you have
anything done for this research study.

Introduction
We are inviting you to voluntarily participate in a research project designed to
assess the use of a new method in the practice of a surgical procedure known as deep
brain stimulation (DBS). This procedure allows electrical signals to be sent to brain areas
related to control of body movement – one area being the subthalamic nucleus (STN).
The device being implanted in the STN is part of the routine DBS therapy; therefore, the
surgery and clinical management of your DBS device will not be changed. However,
during the research visits of this study, we will be exploring a new method of delivering
current to the appropriate brain region.
During DBS, electrodes are placed deep in the brain and are connected to a
programmable stimulator device. Similar to a heart pacemaker, the stimulator uses
electric pulses to help regulate the amount of stimulation delivered to the electrodes. The
doctor controls the stimulator settings with a wireless device and stimulation settings can
be adjusted as a patient's condition changes over time. The surgical procedure to implant
the electrodes will have been clearly explained to you by your surgeon and neurologist,
and you will have already signed a separate consent form for this operation as part of the
treatment of your Parkinson’s disease (PD).
Currently, the delivery of current is directed toward the same brain region for all
patients. A new DBS technique has broadened our ability to control and thus, investigate
different programming settings of the stimulator device. Through stimulating different
regions in the brain, this investigation can help us to determine the best location to deliver
current, for each patient. The ability to change where and how much current is being
delivered is called current-steering. This study seeks to investigate current-steering with

133

the use of your DBS device to determine the effectiveness of this new programming
technique.

Background
DBS of the STN is a therapy for individuals who are no longer responding to
Levodopa (the current drug used to treat PD) as well as they were at the start of their
treatment. The purpose of the method of DBS is to stimulate target brain structures while
minimizing the stimulation of surrounding regions. The success of DBS therapy is reliant
on 3 main aspects: 1) proper patient selection, 2) accurate placement of the electrode lead
within the brain, 3) effective selection of stimulator settings of the DBS device. The
precise location of the electrode lead and the stimulator settings contribute equally to the
therapeutic effect for the patient. However, if the electrode is misplaced within the brain
tissue, corrective surgery possesses an added risk for the patient.
The DBS device being used for this study will allow the current to enter the
patient’s brain through multiple contact points. The device used in this study is not new;
however, current steering or the ability to control the amount of current delivered at each
contact point is a new technique. The technique of current steering will be investigated in
this study. The current steering feature of DBS devices has not been extensively
researched. Current steering allows for a more personalized treatment of PD. The ability
to direct the current to the optimal location for each patient is a very promising approach
to improve the therapeutic success of DBS.
In this study, we attempt to use our lab expertise to investigate the current steering
technique. The STN is composed of many different types of brain cells that respond
differently to electrical stimulation. It is hypothesized that PD symptom relief is highly
dependent on the location of DBS electrical stimulation. Therefore, it is predicted that
current steering can change the area of brain tissue being stimulated, and a notable
change in PD motor and perceptual features will result as different types of STN brain
cells can be targeted. The objectives of the study are:
1. Investigate whether using current steering settings during DBS to direct the
current to an optimal location within the brain tissue has any direct effect on
PD motor and perceptual symptoms.
2. Determine if there are common settings of the programmable DBS device that
are best for treating symptom improvement among all patients.
We are looking to investigate current steering in 16 persons that have undergone
STN-DBS recruited from the Movement Disorders Clinic at London Health Sciences
Centre (LHSC). This study will require you to come to the research lab 4 days a week for
a month post-operation.

Study Funding
The study is funded in part by Boston Scientific who manufacture the DBS device
being used in the current study. Other funding is coming from a research grant from
Movement Disorders Center at London Health Sciences Centre (LHSC).

Inclusion and Exclusion criteria
If you decide to join, you will be asked to sign this consent form and you must
agree to follow the instructions given by the research staff during the study. You may not
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participate in this study if you participated in another clinical research project less than 4
weeks ago. Based on your screening information, the study doctor will determine if you
are eligible to join this study.
Inclusion criteria:
1. Diagnosed Idiopathic Parkinson Disease with excellent response to levodopa
medication
2. A score of between II-IV on the Hoehn-Yahr scale
3. Severe motor fluctuations with disabling off periods and dyskinesia during on
phases
4. Assessed for eligibility for the DBS procedure
5. Able to give informed consent
6. Able to visit the clinic for assessment
7. No dementia or psychiatric abnormalities.
Exclusion criteria:
1. Any previous brain surgery or a cardiac pacemaker
2. If your medication routine is unstable and/or you take levodopa containing
medications less than 3 times a day.
3. Any diagnosis of dementia, severe cognitive disturbances or severe
psychiatric symptoms (in particular hallucinations and depression) as assessed
by DSM criteria
4. Any hip or joint replacements (unless well treated as assessed by the study
team)
5. Lack of compliance at follow-up.
6. Additional exclusion criteria for perceptual test: Severe visual impairment
determined from visual testing (i.e., convergence insufficiency)

Study Tools
The study will make use of several technological devices to objectively measure
all motor symptoms associated with Parkinson’s disease. The whole-body mobility is
assessed using a motion capture suit which houses several motion sensors that track all
body movements. You will be dressed in a lightweight, stretchable, and breathable suit
over your regular clothing. You will also wear a head sensor attached to a lightweight
cap, as well as fingerless gloves and shoe attachments with hand and foot sensors. The
total weight of the suit is 1.5 kg. Walking will be assessed using a pressure sensor carpet
walkway. You will be required to walk across the carpet so that the system can capture
your walking patterns in various ways. Your speech will also be recorded using a head
mounted microphone and a digital recording device. To assess the perceptual capabilities
of the PD subjects, a computational virtual reality environment and haptics-enabled
robots (such as the KINARM Exoskeleton and End-Point robots) may be used.
You will also complete standard clinical scales at each visit that are used to
monitor motor and non-motor features of Parkinson’s disease (Table 1.)
Table 2. Clinical scales used at every visit.
Clinical Scale
Description
The Unified Parkinson's
A widely used clinical scale used to measure the
Disease Rating Scale
impairment and disability associated with Parkinson
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(UPDRS)

Disease

The Montreal Cognitive
Assessment (MoCA)

A brief 30-question test which assesses different types
of cognitive abilities such as short-term memory and
concentration.

Freezing of Gait
Questionnaire (FOG-Q)

A 6 item questionnaire used to monitor freezing of gait
in Parkinson’s disease

Activities-specific Balance
Confidence (ABC) Scale
Beck’s Depression Inventory

A 16 item scale that measures one’s confidence in
maintaining their balance when completing specific
activities
A 21 item questionnaire used to measure affect related
to depression

All visits will be recorded with a video camera for data analysis purposes only.
The recorded videos will be coded and not linked to your personal information. You may
opt-out from these recordings by selecting an option on page 10 of this letter.

Study Procedure and Design
This is a trial seeking to optimize a patients’ DBS device programming using
objective and quantitative data that will be obtained from kinematic technology such as
the motion capture suit and the carpet walkway.
Participants will then undergo DBS implantation into the STN on both sides of the
brain with the Boston Scientific DBS device. Patients will be given at least 4 weeks to
recover from the operation; for instance, from week 0 to week 4. At least 6 weeks postoperation, each participant will undergo a 4-week titration regime to determine the effect
that current steering has on their primary motor symptoms. Classic hallmark PD symptoms
will be assessed using the kinematic technology.
Visit 1: 1 week before surgery
Study participants will be seen one week prior to the DBS surgery to assess their response to the
levodopa medication. You will arrive at the research laboratory after being OFF levodopa
medications for 12 hours. Full body mobility assessments will be conducted in your OFF
state using the motion capture suit, carpet walkway and the speech recorder. Following
these assessments, you will be asked to take 135% of your usual levodopa medication.
For example, if the patient usually takes 100mg of levodopa for the treatment of their PD,
135% of that would be 135mg. During the wait time for the medication to take into
effect, clinical rating scales for movement difficulties and other difficulties (depression,
memory etc.) will be completed (outlined in Table 1.). Once the levodopa medication has
taken effect a full body mobility assessment will be conducted in your ON state using the
motion capture suit, carpet walkway and the speech recorder.
Visit 2: at least 4 weeks post-surgery
At least 4 weeks post-operation a Movement Disorder Neurologist will turn on the
patients’ device.

**Note: The next visit sessions will occur over 1 consecutive
month, with 4 visits each week**
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Visit 3-6: at least 6 weeks post-surgery
During these visits 16 current steering paradigms will be explored, 4 each day. These
setting paradigms will be randomized for each participant so the same settings are not
presented in the same order for each person. Your device will also be set to 20% more of the
therapeutic amplitude (current) you will be at clinically. After each current steering setting is
implemented, a 30-minute wait period will be allowed for the setting to take effect. Full body
assessments will be performed for each setting change as well as the UPDRS. At the end of
each day, following the 4 setting changes, your DBS device will be returned to the original
setting you came in with. At the end of the week you will be turned to a setting that was
found to be most beneficial. You will then be asked to return the following week.
Visit 7-10: at least 7 weeks post-surgery
This visit will be the exact same as visits 3-6 except the amplitude (current) of the
device will be increased by 40% of the baseline setting.
Visit 12-15: at least 8 weeks post-surgery
This visit will be the exact same as visits 3-6 except the amplitude (current) of the
device will be increased by 60%.
Visit 16-19: at least 9 weeks post-surgery
This visit will be the exact same as visits 3-6 except the amplitude (current) of the
device will be increased by 80%.
Visit 20 (optional): at least 12th week post-surgery
During this visit, the subject’s various perceptual capabilities will be measured. The
subject will be asked to perform two-forced alternative choice perceptual tasks while sitting
down. These tasks will be displayed on a computer monitor and the patient will be asked to
provide verbal responses to questions asked during the tasks. The perceptual tasks will
involve tasks to test for temporal perception, displacement perception and velocity perception
(an example is when two objects are shown on a monitor and the participant is asked to tell
which object is moving faster or further). Alternatively, the subjects may carry out
proprioceptive perceptive tests (such as temporal, displacement and velocity perception)
using a haptics-enabled device (such as the KINARM Exoskeleton and End-Point robots).
An example of a task involves the subject comparing two speeds of passive movement
(powered by the haptics device), and verbally answering which of the compared speeds they
perceive to be faster.

Study Tasks
Patients will perform various tasks during the programming sessions including:
1. Relaxed position (20 Seconds): The participants are asked to rest their arms in
neutral position while: back hunched forward, both forearms on legs, and hands
hanging loose between legs. The participants hold this position for 20 seconds.
2. Supported Posture (20 seconds): The participants are asked to rest their arms in
neutral position on the arm rests of a chair. The participants hold this position for
20 seconds.
3. Pronated Posture (20 seconds): While sitting, participants fully extend their arms
forward with hands in pronation at shoulder height level. The participants hold this
position for 20 seconds.
4. Supinated Posture (20 seconds): While sitting, participants fully extend their
arms forward with hands in supination at shoulder height level. The participants
hold this position for 20 seconds.
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5. Pronation-supination (20 seconds): Same position as posture, participants are
asked to turn hands one at a time and as fast as possible so that their palms face up
and down alternatively. The participants keep this motion for 20 seconds.
6. Normal walking (90 seconds): consists of rising from a chair and walking around
a 25 meter track 5 times at a preferred normal pace.
7. Fast walking (90 seconds): consists of rising from a chair and walking around a 25
meter track 5 times at a fast as possible pace.
8. Backwards walking (90 seconds): consists of rising from a chair, turning around
and walking down the 7 meter long gait carpet. Once off the carpet the patient
turns around and walks backwards across the carpet back into the starting chair.
9. 180 Degrees Turn (60 seconds): while standing, the participant is asked to turn
left/right 180 degrees on the spot to face the back. After a few seconds, they are
asked to return to the original position. This task is performed for 8 turns.
10. Speech recording (120 seconds): a microphone will be taped to the patients’
cheekbone and speech tasks will be carried out.
11. UPDRS (5 minutes): this clinical rating scale will be carried out to assess motor
symptom severity after each setting change.
12. Visual Temporal Perception (about 30 minutes): Patients will perform a 2Alternative-Forced-Choice task composed of approximately 160 trials. In each
trial, comparisons between the time of shapes flashing on the screen (i.e., the first
shape appears, disappears for varying amount of time [this time changes between
trials and shapes compared in trials] then reappears again briefly before
disappearing permanently. This is followed by another shape flashing on the
screen. The subject will be asked which time duration between the shape
disappearing and reappearing was faster (or if they were the same) between the
two compared shapes in each trial.
13. Visual Displacement Perception (about 30 minutes): Patients will Perform a 2
Alternative Forced Choice task composed of approximately 160 trials. In each
trial a shape at a certain point displayed on a computer monitor will displace to
twice, the subject must answer which displacement was greater, or if their
displaced was of the same magnitude.
14. Visual Velocity Perception (about 40 minutes): Patients will perform a 2Alternative-Forced-Choice task composed of approximately 200 trials. In each
trial two shapes will be moving in opposite directions on a computer monitor for
10 seconds, the subject must answer which velocity was greater, or that the
velocities are the same speed.
15. Proprioceptive Temporal Perception (about 30 minutes): Patients will
perform a 2-Alternative-Forced-Choice task composed of approximately 160
trials. In each trial, subjects should compare the difference in time between the
release of force applied from the haptics device (i.e., in each trial, the device will apply
force, remove force for a set time, apply force again, remove force a second time, reapply
force, end of trial). The subject will be asked which time duration between the

removal of the force applied to the patient and the force being reapplied was
longer (or if they were the same) between the two compared pauses in force for
each trial.
16. Proprioceptive Displacement Perception (about 30 minutes): Patients will
perform a 2-Alternative-Forced-Choice task composed of approximately 160
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trials. In each trial the subject’s limb will begin at a starting point and be passively
displaced twice from this starting point. The subject should compare the
proprioceptive displacements and verbally answer which displacement they felt
was greater, or that the displacements were the same.
17. Proprioceptive Velocity Perception (about 40 minutes): Patients will perform a
2-Alternative-Forced-Choice task composed of approximately 200 trials. In each
trial the haptic device will passively move the patient’s limb at a certain velocity
for around 7 seconds, and then move their limb again for around 7 seconds. The
subject will then compare the speeds of the limb movements, and verbally
respond which speed they perceived to be greater, or that they perceived the speed
to be the same.
18. Visual Shape Perception (about 30 minutes): Patients will perform a 2Alternative-Forced-Choice task composed of approximately 150 trials. Each trial
will consist of sequential (visual) presentation of two rectangles. The subject will
compare the length of the two rectangles, and indicate which rectangle they
perceive to be bigger in length by selecting one of the two options, shown in the
monitor at the end of each trial, using the haptic device.
19. Proprioceptive Shape Perception (about 30 minutes): Patients will perform a
2-Alternative-Forces-Choice task composed of approximately 150 trials. Each
trial will consist of a sequential (haptic) presentation of two rectangles. The
subject will be able to haptically explore the length of the rectangle by moving the
haptic device along its edge. The subject will then compare the length of the two
rectangles, and indicate which rectangle they perceive to be bigger in length by
selecting one of the two options, shown in the monitor at the end of each trial,
using the haptic device.
20. Combined Visual-Proprioceptive Shape Perception (about 30 minutes):
Patients will perform a 2-Alternative-Forced-Choice task composed of
approximately 150 trials. Each trial will consist of a sequential (visual and haptic
both) presentation of two rectangles. In these trials, subjects will simultaneously
look at and haptically explore the length of the rectangle. In one of the two
presentations, the visually and haptically specified length of the rectangle will be
the same, whereas in the other presentation the visually and haptically specified
length of the rectangle may differ. The subject will compare the length of the
rectangles, and indicate which rectangle they perceive to be bigger in length by
selecting one of the two options, shown in the monitor at the end of each trial,
using the haptic device.
Each task will be performed twice with the exception of tasks 6, 7, 9-11. The total amount
of time for the motor testing sessions is approximately 20 minutes with appropriate rest
periods. Perceptual tests will be done when the DBS system is turned off, and again when
it is turned on during one day of experimenting.

Possible Risks and Harms
This study has some risks that we know about. There is also a possibility of risks that we
do not know about and have not been seen in study participants to date. Please call the
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study doctor if you have any side effects even if you do not think it has anything to do
with this study. Risks are grouped according to two categories; a brief overview is
provided for standard of care risks which your doctor will have discussed with you in
greater detail. The second group is risks related to participation in this research study:
Study Related Risks
Withholding of medication: You may have transient worsening of parkinsonian
symptoms following overnight withdrawal of antiparkinsonian medications. However,
this should be no different from the procedure performed as part of the routine clinical
assessment before and after surgery. You may get tired during the procedure. You will be
OFF medications about 12 times total throughout the study.
Risks of Current Steering: You may experience worsening of motor symptoms during
the setting changes at the research visits. Some common side effects patients report
during settings changes are:
1. Worsening of motor features associated with Parkinson’s disease
2. Tingling and numbness in limbs
3. Dizziness and lightheadedness
4. Upset stomach
5. Blurred vision
6. Slurred speech
While these symptoms do not usually occur it is important to monitor for them.
The study team understands the common side effects and will monitor them throughout
the study. Should you be experiencing any of these symptoms, or others, please let the
study team know.
Risks associated with study tools: The full body suit is a light weight and fully portable
technology for collecting information about your mobility. There is a minimal risk
associated with wearing such a suit as the system only uses simple sensors that are
attached to the suit. Some study participants may experience discomfort such as itching
and sweating in their body while wearing the suit. Some study participants may
experience minor emotional distress with completing the scales and questionnaires.
Scales will be administered by an experienced researcher trained in administering items
in a sensitive manner. You will be allowed rest periods as necessary during the scales and
questionnaires to facilitate comfort.

Possible Benefits
You may not directly benefit from the study, but the information obtained may
lead to new knowledge on movement disorders and may lead to new treatment for
movement disorders.

Compensation
You will not be compensated for participating in this research study, however you
will be reimbursed for parking expenses and potential travel costs.

Confidentiality
Personal Health Information
If you agree to join this study, the study doctor and his/her study team will look at
your personal health information and collect only the information they need for the study.
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Personal health information is any information that could be used to identify you and
includes your:
1. Name
2. Address
3. Partial Date of birth
4. New or existing medical records that includes types, dates and results of medical
tests or procedures
5. Telephone Number
Research Information in Clinical Records
If you participate in this study, information about you from this research project
may be stored in your hospital file and in the LHSC computer system. The study team
can tell you what information about you will be stored electronically and if you have any
concerns about this, or have any questions, please contact the laboratory
The following people may come to the hospital to look at the study records and at
your personal health information to check that the information collected for the study is
correct and to make sure the study is following proper laws and guidelines:
1. Representatives of Lawson Health Research Institute (LHRI) including the LHRI
Research Ethics Board
2. Representatives of the University of Western Ontario Health Sciences Research
Ethics Board.
3. The study sponsor or its representatives’/partner companies (Canadian Institutes
of Health Research and Boston Scientific)
4. Representatives of Health Canada or other regulatory bodies (groups of people
who oversee research studies) outside of Canada, such as the United States Food
and Drug Administration.
The information that is collected for the study will be kept in a locked and secure
area by the study doctor for 25 years. Only the study team or the people or groups listed
below will be allowed to look at your records. Your participation in this study also may
be recorded in your medical record at this hospital.
Following completion of the study, identifiable videos and photographs will be
stored using a code number only and will never leave University Hospital. The videos
and photographs will remain stored in a secure location and will not be viewed by anyone
outside the study team without your permission. If these videos are used for scientific
presentations or education purposes, you will not be identified as all personal identifiers
(such as your face) will be blurred or blackened out. All videos and photographs will be
destroyed after the study is complete.
Your signed consent, which will have your name on it, will not be stored with the
data collected from the study and will not be connected to the data collected. The master
list with your contact information on it will also be stored separately from the data
collected to avoid linking your personal information to your data recordings. Consent
forms and the master list will be stored in a secure location in the Movement Disorders
Laboratory of Dr. Jog at University Hospital.

Voluntary participation
Participation in this study is voluntary. You may refuse to participate, refuse to
answer any questions or withdraw from the study at any time with no effect on your
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future care. You will be able to withdraw from the study at any point in time. However,
to protect the integrity of the study the data collected up to the point of your withdrawal
will remain a part of the study. You will not have the option of withdrawing your data
once it has been collected even if you choose to withdraw from the study. No new
information will be collected without your permission.

Alternatives to study participation
The alternative to study participation is to continue on your current course of
medication and disease management under the direction of Dr. Mandar Jog.

Withdrawal from the study by the investigator
The investigator may decide to take you off the study if he feels your continued
participation would impair your wellbeing or if the measuring devices are causing
discomfort. The investigator may also decide to terminate your participation if
compliance at follow-up is deemed insufficient.

Rights as a Participant
If you are harmed as a direct result of taking part in this study, all necessary
medical treatment will be made available to you at no cost. By signing this form you do
not give up any of your legal rights against the investigators, sponsor or involved
institutions for compensation, nor does this form relieve the investigators, sponsor or
involved institutions of their legal and professional responsibilities.

Persons to Contact with Questions
For more information about this research study, or if you believe that you may
have a research related injury or experienced any side effects as a result of participating
in this study you may call Dr. Mandar Jog. If you have questions about the conduct of the
study or your rights as a research participant, you may call Dr. David Hill, Scientific
Director, Lawson Health Research Institute.

Publication
If the results of the study are published, your name will not be used. If you would
like to receive a copy of any potential study results, please contact Dr. Mandar Jog.
You do not waive any legal rights by signing the consent form. You will receive a copy
of the letter of information for your records.
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Patient Consent Form
Study Title: The use of whole-body kinematic technology for optimizing current steering
deep brain stimulation in Parkinson’s disease patients
Principal Investigator: Dr. Mandar Jog, MD
Medical Personnel:
Dr. Mandar Jog, MD – Neurologist
Ms. Heather Russell – Clinic Nurse
I have read the Letter of Information, have had the nature of the study explained to me
and I agree to participate. All questions have been answered to my satisfaction.
 I give permission for my visits to be recorded on camera for data analysis
purposes only
 I do not give permission for my visits to be recorded on camera
__________________________________ _______________________
Signature of Study Participant
Printed Name
__________________________________ _______________________
Signature of Study Investigator
Printed Name
__________________________________ _______________________
Signature of Person Obtaining Consent
Printed Name

__________
Date
__________
Date
__________
Date
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Appendix C: UPDRS III
18 . Speech
0: Normal: No speech problems.
Speech
1: Slight: Loss of modulation, diction or volume, but still all
words easy to understand.
2: Mild: Loss of modulation, diction, or volume, with a few words unclear, but the
overall
sentences easy to follow.
3: Moderate: Speech is difficult to understand to the point that some, but not
most, sentences are poorly understood.
4: Severe: Most speech is difficult to understand or unintelligible.
19. Facial Expression
0: Normal: Normal facial expression.
Facial
1: Slight: Minimal masked facies manifested only by
Expression
decreased frequency of blinking.
2: Mild: In addition to decreased eye-blink frequency,
Masked facies present in the lower face as well, namely
fewer movements around the mouth, such as less spontaneous smiling, but lips
not parted.
3: Moderate: Masked facies with lips parted some of the time when the mouth is
at rest. 4: Severe: Masked facies with lips parted most of the time when the
mouth is at rest.
20. Tremor at Rest
Extremity ratings
Face/lip RUE LUE RLE LLE
0: Normal: No tremor.
1: Slight.: ≤ 1 cm in maximal amplitude.
2: Mild: > 1 cm but < 3 cm in maximal amplitude.
3: Moderate: 3 - 10 cm in maximal amplitude.
4: Severe: > 10 cm in maximal amplitude.
Lip/Jaw ratings
2: Mild: > 1 cm but ≤ 2 cm in maximal amplitude.
3: Moderate: > 2 cm but ≤ 3 cm in maximal amplitude.
4: Severe: > 3 cm in maximal amplitude
21. Action or Postural Tremor of hands
0: Normal: No tremor.
RUE
1: Slight: Tremor is present but less than 1 cm in amplitude.
2: Mild: Tremor is at least 1 but less than 3 cm in amplitude.
3: Moderate: Tremor is at least 3 but less than 10 cm in amplitude.
4: Severe: Tremor is at least 10 cm in amplitude.

LUE
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22. Rigidity (passive movement of major joints)
0: Normal: No rigidity.
Neck RUE LUE RLE LLE
1: Slight: Rigidity only detected with
activation maneuver.
2: Mild: Rigidity detected without the activation maneuver, but full range of motion
is easily achieved.
3: Moderate: Rigidity detected without the activation maneuver; full range of
motion is achieved with effort.
4: Severe: Rigidity detected without the activation maneuver and full range of
motion not
achieved.
23. Finger taps (patient taps thumb with index finger)
0: Normal: No problems.
RUE
LUE
1: Slight: Any of the following: a) the regular rhythm is broken
with one or two interruptions or hesitations of the tapping
movement; b) slight slowing; c) the amplitude decrements near the end of the 10
taps.
2: Mild: Any of the following: a) 3 to 5 interruptions during tapping; b) mild
slowing; c) the amplitude decrements midway in the 10-tap sequence.
3: Moderate: Any of the following: a) more than 5 interruptions during tapping or
at least one longer arrest (freeze) in ongoing movement; b) moderate slowing; c)
the amplitude
decrements starting after the 1st tap.
4: Severe: Cannot or can only barely perform the task because of slowing,
interruptions or decrements
24. Hand movements (patient opens and closes hands)
0: Normal: No problem.
RUE
LUE
1: Slight: Any of the following: a) the regular rhythm is broken
with one or two interruptions or hesitations of the movement;
b) slight slowing; c) the amplitude decrements near the end of the task.
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild
slowing; c) the amplitude decrements midway in the task.
3: Moderate: Any of the following: a) more than 5 interruptions during the
movement or at least one longer arrest (freeze) in ongoing movement; b)
moderate slowing; c) the
amplitude decrements starting after the 1st open-and-close sequence.
4: Severe: Cannot or can only barely perform the task because of slowing,
interruptions or decrements.
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25. Rapid alternative movements of hands (pronation-supination movements
of hands)
0: Normal: No problems.
RUE
LUE
1: Slight: Any of the following: a) the regular rhythm is broken
with one or two interruptions or hesitations of the movement;
b) slight slowing; c) the amplitude decrements near the end of the sequence.
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild
slowing; c) the amplitude decrements midway in the sequence.
3: Moderate: Any of the following: a) more than 5 interruptions during the
movement or at least one longer arrest (freeze) in ongoing movement; b)
moderate slowing c) the
amplitude decrements starting after the 1st supination-pronation sequence.
4: Severe: Cannot or can only barely perform the task because of slowing,
interruptions or decrements.
26. Leg agility (patient taps heel on the ground in rapid succession picking up
entire leg)
0: Normal: No problems.
RUE
LUE
1: Slight: Any of the following: a) the regular rhythm is broken
with one or two interruptions or hesitations of the movement;
b) slight slowing; c) amplitude decrements near the end of the task.
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild
slowness; c) amplitude decrements midway in the task.
3: Moderate: Any of the following: a) more than 5 interruptions during the
movement or at least one longer arrest (freeze) in ongoing movement; b)
moderate slowing in speed; c) amplitude decrements after the first tap.
4: Severe: Cannot or can only barely perform the task because of slowing,
interruptions or decrements
27. Arising from chair (patient attempts to arise from chair with arms folded
across chest)
0: Normal: No problems. Able to arise quickly without
Arise from Chair
hesitation.
1: Slight: Arising is slower than normal; or may need more
than one attempt; or may need to move forward in the chair
to arise. No need to use the arms of the chair.
2: Mild: Pushes self up from arms of chair without difficulty.
3: Moderate: Needs to push off, but tends to fall back; or may have to try more
than one time using arms of chair, but can get up without help.
4: Severe: Unable to arise without help.
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28. Posture
0: Normal: No problems.
Posture
1: Slight: Not quite erect, but posture could be normal for
older person.
2: Mild: Definite flexion, scoliosis or leaning to one side, but
patient can correct posture to normal posture when asked to do so.
3: Moderate: Stooped posture, scoliosis or leaning to one side that cannot be
corrected
volitionally to a normal posture by the patient.
4: Severe: Flexion, scoliosis or leaning with extreme abnormality of posture.
29. Gait
0: Normal: No problems.
Gait
1: Slight: Independent walking with minor gait impairment.
2: Mild: Independent walking but with substantial gait
impairment.
3: Moderate: Requires an assistance device for safe walking (walking stick,
walker) but not a person.
4: Severe: Cannot walk at all or only with another person’s assistance.
30. Postural Stability (Response to sudden, strong posterior displacement
produced by pull on shoulders while patient is standing with feet shoulder width
apart)
0: Normal: No problems: Recovers with one or two steps.
Postural stability
1: Slight: 3-5 steps, but subject recovers unaided.
2: Mild: More than 5 steps, but subject recovers unaided.
3: Moderate: Stands safely, but with absence of postural response; falls if not
caught by
examiner.
4: Severe: Very unstable, tends to lose balance spontaneously or with just a
gentle pull on the shoulders.
31. Body bradykinesia and hypokinesia (combining slowness, hesitancy,
decreased arm swing, small amplitude and poverty of movements in general)
0: Normal: No problems.
Body
1: Slight: Slight global slowness and poverty of spontaneous
Bradykinesia
movements.
2: Mild: Mild global slowness and poverty of spontaneous
movements.
3: Moderate: Moderate global slowness and poverty of spontaneous movements.
4: Severe: Severe global slowness and poverty of spontaneous movements.
Total UPDRS score: __ __
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Appendix D: The Activities-specific Balance Confidence (ABC) Scale
For each of the following, please indicate your level of confidence in doing the
activity without losing your balance or becoming unsteady from choosing one of
the percentage points on the scale from 0% to 100%. If you do not currently do
the activity in question, try and imagine how confident you would be if you had to
do the activity. If you normally use a walking aid to do the activity or hold onto
someone, rate your confidence as it you were using these supports. If you have
any questions about answering any of these items, please ask the administrator.
For each of the following activities, please indicate your level of selfconfidence by choosing a corresponding number from the following rating
scale:
0%
10
20
30
40
50
60
70
80
90
100%
no confidence
completely confident

“How confident are you that you will not lose your balance or
become unsteady when you…”
1. …walk around the house? ____%
2. …walk up or down stairs? ____%
3. …bend over and pick up a slipper from the front of a closet floor
____%
4. …reach for a small can off a shelf at eye level? ____%
5. …stand on your tiptoes and reach for something above your head?
____%
6. …stand on a chair and reach for something? ____%
7. …sweep the floor? ____%
8. …walk outside the house to a car parked in the driveway? ____%
9. …get into or out of a car? ____%
10. …walk across a parking lot to the mall? ____%
11. …walk up or down a ramp? ____%
12. …walk in a crowded mall where people rapidly walk past you?
____%
13. …are bumped into by people as you walk through the
mall?____%
14. … step onto or off an escalator while you are holding onto a
railing?____%
15. … step onto or off an escalator while holding onto parcels such
that you cannot hold onto the railing? ____%
16. …walk outside on icy/wet sidewalks? ____%
Total: ________
*Powell, LE & Myers AM. The Activities-specific Balance Confidence (ABC) Scale. J Gerontol Med Sci 1995; 50(1): M28-34
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Appendix E: Beck’s Depression Inventory
Instructions: This questionnaire consists of 21 groups of statements. Please read each
group of statements carefully, and then pick out the one statement in each group that
best describes the way you have been feeling the past two weeks. Place the
corresponding number on the score line. If several statements in the group seem to apply
equally well, pick the highest of the numbers. Be sure to not choose more than one
statement per group. This depression inventory can be self-scored. The scoring scale is at
the end of the questionnaire.
1.
0
I do not feel sad.
1
I feel sad.
Score:
______
2
I am sad all the time and I can't snap out of it.
3
I am so sad and unhappy that I can't stand it.
2.

3.

4.

5.

6.

0
1
2
3

I am not particularly discouraged about the future.
I feel discouraged about the future.
I feel I have nothing to look forward to.
I feel the future is hopeless and that things cannot
improve.

Score:
______

0
1
2

Score:
______

3

I do not feel like a failure.
I feel I have failed more than the average person.
As I look back on my life, all I can see is a lot of
failures.
I feel I am a complete failure as a person.

0
1
2
3

I get as much satisfaction out of things as I used to.
I don't enjoy things the way I used to.
I don't get real satisfaction out of anything anymore.
I am dissatisfied or bored with everything.

Score:
______

0
1
2
3

I don't feel particularly guilty.
I feel guilty a good part of the time.
I feel quite guilty most of the time.
I feel guilty all of the time.

0
1
2
3

I don't feel I am being punished.
I feel I may be punished.
I expect to be punished.
I feel I am being punished.

Score:
_____

Score:
______
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7.

8.

9.

0
1
2
3

I don't feel disappointed in myself.
I am disappointed in myself.
I am disgusted with myself.
I hate myself.

Score:
______

0
1
2
3

I don't feel I am any worse than anybody else.
I am critical of myself for my weaknesses or mistakes.
I blame myself all the time for my faults.
I blame myself for everything bad that happens.

Score:
______

0
1

I don't have any thoughts of killing myself.
I have thoughts of killing myself, but I would not carry
them out.
I would like to kill myself.
I would kill myself if I had the chance.

Score:
______

0
1
2
3

I don't cry any more than usual.
I cry more now than I used to.
I cry all the time now.
I used to be able to cry, but now I can't cry even
though I want to.

Score:
______

0
1
2

Score:
______

3

I am no more irritated by things than I ever was.
I am slightly more irritated now than usual.
I am quite annoyed or irritated a good deal of the
time.
I feel irritated all the time.

0
1
2
3

I have not lost interest in other people.
I am less interested in other people than I used to be.
I have lost most of my interest in other people.
I have lost all of my interest in other people.

Score:
______

0
1
2

I make decisions about as well as I ever could.
I put off making decisions more than I used to.
I have greater difficulty in making decisions more than
I used to.
I can't make decisions at all anymore.
I don't feel that I look any worse than I used to.
I am worried that I am looking old or unattractive.
I feel there are permanent changes in my appearance
that make me look unattractive.
I believe that I look ugly.

2
3
10.

11.

12.

13.

14.

3
0
1
2
3

Score:
______

Score:
______
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15.

0
1

I can work about as well as before.
It takes an extra effort to get started at doing
something.
I have to push myself very hard to do anything.
I can't do any work at all.

Score:
______

I can sleep as well as usual.
I don't sleep as well as I used to.
I wake up 1-2 hours earlier than usual and find it hard
to get back to sleep.
I wake up several hours earlier than I used to and
cannot get back to sleep.

Score:
______

0
1
2
3

I don't get more tired than usual.
I get tired more easily than I used to.
I get tired from doing almost anything.
I am too tired to do anything.

Score:
______

0
1
2
3

My appetite is no worse than usual.
My appetite is not as good as it used to be.
My appetite is much worse now.
I have no appetite at all anymore.

Score:
______

0
1
2
3
0
1

I haven't lost much weight, if any, lately.
I have lost more than five pounds.
I have lost more than ten pounds.
I have lost more than fifteen pounds.
I am no more worried about my health than usual.
I am worried about physical problems like aches,
pains, upset stomach, or constipation.
I am very worried about physical problems and it's
hard to think of much else.
I am so worried about my physical problems that I
cannot think of anything else.

2
3
16.

0
1
2
3

17.

18.

19.

20.

2
3

21.

0
1
2
3
4

I do not feel like a failure.
I have not noticed any recent change in my interest in
sex.
I am less interested in sex than I used to be.
I have almost no interest in sex.
I have lost interest in sex completely.

Total Score: ________

Score:
______

Score:
______

Score:
______
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Interpreting The Beck Depression Inventory
Now that you have completed the questionnaire, add up the score for each of the
twenty-one questions by counting the number to the right of each question you
marked. The highest possible total for the whole test would be sixty-three. This
would mean you circled number three on all twenty-one questions. Since the
lowest possible score for each question is zero, the lowest possible score for the
test would be zero. This would mean you circles zero on each question. You can
evaluate your depression according to the Table below.
Classification
Total Score
Level of Depression
Low
1-10
These ups and downs are considered
normal
11-16
Mild mood disturbance
Moderate
17-20
Borderline clinical depression
21-30
Moderate depression
Significant
31-40
Severe depression
over 40
Extreme depression
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Appendix F: Montreal Cognitive Assessment Scale (MOCA)
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Appendix G: Contact Localizations for each Participant
BSC-01

BSC-02

BSC-03
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BSC-06

BSC-07
d)

Note: Contact localizations for BSC-05 and BSC-08 are not available.
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